var title_f24_10_24736="Plugged glands";
var content_f24_10_24736=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F53663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F53663&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plugged glands",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 279px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High magnification view of meibomian gland openings of the eyelid with mounds of thickened, waxy secretions plugging the gland openings.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24736=[""].join("\n");
var outline_f24_10_24736=null;
var title_f24_10_24737="Malignant mesothelioma Light";
var content_f24_10_24737=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F75689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F75689&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Malignant mesothelioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 233px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Photomicrograph of an epithelial malignant mesothelioma. The sheets of pleomorphic cells are epithelial in appearance, with eosinophilic cytoplasm and fairly well-defined cell borders. Cytoplasmic vacuoles (arrow) are present, which can lead to confusion with a signet ring type of adenocarcinoma. These vacuoles can be shown by electron microscopy to contain crystallized hyaluronic acid.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Giuseppe G Pietra, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24737=[""].join("\n");
var outline_f24_10_24737=null;
var title_f24_10_24738="Cardioversion";
var content_f24_10_24738=[" <h1 id=\"patTopicTitle\">",
"  Patient information: Cardioversion (Beyond the Basics)",
" </h1>",
" <div id=\"patTopicContributors\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <table>",
"    <tr>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/10/24738/contributors\">",
"       Author",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24738/contributors\" id=\"au6340\">",
"       Bradley P Knight, MD, FACC",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/10/24738/contributors\">",
"       Section Editor",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24738/contributors\" id=\"se2550\">",
"       Richard L Page, MD",
"      </a>",
"     </td>",
"     <td>",
"      <a class=\"contributor contributor_credentials patTopicContributorsType\" href=\"UTD.htm?24/10/24738/contributors\">",
"       Deputy Editors",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24738/contributors\" id=\"de7537\">",
"       Brian C Downey, MD, FACC",
"      </a>",
"      <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24738/contributors\" id=\"de1101\">",
"       Gordon M Saperia, MD, FACC",
"      </a>",
"     </td>",
"    </tr>",
"   </table>",
"  </div>",
"  <div class=\"rcBottom\">",
"   <div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"patTopicTool\" id=\"patTopicToolTop\">",
"  <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"   Find",
"  </a>",
"  <a class=\"toolbutton printicon\" href=\"UTD.htm?24/10/24738?view=print\" title=\"Print This Topic\">",
"   Print",
"  </a>",
"  <script src=\"file://w.sharethis.com/button/sharethis.js#publisher=357881b8-c7e3-4c31-b7d2-242aeb1528e1&amp;type=website&amp;post_services=care2%2Cfacebook%2Ctwitter%2Cmyspace%2Cdigg%2Cdelicious%2Cfaves%2Creddit%2Cxanga%2Cstumbleupon%2Cblinklist%2Csimpy%2Cyigg%2Ctechnorati%2Cmeneame%2Corkut%2Cmixx%2Cfunp%2Cfresqui%2Cmister_wong%2Cfriendster%2Cfriendfeed%2Clinkedin%2Coknotizie%2Cgoogle_bmarks%2Cyahoo_bmarks%2Cfark%2Cnewsvine%2Clivejournal%2Ctypepad%2Cbus_exchange%2Cpropeller%2Cwordpress%2Cblogger%2Cblogmarks%2Cwindows_live%2Cfurl%2Cybuzz%2Cdiigo\" type=\"text/javascript\">",
"  </script>",
" </div>",
" <div id=\"patTopicMiddle\">",
"  <div id=\"topicContent\">",
"   <div id=\"topicText\">",
"    <p class=\"headingAnchor\" id=\"H1\">",
"     <span class=\"h1\">",
"      CARDIOVERSION OVERVIEW",
"     </span>",
"    </p>",
"    <p>",
"     Cardioversion is a procedure used to treat abnormal and rapid heart rhythms (also called cardiac arrhythmias). The most commonly treated arrhythmia is atrial fibrillation. During cardioversion, an electrical \"shock\" is delivered to the heart to restore its rhythm to a normal pattern. The electrical energy can be delivered externally, with electrodes placed on the chest, or directly to the heart using paddles on the heart during an open chest surgery. Alternatively, the energy can be delivered through the electrodes of a permanently implanted device called a cardioverter-defibrillator. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     The following is a discussion of cardioversion and the situations in which it is used.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H2\">",
"     <span class=\"h1\">",
"      THE HEART'S CONDUCTION SYSTEM",
"     </span>",
"    </p>",
"    <p>",
"     To understand how electricity can be used to allow the heart to beat normally, it is helpful to first understand the heart's electrical system. The heart is made up mostly of muscle tissue. This muscle forms the walls of the four heart chambers. The upper chambers are called atria, with one on the right side and one on the left side of the heart. The two lower chambers are the right and left ventricles (",
"     <a class=\"graphic graphic_figure graphicRef77576 \" href=\"UTD.htm?11/14/11495\">",
"      figure 1",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Electrical impulses cause the heart muscle to contract. During a normal heart rhythm, each impulse moves in a standardized and orderly manner over nerves from the atria to the ventricles, with each impulse resulting in one heart beat. (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 2",
"     </a>",
"     ).",
"    </p>",
"    <p>",
"     Under normal conditions, the electrical impulses are generated from an area of specialized pacemaker cells called the sinus node, located in the right atrium (the upper right chamber of the heart).",
"    </p>",
"    <p>",
"     After leaving the sinus node, the impulse travels through and activates both atria. The impulse then travels through specialized heart fibers that transmit the impulse rapidly to various parts of the right and left ventricles; this causes the heart to contract. Each individual muscle cell of the ventricles is activated. If this pattern of conduction and activation is altered in any way, an abnormal heart rhythm (arrhythmia) may occur.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H3\">",
"     <span class=\"h1\">",
"      TYPES OF ARRHYTHMIAS",
"     </span>",
"    </p>",
"    <p>",
"     During a rapid cardiac arrhythmia, an abnormal electrical mechanism overrides the action of the sinus node. There are a wide variety of cardiac arrhythmias, some of which start in the atria and some in the ventricles.",
"    </p>",
"    <p>",
"     In a normal heart rhythm, the electrical impulse moves from the top to the bottom of the heart, then dissipates. The next impulse begins independently in the sinus node (",
"     <a class=\"graphic graphic_figure graphicRef71235 \" href=\"UTD.htm?4/20/4420\">",
"      figure 2",
"     </a>",
"     ). Sometimes, cardiac tissue can form an electrical loop or short-circuit. If an electrical impulse enters this loop at the right time under the right conditions, it will cycle through the loop over and over again, repeating itself indefinitely. This is called a re-entrant loop. Each time the impulse cycles through the re-entrant circuit, it activates the heart, causing another contraction.",
"    </p>",
"    <p>",
"     Arrhythmias that are generated by a re-entrant circuit are often regular and organized and can be treated with cardioversion. Examples of a single reentrant circuit include atrial flutter and ventricular tachycardia (VT). Under some circumstances, multiple reentrant circuits can develop, resulting in very rapid and chaotic arrhythmias, including atrial fibrillation. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=see_link\">",
"      \"Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     Other arrhythmias, which may be regular or irregular, are caused by a single site (called an ectopic foci) firing repeatedly in the atria or ventricle. Cardioversion is generally not effective for this type of arrhythmia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H4\">",
"     <span class=\"h2\">",
"      How cardioversion works in reentry arrhythmias",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cardioversion involves the delivery of a high-energy shock to the heart muscle. This high-energy impulse activates all of the cardiac muscle and conduction tissue simultaneously. Reentrant circuits are interrupted, breaking the repeating cycle and stopping the arrhythmia. When the reentrant circuit is broken and the arrhythmia stops, the sinus node begins to fire again and a normal heart rhythm is restored.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H5\">",
"     <span class=\"h1\">",
"      CARDIOVERSION PROCEDURE",
"     </span>",
"    </p>",
"    <p>",
"     There are two ways of performing cardioversion: externally or internally.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H6\">",
"     <span class=\"h2\">",
"      External cardioversion",
"     </span>",
"     &nbsp;&mdash;&nbsp;External cardioversion is much more common. It is performed in a closely monitored setting, such as an intensive care unit, an emergency department, or a specially equipped procedure room. The patient's heart rate and rhythm, blood pressure, breathing rate, and oxygen levels are monitored.",
"    </p>",
"    <p>",
"     Because the shock would be painful for a patient who is awake, an intravenous medication is given to sedate the patient. Patients are asleep during the cardioversion and most do not remember the procedure. It is not usually necessary to have a breathing tube (endotracheal tube) placed before the procedure.",
"    </p>",
"    <p>",
"     Two electrode pads or paddles are applied to the skin (",
"     <a class=\"graphic graphic_figure graphicRef83301 \" href=\"UTD.htm?8/41/8848\">",
"      figure 3",
"     </a>",
"     ). One is applied near the breastbone, and the second is placed either on the lower left chest or the back, under the left shoulder blade. When the patient is sedated, a burst of electrical current is sent through these pads or paddles. Most of the electrical impulse is absorbed by the chest, but some makes it to the heart. The amount of energy used depends upon the arrhythmia. If the first attempt is unsuccessful at converting the heart rhythm to normal, subsequent higher energy shocks may be needed.",
"    </p>",
"    <p>",
"     Once the setup and sedation are complete, the cardioversion itself takes only a few seconds. The patient usually awakens 5 to 10 minutes after the cardioversion when the anesthetic drug administered for sedation wears off.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H7\">",
"     <span class=\"h2\">",
"      Internal cardioversion",
"     </span>",
"     &nbsp;&mdash;&nbsp;One type of internal cardioversion uses a device called an implantable cardioverter-defibrillator (ICD). It is surgically placed in the chest and constantly monitors the heart's rhythm. It delivers a cardioverting or defibrillating shock if a life-threatening arrhythmia develops. This device is discussed in detail in a separate topic. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      \"Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H8\">",
"     <span class=\"h2\">",
"      Postprocedure care",
"     </span>",
"     &nbsp;&mdash;&nbsp;After being monitored for several hours, most patients are able to go home, although a family member or friend should drive due to the residual effects of anesthesia. Some patients have irritation of the skin in the area where the shock was delivered; an emollient cream such as Aquaphor&reg; or Eucerin&reg; may be applied to reduce the irritation.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H9\">",
"     <span class=\"h1\">",
"      CARDIOVERSION FOR SPECIFIC ARRHYTHMIAS",
"     </span>",
"    </p>",
"    <p>",
"     As mentioned above, cardioversion is useful for terminating arrhythmias that arise from a reentry circuit. Cardioversion is tailored for each type of arrhythmia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H10\">",
"     <span class=\"h2\">",
"      Atrial fibrillation",
"     </span>",
"     &nbsp;&mdash;&nbsp;Atrial fibrillation (AF) is a common arrhythmia that may be treated with cardioversion. The success rate of cardioversion with atrial fibrillation is generally better than 75 percent. Chances of success depend upon the duration of atrial fibrillation and size of the left atrium. The success rate is about 90 percent when atrial fibrillation is of less than one year's duration, compared to 50 percent when atrial fibrillation has been present for more than five years.",
"    </p>",
"    <p>",
"     Thromboembolism (blood clot traveling through the bloodstream) can occur after cardioversion if a thrombus (blood clot) becomes dislodged from the atria as the heart begins to beat normally. Blood clots can form within the atria during AF since blood flow is slowed. Most patients are given an anticoagulant (a blood thinner such as warfarin (Coumadin&reg;)) for three to four weeks before and after cardioversion to prevent an embolism. Some patients will be required to take an anticoagulant indefinitely. (See",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      \"Patient information: Atrial fibrillation (Beyond the Basics)\"",
"     </a>",
"     .)",
"    </p>",
"    <p>",
"     For a scheduled cardioversion, some patients will be given an antiarrhythmic drug starting 24 to 48 hours before the procedure to improve the chances of maintaining a normal rhythm following cardioversion. AF is most likely to recur within the first few hours after cardioversion; treatment before the cardioversion will allow the medication time to get into the bloodstream, which may prevent a recurrence. In addition, a normal rhythm may be restored with the medication alone in some patients, making electrical cardioversion unnecessary. Pretreatment with an antiarrhythmic drug may also improve the chances of a successful cardioversion and reduce the energy required for the procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H11\">",
"     <span class=\"h2\">",
"      Atrial flutter",
"     </span>",
"     &nbsp;&mdash;&nbsp;Atrial flutter is an atrial arrhythmia that can be treated with cardioversion. The success rate is 90 to 100 percent. Success is not related to the duration of this arrhythmia. Not uncommonly, anticoagulation is also given prior to and after cardioversion, although the risk of a thromboembolism is much less than with AF.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H12\">",
"     <span class=\"h2\">",
"      Ventricular tachycardia",
"     </span>",
"     &nbsp;&mdash;&nbsp;Ventricular tachycardia is an arrhythmia arising in the ventricles (lower chambers of the heart) and may be potentially life-threatening. Cardioversion is very effective (&gt;90 percent) for stopping this arrhythmia. Cardioversion is generally performed urgently for this arrhythmia.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H13\">",
"     <span class=\"h2\">",
"      Cardioversion during pregnancy",
"     </span>",
"     &nbsp;&mdash;&nbsp;Cardioversion can be performed during pregnancy without affecting the rhythm of the fetus. It is recommended, however, that the fetal rhythm be monitored during the procedure.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H14\">",
"     <span class=\"h2\">",
"      Cardioversion in patients with implanted devices",
"     </span>",
"     &nbsp;&mdash;&nbsp;Several precautions are necessary when attempting external cardioversion in a patient with a permanent implanted device, such as a pacemaker or implantable cardioverter-defibrillator (ICD).",
"    </p>",
"    <p>",
"     Cardioversion can change the settings of the ICD or pacemaker, or may damage the ICD or pacemaker, the leads, or the heart's tissue. To reduce these risks, the paddles are placed at least 12 cm from the pacemaker or ICD. After cardioversion, the pacemaker or ICD should be evaluated to ensure that it still functions normally.",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H15\">",
"     <span class=\"h1\">",
"      CARDIOVERSION COMPLICATIONS",
"     </span>",
"    </p>",
"    <p>",
"     There are several complications that can occur with cardioversion:",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Cardioversion can sometimes provoke other arrhythmias or disturbances of impulse conduction (heart block). In an occasional patient, the sinus node may not work properly after cardioversion and a very slow heart rate may result. A temporary pacemaker may be necessary to correct this problem.",
"      </li>",
"      <li>",
"       Cardioversion can dislodge blood clots from the heart, which can travel to the brain or elsewhere throughout the body; this is less likely in patients who have had an arrhythmia for less than 48 hours. Use of an anticoagulant before cardioversion can reduce this risk. (See",
"       <a class=\"local\" href=\"#H10\">",
"        'Atrial fibrillation'",
"       </a>",
"       above.)",
"      </li>",
"      <li>",
"       Some heart tissue may be damaged or may actually die (called myocardial necrosis) as a result of high-energy shocks or repeated shocks. Significant damage is uncommon and there are generally no short or long term complications.",
"      </li>",
"      <li>",
"       The heart muscle may not function as well after cardioversion, although this is temporary and does not usually cause symptoms.",
"      </li>",
"      <li>",
"       The skin may be burned",
"       <span class=\"nowrap\">",
"        and/or",
"       </span>",
"       painful as a result of the shocks. Pre-treating the skin with a steroid cream and taking a medication, such as ibuprofen, can reduce the severity of this pain.",
"      </li>",
"     </ul>",
"    </p>",
"    <p class=\"headingAnchor\" id=\"H16\">",
"     <span class=\"h1\">",
"      WHERE TO GET MORE INFORMATION",
"     </span>",
"    </p>",
"    <p>",
"     Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"    </p>",
"    <p>",
"     This article will be updated as needed on our web site (",
"     <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"      www.uptodate.com/patients",
"     </a>",
"     ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365716\">",
"     <span class=\"h2\">",
"      Patient level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365723\">",
"     <span class=\"h3\">",
"      The Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/56/23427?source=see_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/57/1939?source=see_link\">",
"      Patient information: Heart failure and atrial fibrillation (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?26/51/27442?source=see_link\">",
"      Patient information: Ventricular tachycardia (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?8/16/8451?source=see_link\">",
"      Patient information: Atrial flutter (The Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=see_link\">",
"      Patient information: Long QT syndrome (The Basics)",
"     </a>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365736\">",
"     <span class=\"h3\">",
"      Beyond the Basics",
"     </span>",
"     &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/20/11589?source=see_link\">",
"      Patient information: Implantable cardioverter-defibrillators (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?8/50/8995?source=see_link\">",
"      Patient information: Wolff-Parkinson-White syndrome (Beyond the Basics)",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"     <br/>",
"    </p>",
"    <p class=\"headingAnchor2\" id=\"H365748\">",
"     <span class=\"h2\">",
"      Professional level information",
"     </span>",
"     &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"    </p>",
"    <p>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"     <br/>",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/57/22426?source=see_link\">",
"      Restoration of sinus rhythm in atrial fibrillation",
"     </a>",
"     <br/>",
"     <br/>",
"     The following organizations also provide reliable health information.",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Library of Medicine",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/ency/article/007110.htm\">",
"      www.nlm.nih.gov/medlineplus/ency/article/007110.htm",
"     </a>",
"     , available in Spanish)",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       National Heart, Lung, and Blood Institute",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.nhlbi.nih.gov/health/dci/Diseases/crv/crv_whatis.html\">",
"      www.nhlbi.nih.gov/health/dci/Diseases/crv/crv_whatis.html",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       American Heart Association",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Non-surgical-Procedures-for-AF_UCM_423782_Article.jsp\">",
"      www.heart.org/HEARTORG/Conditions/Arrhythmia/AboutArrhythmia/Non-surgical-Procedures-for-AF_UCM_423782_Article.jsp",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     <ul class=\"bullet-block\">",
"      <li>",
"       Heart Rhythm Society",
"      </li>",
"     </ul>",
"    </p>",
"    <p>",
"     &nbsp; &nbsp; &nbsp;(",
"     <a class=\"external\" href=\"file://www.hrsonline.org/PatientInfo/Treatments/Cardioversion/index.cfm\">",
"      www.hrsonline.org/PatientInfo/Treatments/Cardioversion/index.cfm",
"     </a>",
"     )",
"    </p>",
"    <p>",
"     [",
"     <a class=\"abstract\" href=\"UTD.htm?24/10/24738/abstract/1-4\">",
"      1-4",
"     </a>",
"     ]",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 15, 2012.",
"  </div>",
"  <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"   <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"    Find",
"   </a>",
"   <a class=\"toolbutton printicon\" href=\"UTD.htm?24/10/24738?view=print\" title=\"Print This Topic\">",
"    Print",
"   </a>",
"  </div>",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <div id=\"patTopicRefHeader\">",
"    <div id=\"patTopicRefHeaderHeader\">",
"     References",
"    </div>",
"    <div id=\"patTopicRefHeaderTop\">",
"     <a href=\"#top\">",
"      <img alt=\"\" src=\"./../images/top_arrow.myextg\">",
"       Top",
"      </img>",
"     </a>",
"    </div>",
"   </div>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24738/abstract/1\">",
"      L&eacute;vy S, Lauribe P, Dolla E, et al. A randomized comparison of external and internal cardioversion of chronic atrial fibrillation. Circulation 1992; 86:1415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24738/abstract/2\">",
"      Chen PS, Wolf PD, Ideker RE. Mechanism of cardiac defibrillation. A different point of view. Circulation 1991; 84:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24738/abstract/3\">",
"      Botto GL, Politi A, Bonini W, et al. External cardioversion of atrial fibrillation: role of paddle position on technical efficacy and energy requirements. Heart 1999; 82:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24738/abstract/4\">",
"      Kirchhof P, Eckardt L, Loh P, et al. Anterior-posterior versus anterior-lateral electrode positions for external cardioversion of atrial fibrillation: a randomised trial. Lancet 2002; 360:1275.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
" </div>",
" <!-- patTopicMiddle -->",
"</div>"].join("\n");
var script_f24_10_24738=[""].join("\n");
var outline_f24_10_24738=[" <div class=\"patTopicFancyTop\">",
"  <div class=\"rcTop\">",
"   <div>",
"   </div>",
"  </div>",
"  <div class=\"rcContent\">",
"   <p>",
"    Contents of this article",
"   </p>",
"  </div>",
" </div>",
" <div class=\"patTopicFancySpacer\">",
" </div>",
" <div class=\"patTopicOutline\">",
"  <div class=\"rcbBottom\">",
"   <div class=\"rcbLeft\">",
"    <div class=\"rcbRight\">",
"     <div class=\"rcbBottomLeft\">",
"      <div class=\"rcbBottomRight rcbBottomRightBottomOnly\">",
"       <div id=\"outline\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          <a href=\"#H1\">",
"           CARDIOVERSION OVERVIEW",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H2\">",
"           THE HEART'S CONDUCTION SYSTEM",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H3\">",
"           TYPES OF ARRHYTHMIAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H5\">",
"           CARDIOVERSION PROCEDURE",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H9\">",
"           CARDIOVERSION FOR SPECIFIC ARRHYTHMIAS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H15\">",
"           CARDIOVERSION COMPLICATIONS",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#H16\">",
"           WHERE TO GET MORE INFORMATION",
"          </a>",
"         </li>",
"         <li class=\"plainItem\">",
"          <a href=\"#references\">",
"           REFERENCES",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"       <h1>",
"        GRAPHICS",
"       </h1>",
"       <div id=\"relatedGraphics\">",
"        <ul>",
"         <li class=\"plainItem\">",
"          FIGURES",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?11/14/11495\" title=\"figure 1\">",
"           Cardiac anatomy PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/20/4420\" title=\"figure 2\">",
"           Heart conduction system PI",
"          </a>",
"         </li>",
"         <li class=\"bulletItem\">",
"          <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/41/8848\" title=\"figure 3\">",
"           Defibrillator pad placement PI",
"          </a>",
"         </li>",
"        </ul>",
"       </div>",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"  </div>",
" </div>"].join("\n");
var title_f24_10_24739="IGF1 and insulin receptor";
var content_f24_10_24739=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 573px\">",
"   <div class=\"ttl\">",
"    Schematic diagram of the structure of the IGF-I, insulin and hybrid receptors",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 553px; height: 347px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFbAikDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigArmPiBq9zo2l6bJZTCGa51fT7MkqGykt1GkijPqhYZ6jORg4I6es7xBommeItKl03W7KG9sJSpeGUZUlSCP1AoA5D4k+L73wprelvbxG4tDp9/dTwNcRQJI0ZgWPc8g+Ub5gCwYBQSSGA4wdU+Kevacmo2tz4XsU1OyvWtDs1NpYZQlr9pdk2w+ax2FBtCHG/LFQprqj8MPCEekSafY6LaWcbJOqPFErNEZkVJGUOGXJVEHIIwMYxmsnw18GfCul6BJpep2kWtRyXf2wtdQRxqjhBGNqRqqqNqjPGWOSc8YAKR+LVxdavp6aVoccmkztpJluLi88udU1AkR4iCMpKkZb5/Ydci54U8aa3rvxDtbO6tLSy0S40y8vbWOK5WaWVUuIIkeXC/u2x5h2qxx5mG+ZK6+38JaBbxokGlWyKgtQuF6C2OYB/wAAPSodC8E+GtA1m61bRtGs7LUboOs08KbWcMwZh6YLKD+FAHneu/FiTT/jTb6I1xa2/he2kj0u9lliYs97PG8kbI65G1NkcZyVwZWJBADLStfEPj3Xdat0i1K302yu/E9zo8i20sTPBFbxTEiLzLZslvKdmLlssqBRGrNt9gl0DSJbO8tZNNtGt7yf7TcI0QImlypEjerAqmD1G1cdBT7bRNMtXDW9hbRst1JeqQg4nkDB5B6MwdwT33H1oA84074ha01h4aeOwtLm2n0/RLrULq5uik2b+VoPkRIgjEMu4nKDGQB6LN4v8RtrjW9m1kbAW2tyzPLIDNE1rOIowqqm3gPCwDEkiRs/dXd6JFoOkxRRxxadaJHHHbxIqxABUgYvCo9kYkqOxPFVb/wj4fv3ga80axlaCeW5jLRDKyyZ8x/q2eT9PQUAcB4Q+I2tanf6HarpZvrNreyiv7hBI06zz20cxk3LEtuUAkUsA4YDcQuNoOn4O8aeIte03VDcabo1tqsUdrPbWjXNwi7Jy20SSPCAfukB4vMVmBA6c9VD4O8OQ61ZatBomnxalZQi3tp44FVoYwu0KuOgCnaPQcDiodN8C+FdMsdRstP8P6Zb2mosGu4Y7dQk+DkBhjBUZOF6DJ45NAHSUUUUAeOfG7xZqPhPxv4MurC4k+zpY61dXFn5rLFcmG0EkYkA64YcHtk4rCf45avHHNC+l6U91FPpYJS6ADxXls05Mauy72TCqAG+bP8ADXuWpaPpmqPG+p6dZXjxxyQo1xAshVJF2yKNwOAw4YdCODUF14b0O7jvo7rRtMnS/wDL+1rJaxsLjy8eX5gI+fbgYznGBigDC0vxS2t+AtJ17Tr62LXRj3S2dlcX0TndsdVjASXGQ3JA2kZbIBBx7jxX4zHhDTL+Pw0V8TTR7pNCMTuj5mVB/pQPlxEJl9r5POO1ejwxRwQpFDGkcUahURBhVA4AAHQU+gDlfH+qX+lw6U+kRPcX8lxOsFqJAi3Mi2VzIkbZHILRr0K8gHPBB8buPHNroBSLSvGeuahrl/ot9fXJae3vYIrqO3mmw0TPutmjPAjVFRgFU5KsR9FvGjtGzorNG25CRkqcEZHocEj8TVCz0HSLKa/lstKsLeXUGLXjxW6I1yTnJkIHzn5m656n1oA8h+DA8RaP4a/4SPXYfFOqx3unWUsER1n+0vPMn33jhdUMRAw7Auww+ASRiuh8KatfN4S8V3Vxq91DNbeJL2KGd4HvWVEu8LCsQyzKR+7CpggN8uDgj0q1t4bS1htrSGOC3hQRxRRKFRFAwFUDgADgAUW9tBbeZ9mgih81zK/loF3uerHHUn1oA4jTPEOv3Pg/xNe+I9M/sb7Elx9luw4jNxEitify3JMPTO1ycfSvIYPFU97oI/4SzxfrWktp2haVdadBY3sVpcXxkgjeW5aSdlFwfM3oULYwrcFyDX0yQGUhgCDwQe9ZV34a0K9t7CC80TTLiDTwBZxy2kbrbAAAeWCMJgKOmOg9KAPA7iTxL43+JNk+j3Xi2XRmsNKubiTT9cj05LVJ1LNJJAQ4kJAJKof4SMnINT/HfxprKajoLaY2v+H1+y69FJHK/wBnNwYrNWjlAViGUM2VY8ggkYODX0LFa28VzNcRQRJcTbRLKqANJt4Xcepxk4z0qvqWj6Zqjo+p6dZ3jxxyQo1xAshVJF2yKMg4DDhh0I4NAEXhef7V4Z0i4+0m682zhk+0MVJlygO8lSVOevBxzxWnSKoRQqAKoGAAMACloAKKKKACsDx3f3WmeFb27sJ/s9yhjCy7A+3Mignbg54J7Vv1X1CxtdSspbTULeK5tZRiSGVQyOM5wQeCOKAPHdb8U65bPJrz+JNTh0+LX202fT7HTLW4gtUjuhCqzs5WVfNXy2yGyPNyoxtp/gHxL4l1Lxv4gl1W+8Qy6Lp2pajCsUOmWzWhjid1RA6Azs4GMADJIAyc4PoeoeBfC2o+I016+0DTrjWEKkXUkAZyVGFY9iQMYJ5GBjoMbGmaZZ6Wlwmn26QLcTyXMoT+OV23Ox9yTmgDB8Pa/JrHjDVIYWuV02PTLK4hhubR7aRJHmvEclJFWQZEKcMMYAI65Of4A8V6vr2qXltd2lpd6XHEsttrliksVvdEkDYqSDr33I7rg43ZBFdolrAl5LdrDGLqWNInlCjcyIWKqT3ALuQO24+tTUAeG2XjLxLq3iK60aTU7u0t47zWpI57C3ge7uVtJgkdpCJFKAhXDFmBZsAbhyTnp458S6zL4Wg0jUvE0wuNNvZ7oWOlWC3TvDc+SHkWV2jUDDA7G5O3AG7C+yax4P8ADusaZNp2p6LYXFlNcG8eFoQFM5yTLx0c5OWHJyc9TVrSvD2jaR9m/srSrGz+zQtbwmCBUMcbMHZAQOAWAYjueetAHBeOfGV1o0fhLTrO71iHUpdc07T7uW40wBbhJD+8VpSgiJIBJMJOGAAwM4o/D3xxrN/8CNG8Sapqlk2uXUksYlvLVmS5k+0SJHEEgAIZgqqCqse+1jwfVdQ06y1EW41C0t7oW8yXMPnRh/LlU5V1z0YdiORSaTpljo+nxWOk2dvZWURYx29vGI403MWOFHAySTx60AeX3XxF8VR6Xp86eGo01yQSM/h6RZjPcRK2PtEUqK3loSVGJo0wW5YfLv2/HfijU9G1nwf9lD28N79sku7SVUZm8uyklVGYbsEOoyUbt1Ir0Cqd9pljqEsEl9Z29xJBv8ppYwxj3qUbBPTKsQfUHFAHi9n8WfGMmml5fDuiG5ubTTbyy2X7KrLeOVRWVl3M3yt8qZORxuyK9T8B+Ik8T+G4L/z9PluQzQ3K2MzyRxyqeV+dEdTjBKsoIzjnqZL3wf4avoRFeeHtImjFstkA9nGdsCkFYhxwikAhRwCARWjpGl2GjadDp+kWdvZWMIIjgt4wiJkknAHHJJJ9SSaALlFFFABRRRQAVynxTuns/A2oTxXc9pIrwBZoJfLcEzIAA2R1ztIByQSACTg9XTZY0mieOVFeNwVZWGQwPUEdxQB88eJPGyWHiCa8vrvWD4lg8RtYx6dZ6ikJjsxIiRgWcsg80SxkOHCHJctuUBcWfhu/iW98Uap4mli8S6jpFtqmqMoGv7ldE8xY4RYldvUgKC64YZ4UKD7nJpWnSarFqklhaPqcUZiju2hUzIhzlQ+MgcnjPerFtbw20ZjtoY4ULvIVjUKCzMWZsDuWJJPckmgDi/CWtXOteP8AWnlt9W0+CLSNPZbC+ATY7y3ZZ9gYrnCqpIPO3HOBUPgHWPE93rUllqFtdXnh+K1LR63fWX2C4nuNy/uzbkhsbS3z+WgO3AB+83dLbQLdyXKwxLcyIsbyhAHZFLFVJ6kAu5A7bj6mpaAPleHxHfvr3ii38S6rqK+G4PEGtrAjajJZxXl0iR/Z7F7oEeRHtMrKCyoSOQcYra0X+3fFnhXwLa6XLeXDGx1d3iufEUsLOILyCKMm4tkAmZQcKSoUhic9z9Dy2ltLby28tvC8EufMjZAVfPXI6HNSLFGpQqigou1cD7o44HoOB+VAHlvxD1+70680DQtPsdfs4bfWtLhOpySZguY2miVovNMhkkJDENvHO1sk93+A9U1I/BlNQW61CfUIry62NFbm8mlCX8gWIITyGUCPOVCqc7kC7h6lSABQAAABwAKAPP7/AFTX7r4N+I9Q8RWS6Tqa6bevGschjcIsb7JGUM3lOQM7A77ePmzkB8/ivVY/GJsi+mJpi68mjlZI3ErK2nLdBg+/G7e23G3ke/Nd6wDKVYAgjBB70hRCwYqpIO4HHQ4xn8uKAPO/hB4/k8bf2nFdT2Ut3YpbvKLKNfKXzQ5G2RZ5d4+Qj5hGwxyoJwPRqhtrS2tWna2t4YWnfzZTGgUyPgDc2OpwAMn0qagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKK4f4ux+IJPDkH/AAikepyaks5aMafNHGwkEMnlGTzCFMQl8ssM8gYIYEit7wXJeyeE9IOqwXsF+tsiTretGZi6jaWcxkrlsbuD35AOQADaorxfxj4Y8b3nxattYtY7q90KC7s3ihi1f7LD5Cg7keMD5mSYecxIfem1QQRivaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAorkPidpV9rOi2lpZWUuoQNdA3VrFetZmWPy5AuZVYFVWUxMcZO1ThWPBn+GWm3ukeBdJsNVtZbW/gRknSW9N4zvvbMhlONxf7+MDbu2gACgDqKK8Z+MPhXxtq/jTS9S8LvdyabbwwCWC31g2W8CZvOjK7Sp3q8Tbjn5bdhgkqD7NQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFc18SZkg8DavJLJbpEsQ3i4vfsSSruGYjPx5e8ZQNkYLCuO+Bd/aw2upaR/anh+5ma5ku4I7DxA2pzeUzcK28ZVY08qMEcHaSQCckA9Woryj9oHF9oNrpVt4o0HQ753MyDUtT+wsMAhZUcZb5W42gYO45Ixg9r4C1PTtQ8MWEWmanpmomzt4redtPvBdRpIqAFd45P1IBI5wKAOiooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzzWX0+++I+qWWvaxdWVpbaXZS20UOrzWSl5JboSMRHIm44jjHOcADGMnOr4Qi06DX9Ui0bVLq+thbW7ss2qS3wRy82SDI7lcgDgEZwPQV5d8Vrbw7J8amuPGl2NP0OLw5Gs1yJJ4ml3S3WbbdGQuJEEhKHLt5eE/irpPg3ZQ2njnxw8Phy28NLMli8enQwtGwhHniOV/8AlnufBJWLhcbWJcNQBrWVr4evWvZtY8QXsV79uu1eNPEV1bhAtxIqqI1mULhQowABVj4NXsl5oGsK15PeQW2t39rbSz3D3DeSkzBB5jlmYY7kmvIfEej+CL5tUtZtNto4JfE1wPEHiS4tHcWTvPIyQxzDARj+6UtkxRh/nBZgD6P+zgNMHgXUB4f/AOQN/bV99h+//qPNPl/f+b7uPvc+vNAHqlFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHBarfz33xhsfDsk9zHpy6DPfukFw8W+X7RFGpJQhuBu74+anwNPp/xbsNKt7q9bTptCubl4Z7p5lMqXECq3zkkEK7Dr3qhLNu/aQtodxynhOV8beBm8jHXv93p/jV26ZT8dtMUD5h4buyTgdDdW2Pfsf8AOaANnTtMh1SC4uLy41EytdXEf7q/niUKszqoCo4AwABwKteHg0dxrFt5kzw294Ei82RpGCmCJyNzEk/MzdT3p/hc7tNmIIP+m3g4/wCvmSjRRjUtf971f/SaCgDWooooAKKKKACiiigAooooAKKKKACiiigAooooA4f4kWFjq2teB9O1Wxtr6yn1iRpIbmNZI222F2QCjZzzgjjgj6Vm+IPBvhfSPFPgWfSvDmjWMzay6mS1sIo2IFjdsASq5wGVW9ioPbNavjaQjxx8PIszYbU7lsBMx8WFyPmbs3PA7jd6VZ8alh4h8CbQCf7ak4Jxx/Z95mgDMvtI8GX/AIl1ubxVYeHrm9E8aI2pQwPIIxBGQAXGduS3tnPvT/BGnaDp/jjxAPC0GlW+nvp1hui02ONI/MEt3liE43EFR64A9q89+IsPhm6+JupJ490UTaPEbV7OeHTZpJ768aPatmJ4/vDBVxBj5idxICkHqPgnYGy1jxc76DBoElxPEzWEFm1tHEFMqIFydsnyIpMkeEZi20HBZgD1aiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiivOde+JX/CP622nX1gt232oqXtJR+6gMttErMDyzb7pQQMfdb0oA9GorzaH4uaPvRbyL7G39rf2XMs0oU24InKzOxAQxsLdiGRmBB65BFRaN8TnvtJ1LV2sGaziiSe2tolzM4e1sZlVmLYB3XbAnGMAHjByAenUV5J4q+L0dj4Q1+6021aPXtLmkhMFzbTS2zGK58lv3ygKAcNjcykcEjHXd0v4hpqGn291FZL5l1crZQQ+cpUy/aLiFj5q5BT/R2YEKePXPAB31FeOW3xpi1e+0yDRrGKKOaPzbh7meN3GdPluwEiV95AKxqXYBc71HIyNbxH8W7TQ9Qnt5dGvJkE1xbW7pLGnmywvAjFt5VY491wPnLcBGYgDGQD02isTwbr6eJvD8WpxweQHmngKCVZAGimeIkMvDAlCQR2IqjqWk+INa1ULdaqNK0OIj/R9NYm4uiHz+8mZQY0KgArGA2Sf3lAFjXPFml6beSaYl2J9bMLSx2FtE1zOBjhmjTkLkjliq8/eHWuK8EXnxM8SeI71vE8UXhrQtPuSIEt7WP7RqADHCvukmVVwBuKdc4VuCR6FoPh/StAimTSLKK3M7mSeUZaWdySS8kjZaRuT8zEmtSgDxbx1cXOmfGmTVoNEv8AXltdEtEisbXewFy890IpnUIygLh13scoJGKq3OOh+Gcerr4w8VSa9K11czwWcq3XlzwoULXGIlhlA8sR8rlc7xhm+dmrjvisNXb4uhNI8T6xoMculWcU/wDZujzag0y+ZesCfLU7CNhA7nexHCmtf4DXGsTaxro1zX9S1uR9O064SW+0ySwaLe11lFVwC6jaDvHBzx0NAHP6pr+t3PnbdDmu9K0vxDehdGtWlEusgXMwaXcsZQpG7FvJY/OY2LMNqhu5+A88914a124u7cW1zL4g1GSWAMW8tjOSVyQpODxkgH2HSvK/Emo+J7TUNTfTPHPiPTrdtQ1D/RI/DUtzFGRfsgEcwTaykODkE4IxnLAD079nrz/+EM1MXd5Ne3A1u/ElxNbm3eVvOOXaI8xknJKEAqSR2oA9PooooAKKKKACiiigAooooAKKKKACiiigAooooA8xZif2molwNo8IPz3z9tXj+X51enz/AML704sAD/wjV10Of+XuCuI+Ot1qegfELRtY0HV5dHu7nRb2Ga5TT2vg0cDxyhWjUNtGXOZNvygnn0pfB/X9W174yn+29Sl1Ga00CWJZ5dJfT2YM9nKSVbrzJjIA4UHGGBIB7d4YAGmzY/5/bz/0pkpdFz/aWvZ/5/Vx/wCA8NfP2r+JPF6+NtV07SfGGp6Rpw8QT2EdvbeFzqCxqbd7kuJFQl3L5BjzuAbf90GvRP2c9d1TxN8PZNW125a51K4vpRLM8KxFtoVBlEAAO1QOPTvQB6lRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5748C/8AC0fhkSspcXd+Aw+4B9ikyDz16Y47NyO+x4y/5GPwJ/2GZP8A03XlcZ+0dBM+i+HJLGbU4L9dSkSGbS7eSe7TNlck+Usbo5Pyj+ML3YFQRXEeDJtRf4n+DFvrnxEUGo3yiLVLLUYFcLaTbZFNzczIeGKgAK4w2fUgHXeJ7vWNI+J2oajoemnXp5WhtFtJHuBFpjGAH7WQiOhDDcjHaJMIFUkOwHQ/Cyxu7DW/E6aheXF/PK8EzXdxBcQvMW8wk+XLwirnYqxkoFQc7twHD/E651KHx9dpZS+I44TPFuXTrDUZ45T9lc43W11Eu4FUyu0N8yHcVDBeo+BM1zcW+pS3kmqyyNBaESalb3UMjgq5yBcTSsRkkblIQkNtXuwB6rRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABUN7PbW1u017LDFAhBZ5mCqpyMZJ464/GpqxvFWif27YQwLcC3khnSdHaBJkOMgqyOCCCpYdiM5BBAoArS+LPDVpo7avLqVlDaTWI1dmJxJJb7VxNs++wwUHQnJUdcCrsesaHdyXcUeo6bM8ESy3KLOjGON1BVnGeFZcEE8EV5lqPwF0S+IaTVL5X/s4WBIjiPIto7cOMqdnyxKSFwSSRnb8tas3wi0+ey1K2mv5GXUJo7iUiBBhw9s7hQOFRvskY2gcZOScLgA7ay8RaDdKn2LWNLmVzHt8m6jYMZS2zGDzvKtj1IOM4NSnV9ONxZWl3c29ve3u5ra0uJUWWXZySqZy2AM8dO+K8/1b4NaTfpdCO8ktZZp7idZobeMNGZbq3uAF4/hNvtHs7VoaN8LdO0u3kSK+uTcFUWK6EaCWArdXFxuQkHBJuWHORhV4PNAHXrrmjPpyXiapp7WDy/Z1nFwhjaTds8sNnBbd8uOueKor4h8PaxbXNquqxRiW8m0psTtaytcplXjjbKtvGDgoc8ZB71y+ifCPSdK8P6npAvLm5hvBcYmuERpYmlhhi8wNjBkHkht2Bksanf4X2R1S0u01K6jW21ifWVVYot5klkSVo/MK7lTemCFIDKcNkgMADrvDGg2HhnRLfSdIjkjs4C5USStIxZ3LsxZiSSWZj171qUVx8nglLDVRqPhPUJtDlZna4s0BlsbgsBy1uWCo2VB3RlGOW3E5oA7CiuLtfGVzpMdwnj/AE+LQ/JeJRqMMrT6fMHGN3nFVMWHypEoUZK4Zs10GgeINK8QwTz6JfwX0MEvku8LZUNgNwe4KspBHBBBBINAHgHx7jvz8WLV7PyWjSxsXJmXUyqOJbzyyPsXOcgkbvmzjbxvrb/Zl8z7dr3nJbLnTdMaNrc3xR4ybooR9s+bG3GNmU7g9QNnxfbw3XxdvoZdG8S6nN/Y1lJC2iagbPyMS3ikyN9oiBJDYXOeNw4yc3PgxdaNfalrU/h/TNcsbOO3trVW1O8a6EgiluUxE5mlGxWDD5SB6ZzmgDwf4gRhfEGuXMUViircXwlnnOsjaF1ViuTEDFs39AhC+YWJO/aK9g+BFvqGt/B66XSddbTbubUb14L6ziM6AmViCFuVZ3Qk5+bDkdWDZNY8s3hubXNR0m88O+OdV1I3l/deVY6oyxyRG+k3OkS3SBYxIqj7q5ZQeTzXdfATyz4R1RoobyDdrmoEw3shknjP2hsLIxLEuBgElmJOTk5oApfDrwL4x0mTW38U+MtQuL26ujJFeWjwyCSHnapSaFvKKks2xDsG/A6V6D4gtL+48L6lZ6VeNFqklnLFbXT4BSYoQkhwMZDYPA/CtWigDxjUtL1TwdojWXw30GPw9d6leJZWdtPeCX7S4tZQ0pQ744yixrLu3FpfKIcZIDbC6V44l13U7a/1C+vdE+32d1ZystrbPEsd0rPEPLyZIzHyWbY37sKAd5r0+igDwW00v4yPdzXOtNpl5d2r3RsZI7e0xExsp1Ro2b5grTGIcgNgnd8pIHU+I7L4kpew2ug6tL9gS7fffS2tpPO8IhtymUzEuDJ9pU4w33cDGCPUaKAPPoLHx7c6rcvrd5p32OKe0a1t9NhTypE+1EymXzgz71iVCCpUZY4yQDWRqmi+ONVu4HluryGfT76S4guVNmqZ+zXsYaCPYxCEywL+9Zm5bgbdzesUUAeU/Hzw/wCLvFPgf+yfDUUc4uotl3B5kSMZBJEyklxjYAsoO0htzRkcBqu2Vr8Q501CK+v3tneeNVmhS2YIhvSWa3yp+UWx2nzlLbgNoJyW9JooA8BhT46R6bepLK0l2yWzW8o+wNsfyJfOUphQV80x87sqACN/KHfttJ+I9l4sf7I1tbaC2oyXTJZxWqecr6hFnzcruJNq0zEjDFl5YnAPr9FAHP8AivTvEV+bX/hG/EFto+zd53nacLvzc424/eJtxhvXOe2K4Hwt4V+K9pr962p+ONPOimd5IY208TSPmQs3BIMYPO0eY4UEDaMYHr1FAHzz+1ROYtU0AxgSkaTq/mQmW5T5DHDyfs4LYPOQ+IyAQxA5rmv2bJ5ZvjfrAneMyDRSdqvduQuLIKf9Jw+MAY+hx8gSu8+I3h9fHnxxs/DF/qWqadp9t4YmvBJpkwhlkMtwInjdiGBQqoyuOal8E+C4fBnxyjgg1nXNW+1eHbiVpNWuhO6kXFugCkKMDCqPwHpQB4348N4nxM157f7EsK+Jid0/9qjEotWMZb7L8nHzbdn77dnP7vdXs/7JLK/wghZERFN9cEImcKNw4GcnH1otfhXYeKr/AFLX18UeLdMnm1i8l8nTNRWGGOaOWS28xF2EhzGm0nOcEjpxXYfCXw/Y+FtF1PRtKvbi/tbXUZQLi4kWSRnZUZwzAAFg7MDx255oA7eiiigAooooAKKKKACiiigAooooAKKKKACiiigDxP8Aaqj+0eEtDtmt0uEa/lkKyLK6kpZ3BAKwkSfiPlXGW+XIPn/w28OaZo3xd8Hz6dZWlvI17fW7GDTNUtSVS0lxlrt2TPXKL8y4HJyQPVfinFFqPxb+Fuj6hDFd6Vdvqkk9pOgkilZLX5CynION7Yz61pa/4d0TSPG/gS40nR9OsbiXVbgSS2tqkTODYXRO4qAT0H5UAebfFvwtY658TppdT0+2miaWGHzm0bU76TAtZGK5tnVMA7CEB3ncWOFVQ3T/ALNWkJo2mavDFZ21pHMLadRBbXkAkDI3zst18xJIIyhKEAY5yK0Nan0S48deIrK78CN4l1K1Fvdvcm3sisETRBUUyTyIRykpAGepPrWl8ItR0TVm1G+8MaB/YemzQ25SIQQRLMQ0o8xfJZlYcBc5z8mOwoA9FooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAA8ivPtC+Enhnw1r8Wr+Exf6DcbibiOzuC0V2hIPlyJKHAXg42bSMnBHGPQaKAPEfHj6SnxxMniGaS00qLQreWW5ijkDSOJLsLa+bGwYCQMX8oAmUwqOcFW1fg8u7xx42uH8Nf8IxLPFYudP8Asyx5Um4KzF1Yq7Pk7toG0qVOWVmNLxLb+J9Q+NWq3fgmLQHvdM0ezgkbWJblVRpJLlgUWL5W+UsCWGRkYIywOl8HvDniXRPE/iy68aSaPcavqUdpPJdac8x80Bp1UOHAVdqhUARQNqjOTkkA4jX9R0Z7wolje6fHb6/cw6n4uitJWex3Xk5FtDPkSJv5RnTMaedggmTj0L4Bx20Pg/UotOia3sE1vUFtrd42jaCIXDBUZGAZSB/CeR35rAl0P4g6pr9rdxWvg680LTNWvbm1tr24ukkZ/tMmyVtqMgdBnbwwBJbGdpXoPgR9t/4RfWv7W+yf2n/b+o/a/sm/yvO+0Nv2buduc4z2xnnNAHpFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlyx5/afeTcPl8HKu3uc3p5/T9a0rn/kvunf9izc/wDpVBVKPzP+GlZ8bvK/4RGPdxxn7Y+Ofz/Wrtz/AMl907/sWbn/ANKoKANn4dlDoF35edv9r6p1x1+33Genvmrvh+QS32vMAQBf7eSD0giHYn0/xweKofDkk+H7ss5Y/wBsaqMn/sIXHH4dKveHWLXuvkq6/wDEwxhzz/qYuep4PUe3YdAAbVFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHlXxE/5Lt8I/8AuL/+kq10njVv+Kw+H6566rOcf9uF1/jXN/ET/ku3wj/7i/8A6SrXQ+Nif+E2+Hgy2P7UueO3/Hhc/wCfzoA888bNo8fxU1WfxXolxeaTHAgt1ttMM7anc7IWWzZw2ZMbRIkDLtJ3OSAldH8F5Z7nxB44ubzSptIvJ76OSeyksktxFJtYHayuwmBxu87jeWJCgYrN1jRvG1x8UNf1vwR/wizC32WBOsT3TPE7QQSSFI4/kUsvk5JBYhBzjitb4LeGtd8M3niOPxVJps2rXzwXk09hLK6zEh1Lt5mMOShJCgIONoA4AB6hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHAeFST8ZPHwJJAstKA9uLmr2u+FdK8S+K7g6st4Tb2UAjNtfT23DSSk58p13covXOMcVS8LqV+Mfjwkj5rHSiMH2uR/Suptv+Rq1H/rytv/Q56AK/gmzh07w8llaKy29tcXMMQZ2chVnkABZiSTgdSST3rnfg4Mab4o56+JtU/D/SWrqfDGf7Ml3dftl3n/wIkrl/g6pGm+Jycc+JdUIwf+nlqAO+ooooAKKKKACiiigAooooAKKKKACiiigAooooA88gXP7Ql8+Rx4XtxjPPN3N7e3r+B7ZfjXw8niX4yWFm+parpu3w7cOtxpl41tMD9oiA5XqOc4ORkDI6Vv2cQPxu1aUj5l8O2Sg47G5uj1/AU6WFm+NVtOBHtTw/KhJzuy1zGRjtj5Tn8PegB/witfsPgoWRuLm6+y6lqVv591J5ksuy+nXe7cbmOMk9yTVvwJKZj4jZmLEaxcJk+ihQB+GKb8NP+RdvP+wzq3/pxuKd4EBB8Rgu7/8AE4uDlk2novGPQdAe4Ge9AHUUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVmza/o8MrxTatp8ciMVZGuUBUjqCM8GgDzz4if8l2+Ef/cX/wDSVa1/iLBbXvjT4eWV9DFcW8upXLtBMgdG22U5BKng4JGKxvH0kc3xw+EEsLrJE66syupyGBtVwQe4rb8c4/4WL8NvX7fef+kM1AF7wJbW1nq/jS1sbWC1t4tYjVY4UCLzYWh6Dgda2bb/AJGrUf8Arytv/Q56yvBv/Ix+O/8AsNR/+m6zrSSRIfEmqSzOscSWNszOxwFAe4ySewoA2KKy18RaKzBV1jTixOABdJz+talABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB5v+0Vqt/onwa8RX+kXk9lexrAqTwOUdN1xGrYYcg7WIyPWsTxV8FPAmmeH9U1bTNClXVrG0lubSY6hcMySohZCN8hXhgDzx61o/tPqH+BficM6oMW5y2ccXMRxwDyen484HNdV8VBu+GHjBcZzo94Mf9sHoA434S+KdH8YfEvx5qvhy8+2WDWumRiXynj+ZRcZGHAP6V6Lbf8AI1aj/wBeVt/6HPXK+FP+Sy+P/wDry0r+VzXVW3/I1aj/ANeVt/6HPQBD4NJbQgS0bE3NyS0Ywp/fycgeleQ6Pc6N4k+0eCdWsNSktL3xZqiXZ8meK3uAr3cwQTptBYFIyV3Z49jj2Hwlu/sdt+zf9qus7BgZ+0SdPauC8GuW/s0NJIoXxnrAUdnH+nnHHbknnuPpQBmar8MvBngfxD4P1Xw5p8mm6k+tR26SLdzyeYrxy70w7kAFQST7Y717RXCfFKZ477wKiMQsviOBGAOMjyJ2wfXkCu7oAKKKKACiiigAooooAKKKKACiiigDn/iFqF1pHgDxNqWny+Te2emXNxBJtDbJEiZlOCCDggcEYrk9d+HVvY6HqV1D4n8aebBaySJu1+5IDKhIP3vUV0XxY/5JZ4y/7At7/wCiHrV8Wf8AIq6z/wBeU3/oBoA4X4WeJ7DxZ4t1TUdM1KLUANB0mO5liGAJt94zKwwMN8wyMDGe1dC0ZPxaSXnC6Gy/nOD/AErP8EJ5fjG7RhCHXw1o4xEu1RiS9ztGAQPbA7Vtorn4iTOFYoNKQFhjAJmfAPfPB/I+1AEPw3GPD13j/oM6r/6cLivNtH1/RtR8Uaj4Cudbv7TXLnxHeXDw2UtxBKYAkkq4mUAAYVcgN045616b8PSp0G6KDA/tbUx+P2+fP61yfw7kaR7otgn/AITHVF49ALgD+VAGlceDINCey1C01zxPNNFeWy7LrWriaJ1eZUYMjMVYYY9R2Fd/WV4m/wCQdD/1+2n/AKUR1q0AFFFFABRRRQAUUUUAFFFFABRRRQAV4v8As7eDfD9x8HfDl1qXh/Sbi+nilaSeezjkkcGaQrliuSMEY9K9orzv9nkAfBfwoFkWQfZScrjH32447jofcUAclprm4+IHwihTR7qyt7LT9SSJphGqsBFEm6NVckL0xkL8rrgdQOy8d/8AJS/hp/1+33/pFLWHZ2nl+N/hSPNQbNJ1KXG0Lu3JbHGAOvzde+CTzXReM1ZviN8PSrqoW5vSQf4h9kcYHHuD26fgQC/4N/5GPx3/ANhqP/03WdcR8d7y5Hh/xdYwaXd3EVxpFsr3iPCIbfM03+sDSCQj/cRq7fwb/wAjH47/AOw1H/6brOuU+L5ZvC/j8PEm0adaBRjO8b5Oox65HfgUAa3xS8OaJB8MvF00Oj6bHLHpF26OlqgZWFu4BBxwQOM139cr8WP+SWeMv+wLe/8Aoh66qgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKy/EOsLo1pFL9jub2aaZYIbe3aNXkc5OAZHRBwD1YegySBXKn4t+EoNLXUdSvZdOtCsWXuYTw8kk8Qjwu7LBrabJGVwAQSDmgDvqK43Vfib4Q0m412C+1hY5NDEbagFglcQeYyqvKqQx3OoIXJGecYNVn+LvgRdCudZHiS0k062kiimkiR5GR5U3oCiqW5Ge3BV1OCrAAHd0VyHi/4h6F4TvtGt9Wkn8rVILq5iuYEEkSR28Qldmwc8qeNobPtVXw98VPCWtmwii1IW19e6edTjs7ldsvkDdnOMqWAVjsDFsAnGOaAO5orz2z+MngbUI9ROl62l9LYWM+oywwxOGMUOd+0sApbjhc5I56c1JdfGDwHa6Np2q3PiGGOx1FZHtXaCUNIsbMrnZs3DDIw5AycAZyMgHfUVxlr8UPBl1daJbQ6/a+frSCSwR1dDMpZlH3gNuWRlAbBLDA5IFbfhjxNo3imyuLvw9qEGoWsFw9rJLCSVEiY3AHuOQQRkEEEEgg0AbFFc9D4pjutc1jS7HTb+6n0qSOK5eMwqoZ41kUDdICflYc46/Srn9qXn/QC1L/v5b/8Ax2gDgP2ohn4F+JR6/Zepx/y9RV1vxSAb4Y+Lw3Q6PeA84/5YvXC/tI3V3e/BjX7Y6TeQea1qgkmkgCAm6ixkiQ49M4+vFdl4zvr248Ia5B/wj+oOJLC4TBltxkmNhj/WH+R+hoAzJLHxDofxE8R6zp+ipqtlqtrZxpsvEhaNoRKGDB/XzBjFbfhO41q/1XUb7WtCfRlaGCGKOS6jndyrSlj+7JAHzrjnPXgd9L+1Lv8A6AWpf9/Lf/47QdUvB/zAdTP/AG0tv/jtAHJ2+p+K9AWTTrbwRNqMEc8jJc22pW8cbq7s4wsjBhjdggjqOMjmq3hrSLywtvDTatYfZL648SahqLweakhh86O9dQWXgkK6g4zz+na/2peZ/wCQDqWP+ulv/wDHaw/EOpX51fwyU0K/2rqDlt0lvnH2S4+7+965x+GaAK3xRcpe+BlG7D+I4FOOmPJnPPtx/Ku6rzH4n39xJfeBi+jX8ZTxFCy7pYBuPkTjAxIcnBPp9ex7f+1bzft/sDU8Yzu8y2x9P9dQBr0Vlf2pef8AQB1L/v5b/wDx2mf2te8/8U9qnA/56W3P/kagDYorGOsXwcD/AIRzViCT83mWuB1/6be36j3p39rXmD/xT+qf9/Lbn/yNQBr0Vk/2reYH/Eh1Pn/ppbcf+RaDqt5/0AdTP/bS2/8AjtAGtRWK+sXyyBR4b1Zl5+YSWuO3/TbPOT+R9sy/2pd/9ALUv+/lv/8AHaANWisn+1bzdj+wNTxjOfMtvy/1tI2rXqrkeH9UY+gkts/+jqAMz4sf8ks8Zf8AYFvf/RD1q+LP+RV1n/rym/8AQDXK/FPU7t/hh4vVtD1JA2kXal3e3woML8nEpOBnsCeOAa1vFOp3beGdYU6HqKg2c3zF7fA+RvSXNAHP6c2taJ4jjvrXw5faxp93oOn23n2M9smyWF7hmGyWZTgiZTkE+nNdF4en1LUPEl/fXuh32kW32SGFBeSW7vK4eQnAhkkwAGHUjOehxVy31W/FpEZPDepRybF3RJNbMFOOQD5ozj14qQateZx/wj+qD38y2/8Aj1AHGaR4l1Pw6b3S7jwV4nvHGq3rJcWcVu0Miy3EsyMGaYHGx1ySAAcg8jFN8AadqOn29vJq2nzWEt/4mv7+OCZkZ0imjuHTdsZgDg8jJwa7J9ZvlOB4b1Z+QMiS19evM341n6zql3/aOhf8SLUv+P1v+Wlv/wA+83/TWgDV8S/8g6H/AK/bT/0ojrVrlfEep3ZsIQdC1JR9stTkvb4/4+I+P9b+H41qDVbwgH+wdTB9PMtuP/ItAGtRWSdVvACRoOpn2Elt/wDHaX+1Lz/oA6l/38t//jtAGrRWV/al5/0AdS/7+W//AMdoOqXn/QB1M/8AbS3/APjtAGrRWV/al5/0AdS/7+W//wAdo/tS7/6AWpf9/Lf/AOO0AatFZL6reKhI8P6mxH8Iktsn85qX+1Lv/oBal/38t/8A47QBq0Vlf2peZ/5AOpf9/Lf/AOO0n9q3mSP7B1P6+Zbf/HaANauF+BcE9t8H/CKXUkUkh0+KQGPOAjDcg5J5ClQe2QcYHFdKNUvD/wAwHU/+/lv/APHa5P4SX93D8LvCMY0bVJQNKtsSGS3+YeUuCMyg7fTIBxjODQA+10TUrm48C65pb2bJp2ly288FwzoZFmjgIKsoOCDEOoIIPQHBGtdaPqWp+J9C1O9TT7aLS2nfajm4aQyRlMKWRfLIzncMkjK4wxNJ4V1O7HhfRwND1EgWcPIe35+Qf9Na0v7Vvt3/ACANR2+vm2+f/Rv0oAoWOm6tpWta/c2kNjcwapepeAy3LxNHi2gh24EbA8wk5z/F04rlviNp+oL4M8aX2s/YxFdxW8cUETvIqRowyGZlGclmPCgY9Tknt11W/wCN3h/UBzzia3PHP/TT6f5HPP8AxDu7q88IXtu+h6gBK8KHdNbqDmVOM+YcemcUAXviv/yS3xjjr/Y151/64PXVVxPxEu7288BeJLUaBqBWfTbqJt09umA0Ljr5hx27HHXnod86pe4ONB1Hvj97b/8Ax2gDXorJGqXmOdB1If8AbS3/APjtUNb8UvounyX2oaHqaWkbRqzh7ckF3CDjzemWHTn29QDpaKKKACiiigAooooAKKKKACiiigAooooAyvEWg2XiC3tINRUvDbXUd2EwrK7IcgMGBBH6+hFcz49+GGieNbSe21C41CziljtoithKsQCQedsXBUjH+kPkHI4XGMc93RQBwNx8LdIuNc1TVJtR1h7jUXt5JVM6bFMM0Uy7Rs6F4QcEkDc+3buNYcPwG8MweFpdBi1HXUtZEjjaUXEYkIRrggf6vaci6kBBGMBcYIyfWqKAOX1TwPpOqDSFvvPlj0yBbeKMsu11E1tMN4xyd1pH6AgsMcjHN6X8FvDGl64uqWM2qRzi0a0aMXI8uTKPGJGXby6pIVBPGMHGck+mUUAcP4w+GWh+LZrqXVZb8NcLOh8icR7RLFDG2MDt9njIByM5zlSVqnZ/CHw9aWs8UFxqizXGn3FjPd/aB587TSLJJcPJty025FO48YGMYwK9EooA80sPg1oFpa2cD3+tXSW0UEH+kXCEypDdvdKHwg3Au5U/7IGMEbq6D4d+A9F8AaZeWHh9Zxb3Vy1y3nuHZSQFCBsA7VCgAHJ65JJJrq6KAOL8TfDvT9c1iTU4tW1/RrubZ9oOkai9qLnaMKZAvDHbhd3XAAzwKzX+FNu08kg8ZePFRukY1+banB6Z57jqT0Hvn0aigD57+Nnw+h8O/DPVNUbxV411EW81sxt7zXGMbhrmEYO5SoI5KsQcE5OcDHlf9ra3caTa3l3N8QodH1G4WxivJPG0csUjO5Q7FEAMoBVshew5IyDX0d+0bt/4U/rPmI8iefZbkjlWJmH2yHgOwKqf9oggdSDXF+JvA3jye3kvr660tLeG1T7XGupyTxzbJ/PllEL2oRZH2j/VmPDopBUZWgDr7n4QpNKXj8ffESBSPuR66xA/76Un9aa/wfVlhC/EH4ioUXDEa62ZDknLZXrggcYGAO+SfUaKAPKx8HAAQfiL8SDnudc6f+OVzXjv4dL4b06z1KTxx8SLyCGd3mC69GsiRiCVmdDIEQEBeSWHylhySBXvNcr4/juJ49EtrC5a2vp78rBIkwiYOLeZ+GKSDop4KMCMgjFAHzfbLp/ie78KxaZ4k+KYg1LVIo4rnVNagwF2SEyQqjMxYFdu4LtUhlJDDafXr34T21jb+fe/E/4h20O5U8ybxAEXczBVGSmMliAB3JArntW8L6vonivwTd6l5UFo+s2FpBZW2ovPbweXa3ORGjQoVXJOAWbHIGAcDo/FPwek1jxhpOtxeK9be1s71LttLvrp54AV2gGE5BiYDcQTuJJHI5oAl/4U3/1Uf4k/+Dz/AOwriPFPh6z0Lx74X8Mr4++It5LrEs0M0kXiQbrJkRGTfH5ZJ3eYOpXA556V7np2gR2N5HcpqGqzMoYFLi8eRGzjkqTjIxxXivxP13W7XxF43vbPwn4fv9J0y3+xXt7e6erF4jaRzrG0vnB3/eugKCPAXad2egBR1fR9N0+K9ZPGvxcna3tr+5yusKI2WzeaOf5tvGHiReef38WAfm2tksNGXxXf+HLPxt8WtS1m2CbLa11uJxPuJVyj5CgxMCrhyuCp4YA1uXeu+G9Kv9EtpPh7pCXwd9O2QzQqsStcXVuywbkXzY8iZ5OFCrKGYcnFLSviV4d057bXx8Pbaz166adrk2YR7lj9oihZI5BGpnmbzkkKggFG3biTigDL0iy0vVNatNKi8XfGaO/nkCtEdURzBGUgdZpNm7bGRcxc8lcncFAJp2jadp2spqsmn+LfjI0FjaPeJPJq8ax3KiOKRRGeTl0niYbguA3zbTxXRa34q03TYtDutY8AabdakqDVLS4tcNFCFtwVLSGLKTssKJHGNwZkjG/5QRvaf4h0yC5t9KHhCzTTdWurnR7NYSHM628i20wnjaMKiiGAsAWbKQbTghVIB55b2Fjc27G18TfGue6SJpJLNNVi85GFxLB5ZBOC5aCZgqk/LGx68GWOy8PyT6jFF8QPi47WgUR7dT/4+5CYF8qIbc7911br821cygglQxD7D4geGpE0nwzdeBdBlSfTNIu7jaohtYvPkjOGRoiAqPdlxguDvbJDFhWvr3jLw5oGnyQ6h4Os7m3l08PdMsaQPdCS1SV5IodpBg/cRRs+4YkVFwcA0Aafhr4aW/iHw/p2r2fxD+KEVvewJOiT6zskUMM4YbOo9iR6EjmrGq/C2x0iwlvtV+KfxAsbKLHmXFz4hWKNMkAZZkAGSQPqRXc+DXttU8HfZo9Oj0m3jkutOa1sZmRYvJmkgbypECMAShIYBSMg8GsXxZ8MrPWPDeo6bp+q63a3F3C0AmutZ1C6jRW4bMRuAH+UnAbjOMgjIIBxHj34WR2nw78RalD8QfHt9HDpVzcLFPrXmwTgQswVxs+ZG6EZ5BrzW/1vw/c6Rq7Wnij4yXAs7YPcNLq1ubeISDEfmPv2lXLAAKTuzxmvX9S+GWgfD74PeL7fQpNUbGkX7u1xfSssrNA43NEpEW4AKuQgOFHfmuF1Dw7480/wounQeHdd07T7GIlruz1izWe5gS1MSx3KghGK4GHAJ8tEQgsocAHo/wDwpv8A6qP8Sf8Awef/AGFH/Cm/+qj/ABJ/8Hn/ANhXqtFAHlX/AApv/qo/xJ/8Hn/2FYHi/wCGT6LBp9zH40+J+ps10IxBb60hl5jf5kLhVXGOSWAC7q90rgPjTour+IvDFnpPhzUm0vVLm+QRXayvGY1CSM+GTnJRWGO+cEgEmgDwrSbnSPFF9p9hpPin4uMk+rR6c13da1A1ukgzJw0bPuOIyVI4yM5OK9f/AOFN/wDVR/iT/wCDz/7CuY1DwN4msfGHg7VbiKzi0+31sy362V47rdSSApHdzReWiCbAVHZc7mckBQSK98oA8q/4U3/1Uf4k/wDg8/8AsKP+FN/9VH+JP/g8/wDsK9VooA8r/wCFN8f8lG+JH/g8/wDsKT/hTf8A1Uf4k/8Ag8/+wr1WigDyxfg6FdWPxE+I7AEEqddOD9cJmiT4Oh5GZfiJ8R0BJIVddOF9hlCfzr1OigDyr/hTf/VR/iT/AODz/wCwo/4U3/1Uf4k/+Dz/AOwr1WigDyr/AIU3/wBVH+JP/g8/+wo/4U3/ANVH+JP/AIPP/sK9VooA8q/4U3/1Uf4k/wDg8/8AsK+ffDOo3S+FvDaR3nxO+03ttstLSw8TQIsvlFkbyYdpkEYCfKNvYqCcZP2vXzb8Ivh94vg+HGkNFqTyW2owNeqBq727WvmQgQtARbuUYKSrclcOflYhSADqPCPwne/8JaNeTeO/iLZy3NlBM1umt4EJaMEoBs6DOPwrXHwdAQqfiJ8RySQdx105HXj7nf8ApXXfDG3ltPht4Ttrhdk0Ok2kbrkHDCFARkcdRXS0AeW/8KdHl7f+Fh/EfdnO/wDt05+n3MfpXM/Ev4dL4a8DalrR8cfEK7GnRrO0D66QJtsgPUocN6EDggHB7+8Vx3xgtLnUPhvrdlYRtJeXEaQworqhZ2kUKAzcKckcngd6APnzxNdWGkrf6dqGs/FptSexubiOyn8RWkoMaxE75ESXcFAO/GDlVJwyg16//wAKb/6qP8Sf/B5/9hXM+IPCvi2Pwx4ktbu3u7qOSG+aO8n1WNmgjkkMnlxnZvaFkCrIjn5tilQh5HvdAHlY+Df/AFUb4k/+Dz/7CkHwWtJZYP7R8bePNStY5o5mtL3V/NhlKOHAddnIyo9D6EGvVaKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPOf2hVR/hNqqyuiRtc2IZnkEagfbIcksQQo9yMCrfiPx54NvvD2qWlr4r8PXM9xayxRwx6jC7SMyEBQobJJJxjvWP+1AwX4F+Jyyhhi2GCcc/aYsH8OtfCnhP/katG/6/Yf/AEMUAfp9RWdoetWGu2stxpcxliinktpN0bRsksbFXUqwBBBB7Vo0AFc34rZl17wYFAw2rSBs+n2G7/riukrwb9rXVbK5+FupWMMjSXNpf2qTARsVjdgzhS+Nu7bhiM5AZScb1yAd18V/+Qj8Pv8AsZoP/Se4rv6/Ov4A/wDJZfCf/X6P5GvrTx58ZZ/DviLStItfCGuyC/vYrRb26tzFC4Z1H7kdZHwWwjFDnHagD2CiuW8P+LpdX1CO1l8L+I9MDgnzr62jWMYBOCVkbHT9R+GR8QPiHJ4N8WaBptzp1vJpupw3NxLfvdOrW0dsnmzMYliYtiPlcH5jkHaOSAegV5F8TvFs3hf4n+HpppIEtBYvHHHHYyz3d00tzCkkMQ3ojZxEQELyKVyUKHntm8e+GhYJfRapHcWkis0c1ujSq4WYQfKVBBzKQi4+8Txkc1h6v8XfCVgL5G1BY7m2tZrnF7DNbpmOVodpJjL/AOtVk+VGI2ngnAIBymo/GnUtC1tLLWfDkf2WeS38i5F+sKCB4WlMkkkqpGHYKQiZCs0cq7/kyeo8FeLrbxl8QvE9jc6PHb3nhOY2sF0t6LhZFmLBm2qAqNiFRgksu5l4+YF2sfGbwLpFol1fawyRvII0/wBFmDSfvHjZlBXLKrRvuIyBjHVlB2PEfjW00HW7nT72Boli0mbVVuZN/lOsWd6/IrH5QAWODjcuASQKAOsorhPEXxX8JaCt+L3UJDLZeZ5sawOufLkWOQIzAIxVnXIDE+gNW7r4leFLTS9U1C71KS3tNM8o3TS2k6MiynEbBSm5lY9GUEHB54NAHYUVR0/VbTUNEttXspHnsLm3W6hdImLPGy7lITG7JBHGM9sZrDvfGlkmnXM1paau06RM8a3GjX0SFghYBm8glRxyQCR6E4BAGfF1gnwq8Yk7sf2Pdj5RnrCwrY8Wf8irrP8A15Tf+gGvKP8AhammfEj4O+Np9O0zVrNodIu4pDcW5MPmfZnZlWVcqccfe2nleORXwvQB+qlFZWj65b6nqGp2AjkgvtOlCTQSlS2xsmOUbSfkcAkd+CCAQQNWgArB8Rsy6x4WCqWDak4YgZ2j7HcnJ9OQB+Nb1eB/tPeI4774Ya1HpZuANO1G3ga8jdfLaXLCSNGVs7kxhsgYJxyQcAHr3jBZTa6aYz8o1K1Mn+75q/121vV+enwJv7y5+MHhOO4uriaP7crbZJCwztYZwT1wTX6F0AFFFFABRRRQAUUUUAFFFFABRRRQAGvL/hl4+8HWfw28J2t54s8PwXMGk2kcsUuowo8brCgKsC2QQQQQa9Qr8q6AP068EyLN4M0CSMoyPp9uymNtykGNehHUe9bVed/BjXBN4R8P6LdQC1ubfQ7Ce23Sqxu7c20QaVVHI2yFkIPTCno4r0SgArE8ZXENnoRubueO3t4bm2kkmlYKkaieMlmJ4AAGSTW3XkHxq1/+1/AHjqz0z7LcaXp+ntDd3aTbit5vX9wAOMooJfJBBdAP4sAHX+I/Fvhy68O65BbeINImmjt5IXjjvY2ZXYFVQgNkMWIAHUk4rsK/MHwn/wAjVo3/AF+w/wDoYr9PqACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDz3492EOqfDDUNPu3dLa7u7CCVkOGCvewKSDg84J7H6GvPbz9mrwdoVtPrFnqOvtc2CNdxJJPCULxjcAwEQJGQM8g+9enfGKLz/A5hyB5mp6YmSM4zf24rofFn/Iq6z/15Tf+gGgDm/FjHwdq03i9JLs6NIiprVnBD5oAGFW9AHzAxqAr4BzGAcfuxXbxusiK8bKyMAyspyCPUU6vPLXUbb4aK+k6pcXk2iP82jHyTI4Yt/x4oVOXcEjyk2glPlG7yyaAN7xtrd3p0Vppmi28k+u6qzwWZCgx2+Fy1xLkgeXHkEjqxKqBlq4r4gfD/SLzw34b8GPNfJp+q6y7XtysoNzNJ9mubhpSxUruaSME/LjkgAcY7DwXpF2JZ/EXiGDyfEWpRJHNBvWRbKFWdo7dGUc7d5LNzuYk8DaqnjL/AJGPwJ/2GZP/AE3XlAHjU/wU8OfDjxh4G1fQ73V57mbXYrRlvJY2QI0MzEgLGpzlB39a+jZY0ljeOVFeNwVZWGQwPUEVwXxX/wCQj8Pv+xmg/wDSe4rv6ACsrWNBsdUvLS+mj8vU7JJksr1ApltTKmx2TcCucY+8COOQa1aKAOd0nwboum+GrHQltftFlZ2i2SGc7mZBtOSRgbiyhsgDkZGMCqy/DvwmlhHYpodqtlGjxpbruEahxh8KDgFhwT1PcmurooA5qXwL4YlsJLKTRLNraQYZSnbdKxweoybifOOolcdCRV3WfDOja3cx3Gq6dBdTRo0StICcIysjL9CsjgjuGNbFFAHMXngDwreXlxdz6FZfarhJY5pkTY8iykmRSVwSGLNkd9zf3jme08G+H7MXQtNMhgNyVaVo2ZSSrBgQQcqcqpyMcqPQV0FFAFfTrK307T7axsYlgtLaJYYYl6IigBVHsAAKfd20F5aTWt5DFPbTI0csUqBkkQjBVgeCCCQQalooA434wv8AZvhJ4v8AKVFA0m5jAIwADEy8fgeK8i8Q/sweDdP0DU7221PxC09tbSzRiS4h2llQkA/uhxketeq/HSQxfB/xcwPXT5F/MY/rXQeNsf8ACG69nbj7BcZ3dP8AVt1oAy/Guj3Md5a+KPDtnBN4g09DE6n5WvLMndJbZ/vEgMmeA4HIVnB6TS7+21TTra+spFltriMSRupzkEVarzwmT4eazNDYaTqN54a1WUywx2p802l9I/MSqxxHFKTuBJWNH3ZIEg2gG14z1HUXlttA8OOkesX6M7XTEYsbdSokmweS/wA21BgguQSNqtXNfEHwLoF74S8MeBI7ebT9Cur8WyLYkK0QS3nnzuYNklouSQSSxJ5Oa6fwJoEulWlzqWrJA3iTV2judUmiUBfMCBREh5PlxgbVBJ7nqxpvjFiPEXgYDvrMgP8A4L7ygDyBPgZoPw+8WeEta0TUtRmkGrwwtFevE24MsmdpCqc/d4GeASR3H0RXDfE/zPtngjy0DL/wkUHmH+6vkzc/ngfjXc0AFFFFABRRRQAUUUUAFFFFABRRRQA2RtkbOcYUE8185/Dz9nXwRq3hDw1rWonVZp73ToLqeL7SFjZ5EVz0UMAM4GD065PNfQ2oZFhc7eT5TY/I1zvwn/5JZ4N/7Atl/wCiEoAx9F8Ox3fw38GXGmRQNrOj6dayabcT/Ky/ukDxl9pKrIgKNhejZxlRjsPDuqrrWj218sLW8jgrNbuQWglU7XjbHGVYFTj0rK+F2z/hWXhHys+X/Y9ntyMHHkpisrxIT4G1i58S2Fhd3Wlag2dZgtmaR45AirFcxxE4/hEbhQMhkc8RnIBq+NtVvY4I9F8OXNrH4j1FXS2aV1/0VNrFrlkwSyrgAfKQXZFOASRU8W+F7Cb4eT+GszR2N28VrLIjDzW82dRJIWIOZGLsxYg5YknOat+C9Jv4Gvda8RJCmv6kQs0cEzSx28CM5hgUkAHaHYswUbnZj024v+Kn8vTICcc31mOfe5iH9aAPFbz9mzwboVpc6vZ3+vNc2KG7hWS4iKboxvAIEQJGQM85x3FfQVZXiz/kVdZ/68pv/QDWrQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch8VV3+E4VGcnV9KHChv+Yhb9jwfoa2vFn/Iq6z/ANeU3/oBrjf2h4YLn4SatBebjay3FikuyZITsN5CGxJJ8iHGfmb5R1PFeNeIr1I9Hs30fxF4g1HRWktTBrT6xIz6hJLcuptp4pWXcqRKcxxruXcrldrNQB9WV5g2lTfEy+GtyTahpelac7f2C6SD99MCMahs5Vl4Kxq+QyMzYAcVz/jnxN4h134tS+BdK0ye+8N+RAuqmPbGBkMzo0rDCxsksO8AFioIUAtmvbIIkggjihRY4o1CIijAUAYAHtQBz3gjxDJrFpc2WqtaReJNMcQapaW7HbFIRlXUHny5Fw6E9jg/MrAR+L1Y+IfA5UEgaxITjsP7PvOv44rm/jNeav4Yt7fxX4Y0e5v762je3vfsqRlntirbQ2QXISRlkG0HG1gcKzMMjxt4g07xl8N/Buui7u9Ptr65+0mew1FLWa0dbO5MirO+1QwKvHltqk8EqCSADpPiv/yEfh9/2M0H/pPcV39fMltLLceN/AkcGp6nqWnWOqW0UN7NrL3cWos9tLI8+xhkMuQvGAnzA53DH02eOaACiiigAorzb4u+MfEHhe506Lw5a20/m2l1dTtNatOIxE9uis2JoykYM5LuA5UDO3AYiNPimXu9ZhfSI7KLT9VOmfa7++WCDAWVmllbaTEuIflypDGSMZGTtAPTaK8ksvjEmqS/ZrTS3s7sagluy3bZ/cfbLKBpdowQGW7Yo3TMR68ik034yJfw3FxBo7Nb27XsbsksmWMP2YoQGjVgCtzubcoKLG55C8gHrlFeYwfFqzSwuNT1OyW00axRHvr9J2mjQSTzwRvDtjzNGzQghgB8sqHHXHo9hNJcWNvNPCbeaSNXeEnJjYjJXPfB4oAnooooA4D4+f8AJG/FnGf9Cb+Yro/HZK+CPEJHUadcEf8AfpqyvjKFPwm8YbkDj+yrk4IB58tsH8Ov4V4T4sOo3fh7xRDa6rrct5cpcnVbCXX5JxoSw2jTGHKko6yS4Uufl2t5WEbcwAPqevMzoKfEy4v9S1yC6tdFWF7TRMFUlKuELXy9Sj5XEZOCE3bl+fFc3491jxT4i+LEvgzRtPkvfCyW0B1TDGBBJh5PKecK21JFaFXTazFAdoG4k+3QxpDEkUKLHEihVRRgKB0AHYUAcx4K1u4uGutC1yQnxBpeEmd0Ef2yHOI7pFHG1wOccK4degBK+MCf+Eh8D4zj+2JM/wDgvvKxvjJJ4i03RLXXPB2nzX2q6c0heKOUANbsh8wFCRv+6rLgM29UwrAsDxup+LLvxH8JPh34gsLW71vWbi9ij+y28rWklzdfZ54pf3kePKUN5jlhhdqEEhSaAO2+KrMt/wCAQpIDeJYAfcfZ7g/0Fd7Xy1p188XjPwDp2m69q3iTT5Naea81C+1GW6a2mXzUjtCAfKUqqud3JkwXUhMCvqWgAooooAKKKKACiiigAooooAKKKKAK+oxvNp91FEAZHiZVycckHFeW/DD4l+ELb4YaCk2twr/Zel2UF84jkKW0hiChZHC7VJZWAyeSK9YlLCJyhAbBwSM4P0HWvkzwh5Q0nw4y6JfRPHoMmzRhqVrFba6jxwLM+8MHUsWV2RgQwhx96MoQD6O+F4A+GfhEJJ5qjSLTEnPzDyU555596zEtR458Q3b6tp8UvhjS5GhshI7Mt/OVAkmZDgbYzvRc7gTucEYU15b/AMJb4igtPhN4R8MWs1zBf6BZvqgjDoUhdYgriZMNEQsM43A8BicEha+gtJs4tP0qzsre3itobaFIY4ImLJGqqAFUkAkADAOBQByng28fQNQXwXqtzdTz20Ak0y9u9u6+tVABBZQAZYj8rDGSpjc5LHGr47u4LDw99ru5EitoLyzklkdgqxoLmIs7E8AAZJPoKqfEu01i48NG48MWwudesZ0urKMzCMGRcgqckBlZWZGBI+VmIIYCvPfDHjW98Z/Bi8utWN3pus22qx2F28gWF7dzdRFXB2naESVPmZOCpJBA5AOz8Q+PvB15oGp2tn4s8P3FzPbSxxRRajC7yOyEBVUNkkkgACu6r5c8TG0kTULjU2ksNReSNYdJGqW5R4TqMbxzpsUySHd+8YSkh/OZkbOdv1HQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAcH8b7drv4dXNtHD57zX+nRrF5Ucu8m+gAXZIQjZzjDkKehIGa8K1m4vbzRIbnULW80+QWunAeHkiiS104G/VXmCna8YaVGVUXfICuJPk2ge6fHO2e9+G93axRtLJPfafEsaxxSFy19AAAsv7tic9H+U/xcZrxC68IePIfDdiuo+F7p7+P7I2p61c3Vk8nkwyM5iXaxbYBgluZHJIZtqhCAfUlnZWtisq2VtBbrLK08ghjCB5GOWc46sTyT1JqxRRQAV558Q9Hit/7Cj0WM2lzc6xcXWy1ghczzGwuyw2ykR5fB3ZK5y3zKWLD0OvOvjZDqk+kaLHoOnJqOptfyiCJ0iba5sboK4ErBOGIOWzgZO1vukA4Gxk1S78SeFZVbMjXttJb6IJofsumFdJnZImMaloyzbyoVWAjAYjLKta/iHxH8YbTxdpyf8Izpi6BNeLF/xL7hpnPGQsspjYpGzLy/kqAGwWQ4Yct4W8PeIdH+JfhK68R6FcwfatTZ59Wvp7My3Nx/Z8qhNsBJRRsbHJ3kFnJLKE+laAMvw7c6vdWcj6/ptrp10spVIra8N0rJgYbcY0wScjGO3XnA848Y+LPE1rqPjZ9FljNn4ft3lfdGmyMf2dJMoOfmZ/OMJ4+XYSDzXrdFAHk958RfEOkXXg7TtU0exuNT1W5lt7sWbTMkhjm8pzbgIzfIv75vNCgICAzHJXg/EnxfuNa8FWK6p4d0vUhqt3PHFaWuoXCm5iU2+yCJo49zyut1sZeB8sisAS0a/SlcF8Z9QvdE8ISavo91Z2GowHylvZ4xuSNiC0ayGORY97JGuXXaTgZBKkAHJ3/xJ8R+FvDc8moaLpN3LCLW5gFk80cSWU0cxjWT9222ZntjEABs3zRDtz0LeNvE0WsWSv4bt2sNWn+x6dD9qK3EU0bnzhcttMa4jSVwEL58kjJLDHN6x8SPFei6xqk0ukyy6KqLNF51i0cifuLJ5EzuCqEE1zKQ7H/VOu8AZXf8DeLtd1/xuNM8UeFYdImttLS9hldvNkLuEEm04+RcsVweTtPXBwAcFq/xX1O70ixsb+18MTm50vS74vqkrxxpcPLZs7ypjiIfaVZWHAML/eKlR0+ufF+70QWMj6Rb3UM2n3F4YftjLcsY0uXBUGJVaMLa4dhypmTgjBf2OigDJ8Majd6npZm1K2t7a9SeaCWK3mM0alJGUbXKqTwAeVH0rzPx940+JuleHJLrTvAtrHeCWMRCDUTfs/zAsvkpCrMCobOGUgc54wfYqKAPHvF+ueMb/wCDfjE+KPCsWiXQ0iVQYb9LoSZQrJlVHycHI5bjOSMc8J4y0y6i8J6rbJNf6HZ2NvfNCIo7KKPXSdN4dY4/lwsW4MyArtT5MSE7PZvjdM0Pwi8XssgjJ02ZMn0ZSpHQ9c4/HqOo8Z8Y+HvEcWh+Ip7/AMF3MmmQRXsmnh/sUUWlQPZBD5cMdw38St8oyBkyAM520AfS1ta29qJfssEUPmyGWTy0C73PVjjqT3NTUUUAFeS/HnSdNTwpptvHfWnh1JtYNw955SCPe0E7S+YrMqP5q70Ic7XMmGzur1qvN/jbayX9j4WtE0NdeSXW0Mmns6KJVW3uHyd7KrBSofYWUPt2kgMaAPLZi/8Awn3gJJHu9H8vXp4zocxi/wBIlDTebe4iOFyduAwP+tYRnYAW+mq+XYtA8SWPj/wHfeJtGvlZdae3i1C7ltx5cbNcSRwJHFK5IKEE7shPLCJgD5vqKgAooooAKKKKACiiigAooooAKKKKAGykLE5YEqASQFJJH0HWvmHwc+sx+B/C00Grrdzz6XO9jrHkWixaFLHbKoiknLMFj8tB5iFN5ClshkYV9L6pc/Y9Mu7rj9xC8nJwPlUn+leCeAfg6dS+HugXEfiBbaHUNMhmmtxo9pJG/mxwt84ZCHZTGmHI3ZBOcsxIB6l8H7K1t/hr4Xube2giuLrR7Fp5UjCvMVto1UuRyxCgAZ6AAV2Vcr8J/wDklng3/sC2X/ohK6qgArlfHsMNpoFzd2tmxvJryxLG1jj8+ZxcxBMFyFLDgAudo4zxXVVyfxR3nwkI4vK8ybUdPhXzkLxgvewKC6gqXXLcrkbhkZGaAPFvFljqqaM6yy3t0PMMjajO9gNrDVIzcWxlXDsu5lGxUTEkQC7lfYv0rXhXin4V6vY+HpTY6zoMenWscE01jBogtBNJFOk0k4kWQkSnYwUbdgVtgC5LV7rQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAch8UP+QBpvP/Mc0n/0vgrQ8ezGDwdqzBC+YCmN+z73Gc+2c479O9ZnxVcLoekAkZfXtKUe/wDpsJ/pUfxnuGtfh1qEisykz2keQ2OHuolI6HqGxjv7daAO2ooooAKw/EIB1fwxntqL4/8AAS4rcrF18H+1fDfAONQftnH+i3H5UAYvxD/5DfgLlh/xPx93/ryu/b/Pt1rtK5Dx3u/t/wAB7MZ/txu2ePsF5n9K6+gAooooAKKKKACiiigAooooAKKKKAOA+P3/ACRvxZ/15H+YrV+LHPws8ZY/6A15/wCiHrK+PoJ+DnisAZJszgf8CFa3xWBb4XeMQOSdGvAP+/D0AdTRRRQAVz3icZ1vwjkdNUc/+SV1XQ1g+IwTrHhU+mpOf/JO5oA574r/APIR+H3/AGM0H/pPcV39cB8V/wDkI/D7/sZoP/Se4rv6ACiiigAooooAKKKKACiiigAooooAy/FX/Ir6x1/485un+4ayfhP/AMks8G/9gaz/APRCVq+K/wDkVtY/68pv/QDWV8J/+SWeDf8AsC2X/ohKAD4T/wDJLPBv/YFsv/RCV1Vcr8J/+SWeDf8AsC2X/ohK6qgArlfiX/yLtn/2GdJ/9ONvXVVyvxL/AORcs/8AsNaT/wCnG3oAveOJhB4Q1d2IANs6dQOWG3uR6/4A9DuVz3xBntrfwZqz3kixxGHy1LHHzsQqDr3YqPx79K6GgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4P4yzR2vhzSLu5lSG1tte0yaeaRgqRRi7jyzMeFUep4rB+LPjTwvrHga6sdH8VaFdX0t1Z7IYNQid3AuomYBVYk/KD2rV+PqyyfDeaG2t/tVxNqFhHFb7o181zdxYTMitGM9MurL6gjivnXxLokMkttrNlbWFjrLvpU2s6LbiAppaGTYCqsvmRM0nljylO6NSVclXUKAfZ9FFFABWTrZA1LQAWAJvmAHr/o09a1eZ/HnSTrXh/RrSK2hu7z+0WktIJ5IVjlnW0uTGjCVWVgWwNpHJI5AyQAdD4zGfEXgT/sNSf+m+8rq6+RPBumafpv7RnhaXR7axtb2dbl59MtmIhs3/ALOB8ouRncSSzYBCl9oJKtXquveJ/imnxJ0nTY/DunWHhyW5ZEuftgZborE7BHm8tzErEDA8oMSNobnNAHs1FZ+iy6rNas2uWdlZ3IchY7O7e5QpgYJZooyDnPGD0HPOB5p8W/Fni7T9XvtG8KafLdK+ktKGt9PnlmjkeK8w6zKSiFXghARlJcycHjgA674iXusWlppi6TLd2trNdbL+9srI3lxbQiN2BjiCPks6ohJRsBycdxh3PiLxbBo+l/YtC1e5uoreWWae7toIxeOtpMyRMkcrNE5lEYLbQhIIUgMoNHVtd8eaJD4etFjXVLrzjDc3Q0iZhe4uhESwjJW2AhPnb2yrEYUAAg85f/Eb4j2llosFlodvqOs38twRbnR7q3DojWgAAeQNEim4lBlkAXMY4wQ7AHUaN4q8eanotvczaHbabdlbQSRS2VxJ8011JA5wWQr5SKkrDnKn7yghqf4N8YeMNXOpnWfDc2ntbacLm3/0eVUmmeKOQRkMMlkZmQ4bkhuARxkar4j+JOgaNOI7KDVpEtorqKcaTcSSL5i3TC3aON8yOGit4y67dnnBmUjmtSfxT4+t77SBNo2mKur3hso7PY3m2W0qzyySGQCVAiz8qi5IjwTuAIBU1Txj45e21a0tdAuorm3sNSC3cenSbXuYjKts8OWcMHEQbYy/xoAXDV61Bv8AJj8w5faNx98c14Ff+K/iNBoWk6bbWmqW8p0yxkub86FcXVzHOWtTMxwSjjElwDHtDgwsMAFWOxe+NfHlhZW32DQTdXDW13K1q2kXrEMgvChMzPgfNDbr5Zyz+ZlCAy4APaKKwfBl9q17pcy+IYYo9StriSCR4IJIYpgMFXjVyTtIIGckEg9Og4z4qf8ACyF8PaofDEmnCUzRLYrZQyNd8zIFyXby8YJ3kjaFLHtQBq/HcgfCHxSSSALQ8jr94etYPjr4peBtY8E+IdMsPE2m3F7e6dc28EIc/vHeJlVenckCsXxkfHo+AvicfEJdENwdNXa1gziUHC7vNGNhcnOdhCgjjIIxxl3fLqFvd/aI9T0yfT7ucJv1eyWXWZGRF86RP9W5WDerNEdz7sKW+bYAfU9FFFABXJfEDWtN8PyeHNR1u8jsrKLUmDSyEhQTaXAGcV1teVftCCH+yPCbXGr3WkKuvxEXNoQJmb7PcYjQsQis5wm5yEG7LfKCKAM3xd4+8LeK/EPgKx8Oa3aahdx+IYp3ihJJCCCcFunTLD869nr5T8J3I1b4jfDe9JbTL6C8vLVdFjuVlVgBObi7G07YtzBQU/jO4qAAC31ZQAUUUUAFFFFABRRRQAUUUUAFFFFAGf4hga60DU7dGVXltZYwWOACUI5PpXjPgD4u2WleEPBehS+GfEs2pS6TCtvBDHbGS4SKNVMiRmYSbDgsrFRuUMw4Vse16s6RaVeSSqrRpC7MrHAICnIPTivkTwxN4ptdA0nTorTxjdx3WnIYdat9FlRtIldY0CwyCMu8AiRBIFGW8tShHUgH058J/wDklng3/sDWf/ohK6quY+FqlPhl4RU9Ro9mDxj/AJYp2rp6ACuH+NGoppHgCbU5EMkdjqGnXTIHVNyx30DEZYgDgdSQK7iuA+OsssHw0vprdL2SZLywZEsQDcMwvYMCLII8zP3eDzjg9KAOC8afGFLu3m8L32hX2ka5ez20McUt3auUSSSLJkUOzocMfl2ElcHK5yvvlfJ2q67rAksNNvNA8avpaapYzprGr2X2dxuvFkkgnYRhWi3FNvRvMUnO1gg+saACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDzn46yWqeFtIXUzbjS313TlvftO3yTB9oUv5m7jZgc54x1rgviRD8KovB8g8JHwYdZ+22Pkf2e9s1x/x9xbtm07vu7s47Z7V79d20F5A0F3DFPC2N0cqBlODkZBrhfAeueC/GU9+NC0q1EtiYpD5lkiFo5FLRSrjOA4BIDbXGMlQCMgHf0UUUAFeb/GOz8N6tJ4c0zxx9mXw/LdSzySXNybaMSJC+wGQOpBwzHHfB9K9IrN8Rvpdvot3e69HA+nWUT3Uxmh80Rqiks23BJIXPQZoA8c0rQPhjp/xJ8Iah4FvNMutcuNTuBcPb6w95K8bWV0zswaV/wCMJlsZyRzzXutcD8K9a0jxVY3d/beHLbR9Q0+7e0mjUQybG2hhtlj4zsdQy8FW3KRxk99QAUUUUAFcr8Tb7VtN8H3N1oDOt6ksILRwNKyxmRRIQFjkIIUsc+XJjqVIzXVUUAeMeLvGPxB0pvD1zoeiS6jYzaQtzeI1jI84ujBMyoyLtKBnVA3GQcDAzhtXwz468S6v4h8KWcmkGPT9QguJ7u8bTbqIFVaZYyN3ywk+XE212fIlwCMKZPUqKACiiigAooooA5L4sQLdfD/V7eSIypKscZjCF94MijG0dc+nes3xZ4C8H2PhbWbuz8KeHre6gsppYpk02FWjdUJVgQvBBAOa7i/s7XUbOa01C2hurSZdkkM8YdHX0ZTwR9a5XTLTwbrF/cW1toWnSSwySJvfTFCOYZAkmxymG2yfKcHII9MEgHY0UUUAFc/4t0yw1abQ7XVbK1vbZr1iYbmJZEP+jTj7rAjoT+ddBWZ4i03RtT0x08SWWn3mnQfv3W/iSSKPaD853ggYBPPYZoA4fxJ4Y8PeHfEngW50LQNK06d9bMTSWVnFCzKbK6yCQBxkA49vXFel1wHgSz8AanfT3nhnw3pVnqGnSKGcaQltNFvTcjA7AQHjYMMHOGAODkDv6ACiiigAooooAKKKKACiiigAooooAyvFnPhbWAP+fKb/ANANcl4O8f8Agq08IaHbyeLvDsTw2MEbI2owIVIjUEFdwwR6dq9Crlkm8KHXn0pLG0+3iUwtjTzsEvlLNsMmzZu8tlfbuyRk9jgAd8Ljn4ZeETnP/Eos+c5z+5Tv3rp6AAAAAABwAKKACuQ+Kk8Nr4TiubqWOG3g1bS5ZZZGCpGi39uWZieAAASSeABXX0UAeRfF3xp4X1nwRLp+jeJNG1DUJr6wEVtaX0UskhF7CTtVWJPAJ47CvXax9N8SaVqWs3ek2ly7ahap5ksTwyJhPMePcCygMN8bjKk9PcVsUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXknwJ8H6lo1hp+s6lElhLcaHaWM9kIikjyRFyJJgQPnCMqYIJAXr2r1uigAooooAK574iWFzqvw/8T6fp8RmvLvS7qCCMEDe7xMqjJ4GSQOa6GigDiPhl4W1TQP7V1DX723udS1VoHljt4DEkPlQrEo5dskqgJOcZzjjFdvRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXnXgLQ9Tj8S3WrXthZWVvHLqlqjq8n2i6STUGljZ0ZFCqoDlcM4bzSw2g4PotFABRRRQAVR12NJdD1GOVJZI3tpFZIlLOwKnIUDkn0xV6igDhfhfoWoaZDcX2o2dnpzX1raBrO1neUGSNGDTPujTbIwKKVwf8AVDk547qiigAooooAKKKKACiiigAooooAKKKKACvPLXQ7y++I11qiW1vDDpusM5uHdxLNFJpkMbIq7dpUyeUSQ3/LLHXNeh0UAFFFFABRRRQB574G8OXFv4outfNnb2Mdwt3DOVdzPfMbnMMkylFClI0IHLZ80jgKM+hUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUVzGteILqx8feGNDijha11S3vZZnYHephEW3ac458w5yD0HSgDp6K4XRvix4O1e+jtrbU5IVltnu4bi8tZbWGaNAWkKPKqg7FAZu2055wcS6P8TvDOq2uo3UM97Bb2Vm2omS6sZoRNaKoYzxblBdOccc+3IJAO1yN2O/WiuO8c+OLHw/Z6/aWtxE3iKw0OfWorWWJyjRpuVWZhgYLgDaGDfzrntG+KUEOmRap4sv9NsbFdAsNUuI4Le4eWOS4IUtwCvllmCqoLMMEk4oA9SorlPCfj/w94q1a/wBM0m6m+32aJK9vdW8lvI8TAESokgDFMtjOODjsyk8P4q+ImvQeN/EOjaXrHgXR4NJECqNfuJEluGeFZCw2uoVBvVeh7n2oA9jorznTfirpaeB9A1zXop7a71S2W5NlaQSXLomfnlIVSRGoyxY9gcZOAdDxR8UfCXhs2f27UxcC5iFyDYxtdeXbkAid/LB2xnIw3fPGcHAB21Fcnq3xE8K6TqkdhfaxEkzBGZ0R5IoQ4BTzZFBSPIII3kcEHoQaqah8VfBmnazPpd5rIivLe5W0nBtptkEjYC+Y+zaiksAGJC9eeDgA7eiuFtfij4bbVfE1nf3ZsBoMrJPPcxSRxsqrFuYOyBc75NgUEs2AVBDA1PF8TvCEnh7U9b/tYpp+mPHHeNLazRyQmQqqFomQPhiwAbbg4PPBwAdnRWX4Y1/TfFGh2usaFcm50653eVKY3j3bWKn5XAYcqRyK1KACiiigAooooAKK53xF4mTRfEXhzTJLdXTV5Z42naXYIBFA8pYjHOdmOoxnPtXD2fxX1nWPCT+K/Dvge+1DQPOEUafaSL+ZchWkS3SN1ZQxI/1mflY4AFAHrVFcRqni7WV1eez0XQ7KVLewtr2Z9T1FrJlM7TARgeS4JUQknLDrjtW3rut3GieB9Q129sU+1WOnSXs1mk+V3pEXaMSbeRkEbtvvjtQBuUVyvxP8WP4H8D6h4hj0/wDtFrQxD7KJvKL75Uj4ba3dwelZ+k+Nr4+OB4Z8QaVZWU0mnNqUV1Y6g13EUWTYyvuijKEZByRtPTOeKAO6orB0nxj4a1hbxtJ8QaVerZqZLhoLuNxEmM72IPC/7XTg+lLY+MPDV/p95f2XiDSbixs/+Pm4jvI2jh9N7Zwo9zQBu0Vzx8b+FRpf9pnxNon9necLf7V9vi8rzSM7N+7G7AJx1wM1g+Lvix4W8P6DaatDqdnqdtc36acj2dyjokh5YuwJwqr8xPPVf7woA7+isG/8ZeGdO1KPT7/xDpFtfybdtvNeRpId3K/KTnnIx69qWLxj4bn11NFt9e0ufWGkeL7FFdI8wdAS6sgJKkBWznHSgDdooooAKKKKACiiuX1bxpp2ka/qWm6jmCPT9KXVprl2AQRtI6bef4sxn8xQB1FFeZ+HPis2q+IrHTb/AMG+KdEt79jHbXupWflRFtrEK5z8rNsIA5J47HNVND+Mi65rMVlpvgvxZNbyX/2E6gllutUxJsZ2kBICryT6YoA9Xorhbf4i20/jn/hG00y75v305b0unlNKlqbhwADu+UbQcgcsPcDrbXVtOu5VitNQtJ5GUsqRTKxIHBIAPTigC7RVSHU7CZbhob61kW2GZykqkRdfvc/L0PX0NMvtUtrTTpbwSJKiWz3SrG4JkjUAkr6jkc9OR60AXqK4fQPiJZ6vqlnbPp95ZWd1okGtpf3JVYAkpUCItnAf5hwfQ9sE9faX9nevKlnd29w8RxIIpA5Q88HB46H8qALNFczo/i+31Tx14g8MQ2d0k+jRW8k1y4XynMy7lC856eo6hvTlvw78a6f448M2GsWKtbfbFkkS1mdfOCJK0W4gHoSnXpzigDqKK5248XabbeJ7fR5pFQTac2pLdtIoh8sSJHjdnqTICO1akur6bEYhLqFmhmVXj3TKN6t90jnkHBxjrigC9RXN+GPFtrrXh/8Ata8gfSIftEtuEvpYwco5UHcrFSDjIwTnqCRgmx4L8R23izw7DrFjG8dvNLPEiuQSfLmeInjjkoT9DQBuUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy2u+HrrUPHvhnWopIVs9Mtr2GdSzCRjMIgu3Axx5bZ5HbGa6migDyK++GOrXafDaP7VpYXw5o91p1750bTo7y2awKVjKgSJuBJViuV471zvgL4PeJ9G07xPYX0+gadYaro1xp622lT3ckT3EoCi4kSY4BABHyAcNjAxXv8ARQB4PqPw4+IfiPWPEWq+JNQ8MQXuoeG5dDgGmtcBFLTLIN29c7SN4JBPUfKaZrXwf8S3nhm906C90YzzeGtM0WPzS5RZLeRWkJ/dn5SA21sbskcDGa97ooA8/svBeoQfHHUPGbzWh0u40YacsQdvOEgkRskbdu3CH+LPtVHUPhdbeINc8fN4ljs59K8QPaPaGJQbm3eK38pn3MpCsCTtIzwWz1Ir06igDwHxd8JPFviGDw/q97caDf8Aiy109tMvnurq7it2QOzJLG0Gx/MIdgwb5Tngcc7EXw68YeDJon+GWoaAEuNNgsb2PV0nwskO/bLCVLkZ8x/kYkLxyw4X2aigDwfx38HNf1/xdf3sV7ot3purfZzem9e8ieJo4442KRQSrHJuEYbD45OMjGay28M+NPFmq/EjRNHudBh8L3+uGG+N7HI1zGfLhLtDhSmSmzG7oRkbeDX0ZRQB5J4u8C+LtY1bxMLC70GDTLm8ttZ0ySUSvOl9AlsirKMbPJIgccZPzA88io73wP4y8SaT4ibxe3hqTUNROmQxW9m0wtvs9rdNOyuXUtuYSOOBjp0r1+igAooooAKKKKACiiigDjfG3hm417xP4TuVVWsLGW7+2fPtYJLayRDb6nLivJvEHw28a6h8O7XwJfaPo+tR6dIY9N12fVJYRFHkhHe3UZLJGxUDcwGBwwHzfRdFAHkEvwa03xF4nubvx5aQaraQ6ZY2eneXPNCYDGsgmQ7GXcCxVgSP4sY4Oeq8b+Er/VtK8U/Yda1OSTUtLubSHTJXiFosjwbFI/d7xyAc7+pbscV2tFAHCfHHw1qPjD4X61oWipG9/d+R5YkfYvyzxucn6Ka4vUvhDcaGviLRvAEFvZeH/Eelvb3AknYva3Sg+W29su0ThmVly2NxIGOD7fRQB85j4UeL9a8P3emaxHY2n2Pw/b6TYvLeNcrNJFPFNwqhAkTGFVOQXAI5YAAdN4s8L+N/FdpqV7/ZegaLex3Fhd2kKTF7i4kt3LnzLhVACjJCAqeeu0Zz7NRQB83eK9F8S6Y+jarqelWP9q3/AIw0+e3tZtQM7SmK1kUCSYIFDHaApCccEgkEm3rXwv8AF17qGo+Kra10uHV7nxJp+sJpIuTtWK0SVQDLtwZHMm4jGAATkk7R9COivgOqsAQwyM4I6GnUAeA+I/AXji88P+MPDlhp2lSWPiq8XVWu7zUCW0+Z/LaWJlEZ8xVaLajLjA2nnoOx+DXgvVfCGp+N5dVKvFqmsSXlrJ5okeSIs2Gf0Y5Ga9NooAKKKKACiiigAryf4j+BNU8U+I/ET26LHbXXh+1t7W4d12tdwXck6oy8ttyI8nHRjg5r1iigDyHVovGmt+IvDuo2Ok+J9DmF5ZnU7eXVbRtPS3RmaYKqSM8jNnbnauQATjGKrfCr4YT2mo32v+KU1Sz1w6zdXqxpfD7POHbKyGONivIOCDg/L06Z9nooA8sh8Oa9cah4JvrmxlQ2upate3kcs8btbJcrcGJCQ2Gx5qLhSQPoM1ynw4+FV1oHhXwHd3PhyG38V6dPfjUJobiOKUwyw3SoGlRjuJLW4DDcUzxgbq9+ooA+X7T4Ua5He+TpHhd7S3bQ72wafUjaRSxSSWrRoqyWkgFxuduXmiyBk5JI2994e0TxBPouh6fe+Gr2ybSvCN1o8jXM9qyT3DraKqpslY4PkPywUYx617FRQB8s+LPhT4v1DR54bTQma5Pg3TNJGLm3UNcxXFu8qHL8kLGfm4X5SBnjPrPhDwQnhv4nG+0rw/babo8nh6G1aW2ESL9pWZmdWVTuZipQ78EHb17V6bRQB4jffB3TfFfxg8Yax4y0GS50m5jtP7PuPtpQO6whJPljcMOij5h2JHWuB1D4fa/4Z+FHhCO3s47Txpfi48K3UM0wkja1u5p5P4CRlc79y5wrOWB2jb9WVRm0jTZ9Wt9Um0+zk1O3Qxw3jwKZo1OcqrkbgDk8A9zQB5h4m8FRw+PNEuW8FDxJ4csNBOmRwhbR/KkEqFPknkQcIrDI/vYrJ+GvwsnttZ0C48YaFa3Een+GYLFTcGKdYboXMsjADJwyqyYcDHJwete50UAfN3hP4Z65ol5oNzrPhZNW0eyk1OM6Mn2WRoxO4KSjzZRGysgVduQV2993HrXwW0O98N/DfTNL1OxOn3MMt0xtTIknlI9zK6DchKn5WXoTXb0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of David R Clemmons, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24739=[""].join("\n");
var outline_f24_10_24739=null;
var title_f24_10_24740="Desoximetasone: Drug information";
var content_f24_10_24740=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Desoximetasone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/3/41011?source=see_link\">",
"    see \"Desoximetasone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F157972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Topicort&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F157973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Desoxicream;",
"     </li>",
"     <li>",
"      Topicort&reg;;",
"     </li>",
"     <li>",
"      Topicort&reg; Gel;",
"     </li>",
"     <li>",
"      Topicort&reg; Mild;",
"     </li>",
"     <li>",
"      Topicort&reg; Ointment",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158003\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Corticosteroid, Topical",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F157974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued when control is achieved; if no improvement is seen within 4 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Steroid-response dermatoses:",
"     </b>",
"     Topical: Apply a thin film to affected area twice daily",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F157990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued when control is achieved; if no improvement is seen within 4 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Steroid-response dermatoses:",
"     </b>",
"     Topical: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F157975\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.05% (15 g, 60 g); 0.25% (15 g, 60 g, 100 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topicort&reg;: 0.05% (15 g, 60 g); 0.25% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, topical: 0.05% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topicort&reg;: 0.05% (15 g, 60 g) [contains ethanol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.05% (60 g); 0.25% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Topicort&reg;: 0.25% (15 g, 60 g) [contains coconut oil]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F157958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     For external use only; avoid contact with eyes. Apply to clean, dry skin and rub in gently. Wash hands thoroughly before and after use. Unless otherwise directed by healthcare professional, do not use with occlusive dressing.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F157956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relieves inflammation and pruritic symptoms of corticosteroid-responsive dermatosis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Desoximetasone may be confused with dexamethasone",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Topicort&reg; may be confused with Topic&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     &lt;1% (Limited to important or life-threatening): Acneiform eruptions, allergic contact dermatitis, burning, dry skin, erythema, folliculitis, folliculopustular lesions, hypertrichosis, hypopigmentation, itching; local burning, irritation, miliaria; perioral dermatitis, pruritus, secondary infection, skin atrophy, skin maceration, striae, vesiculation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F157961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to desoximetasone or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F157946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Adrenal suppression: May cause hypercorticism or suppression of hypothalamic-pituitary-adrenal (HPA) axis, particularly in younger children or in patients receiving high doses for prolonged periods. HPA axis suppression may lead to adrenal crisis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contact dermatitis: Allergic contact dermatitis can occur; it is usually diagnosed by failure to heal rather than clinical exacerbation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Immunosuppression: Prolonged use may result in fungal or bacterial superinfection; discontinue if dermatological infection persists despite appropriate antimicrobial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Kaposi's sarcoma: Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Systemic effects: Topical corticosteroids may be absorbed percutaneously. Absorption of topical corticosteroids may cause manifestations of Cushing's syndrome, hyperglycemia, or glycosuria. Absorption is increased by the use of occlusive dressings, application to denuded skin, or application to large surface areas.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin infections: Use appropriate antibacterial or antifungal agents to treat concomitant skin infections; discontinue desoximetasone treatment if infection does not resolve promptly.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Children may absorb proportionally larger amounts after topical application and may be more prone to systemic effects. HPA axis suppression, intracranial hypertension, and Cushing's syndrome have been reported in children receiving topical corticosteroids. Prolonged use may affect growth velocity; growth should be routinely monitored in pediatric patients.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157951\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157952\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F157964\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticosteroids were found to be teratogenic following topical application in animal reproduction studies. In general, the use of topical corticosteroids during pregnancy is not considered to have significant risk; however, intrauterine growth retardation in the infant has been reported (rare). The use of large amounts or for prolonged periods of time should be avoided (Reed, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F157976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F14731712\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Systemic corticosteroids are excreted in human milk. It is not known if sufficient quantities of desoximetasone are absorbed following topical administration to produce detectable amounts in breast milk. Hypertension in the nursing infant has been reported following corticosteroid ointment applied to the nipples; use with caution (Reed, 1997).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F157963\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Desoximetasone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $277.79",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (60 g): $197.03",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Cream",
"     </b>",
"     (Topicort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $67.29",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (60 g): $221.38",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Desoximetasone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $87.57",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Topicort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $93.24",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Desoximetasone External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (60 g): $291.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (15 g): $88.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ointment",
"     </b>",
"     (Topicort External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.05% (15 g): $70.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.25% (60 g): $373.43",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F157965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Actiderm (AR);",
"     </li>",
"     <li>",
"      Decilone (PH);",
"     </li>",
"     <li>",
"      Decilone Forte (PH);",
"     </li>",
"     <li>",
"      Deoxon Gel (KP);",
"     </li>",
"     <li>",
"      Deoxon Lotion (KP);",
"     </li>",
"     <li>",
"      Desone (TW);",
"     </li>",
"     <li>",
"      Dethasone (KP);",
"     </li>",
"     <li>",
"      Dexigen (ID);",
"     </li>",
"     <li>",
"      Dexocort (ID);",
"     </li>",
"     <li>",
"      Esperson (BD, BG, BR, CL, HK, ID, IN, JP, KP, MY, PH, PK, PT, SG, TH, TW);",
"     </li>",
"     <li>",
"      Flubason (ES, IT);",
"     </li>",
"     <li>",
"      Ibaril (BG, DK, FI, NL, NO);",
"     </li>",
"     <li>",
"      Inerson (ID);",
"     </li>",
"     <li>",
"      Pyderma (ID);",
"     </li>",
"     <li>",
"      Stiedex (GB);",
"     </li>",
"     <li>",
"      Topcort (ID);",
"     </li>",
"     <li>",
"      Topicorte (AE, BE, BH, CY, EG, FR, IL, IQ, IR, JO, KW, LB, LU, LY, MY, NL, OM, PT, QA, SA, SY, TH, YE);",
"     </li>",
"     <li>",
"      Topisolon (AT, BB, BM, BS, BZ, CH, DE, GY, IE, JM, PR, SE, SR, TT, ZA)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F157945\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Desoximetasone topical corticosteroid is considered to be of intermediate- to high-potency. Corticosteroids inhibit the initial manifestations of the inflammatory process (ie, capillary dilation and edema, fibrin deposition, and migration and diapedesis of leukocytes into the inflamed site) as well as later sequelae (angiogenesis, fibroblast proliferation).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F157960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: May be increased with occlusion, inflammation, or vary with site of application",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine, feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24740/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Reed, BR, &ldquo;Dermatologic Drugs, Pregnancy, and Lactation. A Conservative Guide,&rdquo;",
"      <i>",
"       Arch Dermatol",
"      </i>",
"      , 1997, 133(7):894-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24740/abstract-text/9236528/pubmed\" id=\"9236528\" target=\"_blank\">",
"        9236528",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9333 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-217.117.136.88-D8E73D39BC-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24740=[""].join("\n");
var outline_f24_10_24740=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157972\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157973\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158003\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157974\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157990\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157975\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157955\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157942\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157958\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157956\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158009\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158002\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157961\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157946\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299140\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157951\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157952\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157964\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157976\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14731712\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157963\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157965\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157945\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157960\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9333\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9333|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/3/41011?source=related_link\">",
"      Desoximetasone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_10_24741="Fospropofol: Drug information";
var content_f24_10_24741=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"16\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fospropofol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2803?source=see_link\">",
"    see \"Fospropofol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F6855409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lusedra&trade; [DSC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F6855413\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Sedative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F6856329\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Onset of effect is delayed as compared to propofol-emulsion due to need for conversion to active component.",
"     </b>",
"     If &lt;60 kg, base dosing on 60 kg; however, lower doses may be used to achieve lower levels of sedation. If &gt;90 kg, base dosing on 90 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Monitored anesthesia care sedation:",
"     </b>",
"     I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Healthy adults &lt;65 years or with mild systemic disease (ASA-PS1 or -PS2):",
"     <i>",
"      Standard dosing regimen:",
"     </i>",
"     Initial: 6.5 mg/kg (maximum initial dose: 577.5 mg or 16.5 mL), followed by supplemental doses of 1.6 mg/kg (maximum supplemental dose: 140 mg or 4 mL) no more frequently than every 4 minutes as needed to achieve desired level of sedation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Patients with severe systemic disease (ASA-PS3 or -PS4):",
"     <i>",
"      Modified dosing regimen:",
"     </i>",
"     Initial: 4.9 mg/kg (maximum initial dose: 437.5 mg or 12.5 mL), followed by supplemental doses of 1.2 mg/kg (maximum supplemental dose: 105 mg or 3 mL) no more frequently than every 4 minutes as needed to achieve desired level of sedation.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F6856330\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note: Onset of effect is delayed as compared to propofol-emulsion due to need for conversion to active component.",
"     </b>",
"     If &lt;60 kg, base dosing on 60 kg; however, lower doses may be used to achieve lower levels of sedation. If &gt;90 kg, base dosing on 90 kg.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Monitored anesthesia care sedation:",
"     </b>",
"     I.V.: Patients &ge;65 years:",
"     <i>",
"      Modified dosing regimen:",
"     </i>",
"     Initial: 4.9 mg/kg (maximum initial dose: 437.5 mg or 12.5 mL), followed by supplemental doses of 1.2 mg/kg (maximum supplemental dose: 105 mg or 3 mL) no more frequently than every 4 minutes as needed to achieve desired level of sedation.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F6856331\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment recommended. Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); limited safety and efficacy data available in these patients.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F6856332\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment recommended. Use with caution in patients with hepatic impairment; has not been adequately studied in this population.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F6856337\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as disodium [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Lusedra&trade;: 35 mg/mL (30 mL [DSC])",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F6855411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F9604736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F6856333\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer as an I.V. bolus (no recommendations on rate of administration provided by manufacturer) via via a secure, freely flowing, peripheral I.V. line. Flush I.V. line with NS or other compatible fluid before and after administration. Strict aseptic technique must be maintained in handling. Discard any unused portion at the end of the procedure.  Do not filter.",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F6855755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS with 20 mEq KCl, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS. Per manufacturer, do not mix with other therapeutic agents prior to administration.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F6855415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitored anesthesia care (MAC) sedation in patients undergoing diagnostic or therapeutic procedures",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6855407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fospropofol may be confused with fosaprepitant, fosphenytoin, propofol",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Onset of action: The onset of action will be delayed due to need for conversion to the active metabolite, propofol. If supplemental doses are administered before full effect occurs, the risk of dose-stacking may be elevated resulting in deeper sedation than intended.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F6855545\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Pruritus (see",
"     <b>",
"      \"Note\"",
"     </b>",
"     below; 8% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Paresthesia (see",
"     <b>",
"      \"Note\"",
"     </b>",
"     below; 52% to 74%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Hypoxemia (1% to 11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Hypotension (2% to 7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Headache (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (&le;4%), vomiting (&le;3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Procedural pain (&le;2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1% (Limited to important or life-threatening): Apnea, myoclonus, systolic blood pressure increased, heart rate increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Paresthesias (including perineal discomfort or burning sensation) and pruritus (including genital, perineal, and generalized pruritus) are mostly limited to the first 5 minutes of administration and usually described as mild-moderate in intensity. No pretreatments are helpful in reducing the incidence of these adverse effects.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F6855420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications in the manufacturer&rsquo;s FDA approved labeling.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Applicable contraindications to propofol include: Hypersensitivity to propofol; when general anesthesia or sedation is contraindicated",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F6855421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypotension: The major cardiovascular effect is hypotension. Use with caution in patients who are hemodynamically unstable, hypovolemic, or have abnormally low vascular tone (eg, sepsis), or compromised myocardial function (eg, heart failure).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory depression: May cause loss of spontaneous respiration and/or hypoxemia; supplemental oxygen is recommended for all patients receiving fospropofol; monitor patient closely. The risk of these effects may be increased with the concomitant use of opioids and/or other sedatives.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Unresponsiveness: May cause patients to become unresponsive or minimally responsive to vigorous tactile or painful stimuli.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; has not been adequately studied in this population.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with severe renal impairment (Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute); limited safety and efficacy data available in these patients.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Respiratory disease: Use with caution in patients with respiratory disease; risk of cardiorespiratory depression may be increased.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorder: Use with caution in patients with a history of epilepsy or seizures; seizure may occur during recovery phase.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Opiates/sedative-hypnotics: Concomitant use may lead to increased sedative or respiratory depressant effects of fospropofol, more pronounced decreases in systolic, diastolic, and mean arterial pressures, heart rate, and cardiac output.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; ASA-PS (American Society of Anesthesiologists - Physical Status) 3/4 patients: Use lower doses in ASA-PS 3/4 patients to reduce the incidence of unwanted cardiorespiratory and neurologic depressive events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use lower doses in patients &ge;65 years to reduce the incidence of unwanted cardiorespiratory and neurologic depressive events.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in patients &lt;18 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Fospropofol should only be used in pregnancy if clearly needed. Not recommended for use in obstetrics, including cesarean section deliveries.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Analgesic supplementation: Fospropofol lacks analgesic properties; pain management requires specific use of analgesic agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: Use only for sedation during procedures as an I.V. bolus with supplemental doses as needed; not recommended for use as a continuous infusion (safety has not been established).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Experienced personnel:",
"     <b>",
"      Use requires careful patient monitoring; should only be administered by persons trained in the administration of general anesthesia and not involved in the conduct of the diagnostic or therapeutic procedure.",
"     </b>",
"     Sedated patients should be continuously monitored, and facilities for maintenance of a patent airway, providing artificial ventilation, administering supplemental oxygen, and instituting cardiovascular resuscitation must be immediately available. Patients should be continuously monitored during sedation and through the recovery process for early signs of hypotension, apnea, airway obstruction, and/or oxygen desaturation. Use to induce moderate (conscious) sedation in patients warrants monitoring equivalent to that seen with general anesthesia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Onset of action: The",
"     <b>",
"      onset of action will be delayed",
"     </b>",
"     due to need for conversion to the active metabolite, propofol. If supplemental doses are administered before full effect occurs, the risk of dose-stacking may be elevated resulting in deeper sedation than intended.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F6855422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (major), CYP2C9 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2C9 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6855443\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: May enhance the adverse/toxic effect of Fospropofol. Specifically, the development of opisthotonus (severe hyperextension and spasticity resulting in arching or bridging position) and/or grand mal seizures.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Moderate): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2B6 Inhibitors (Strong): May decrease the metabolism of CYP2B6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quazepam: May increase the serum concentration of CYP2B6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ropivacaine: Fospropofol may increase the serum concentration of Ropivacaine. Specifically, propofol (the active metabolite of fospropofol) is the entity with the potential to interact with ropivacaine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F6855416\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6855417\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies; however, fospropofol should only be used in pregnancy if clearly needed. Fospropofol is not recommended for obstetrics, including cesarean section deliveries. It is not known if fospropofol crosses the placenta. However, propofol crosses the placenta, and therefore, may be associated with neonatal CNS and respiratory depression.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6855419\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Propofol (the active metabolite of fospropofol) enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F6856336\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     ECG, blood pressure, respiration, oxygen saturation; patient responsiveness",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F6855756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fospropofol disodium is a prodrug of propofol. Propofol interacts with the GABA",
"     <sub>",
"      A",
"     </sub>",
"     receptor, which is the presumed mechanism of action whereby it produces a sedative/hypnotic effect.  Propofol is an alkyl-phenolic compound with intravenous general anesthetic properties.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F6855758\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset of action: Bolus (dose dependent): Attainment of adequate sedation was achieved between 2-28 minutes (median: 8 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration of sedation: Time to fully alert: &le;1 hour (median: 5 minutes)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fospropofol: V",
"     <sub>",
"      d",
"     </sub>",
"     :  0.26-0.4 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Propofol: V",
"     <sub>",
"      d",
"     </sub>",
"     : ~6 L/kg; decreased in the elderly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein binding: Fospropofol: ~98% to albumin; does not affect protein binding of propofol (also ~98% bound to albumin)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Fospropofol is completely metabolized by plasma alkaline phosphatases to propofol, formaldehyde (rapidly converted to formate), and phosphate. Propofol is further metabolized hepatically to water-soluble sulfate and glucuronide conjugates (~50%).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fospropofol: 0.8-0.96 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Propofol: 0.85-1.41 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak: Propofol (from fospropofol): Median: 12 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Fospropofol: Urine (&lt;0.02% unchanged)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Propofol: Urine (~88% as metabolites, 40% as glucuronide metabolite); feces (&lt;2%)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Cohen LB, &ldquo;Clinical Trial: a dose-response study of fospropofol disodium for moderate sedation during colonoscopy,&rdquo;",
"      <i>",
"       Aliment Pharmacol Ther",
"      </i>",
"      , 2008, 27(7):597-608.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24741/abstract-text/18194506/pubmed\" id=\"18194506\" target=\"_blank\">",
"        18194506",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Silvestri GA, Vincent BD, Wahidi MM, et al, &ldquo;A Phase 3, Randomized, Double-blind, Study to Assess the Efficacy and Safety of Fospropofol Disodium Injection for Moderate Sedation in Patients Undergoing Flexible Bronchoscopy,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2009, 135(1):41-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24741/abstract-text/18641105/pubmed\" id=\"18641105\" target=\"_blank\">",
"        18641105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9083 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-183.1.191.153-3399DFF423-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24741=[""].join("\n");
var outline_f24_10_24741=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855409\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855413\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6856329\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6856330\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6856331\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6856332\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6856337\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855411\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9604736\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6856333\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855755\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855415\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855407\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855545\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855420\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855421\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855422\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855443\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855416\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855417\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855419\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6856336\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855756\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6855758\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9083\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9083|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/47/2803?source=related_link\">",
"      Fospropofol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_10_24742="Lymph node LCH";
var content_f24_10_24742=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    Lymph node biopsy in Langerhans cell histiocytosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Langerhans cell histiocytosis extensively involving lymph node in a patient with widespread disease and symptoms. The Langerhans cells have inconspicuous nucleoli, thin nuclear membranes, and prominent folding of their nuclear contours, imparting a \"twisted towel\" appearance.",
"    <br>",
"     (A) Low-power view showing subtotal replacement of lymph node.",
"     <br>",
"      (B) High-power magnification showing cytologic features of Langerhans cells and a mitotic figure. Hematoxylin-eosin stains.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Reproduced with permission from: Ioachim HL, Medeiros LJ. Dendritic cell neoplasms. In: Ioachim's Lymph Node Pathology, 4th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2009. Copyright &copy; 2009 Lippincott Williams &amp; Wilkins.",
"      </div>",
"      <div class=\"contractual\">",
"       <br/>",
"       <a href=\"file://www.lww.com\">",
"        file://www.lww.com",
"       </a>",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24742=[""].join("\n");
var outline_f24_10_24742=null;
var title_f24_10_24743="Alendronate: Drug information";
var content_f24_10_24743=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Alendronate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?42/29/43477?source=see_link\">",
"    see \"Alendronate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F10911786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      FDA Review of Long-term Bisphosphonate Efficacy for Osteoporosis",
"     </span>",
"     <span class=\"collapsible-date\">",
"      May 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       In response to serious postmarketing adverse reactions, including atypical femur fractures, osteonecrosis of the jaw, and esophageal cancer, and a paucity of long-term efficacy data, the FDA conducted a systematic review of long-term bisphosphonate therapy for osteoporosis. To date, randomized controlled trials have shown that bisphosphonate therapy is effective in preventing fractures in trials of 3- to 4-years duration. Therefore, to examine long-term efficacy, three long-term extension trials (involving postmenopausal women) ranging in a duration of treatment from 6-10 years were used in the FDA&rsquo;s analysis. Based on the available long-term clinical trial data, the FDA was unable to identify subgroups of patients who are more likely to benefit from therapy beyond 3-5 years. Continuation of treatment should be based on individual assessment of risks, benefits, and preferences of patients and their physicians.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Until further data are available, the data suggests patients at low risk for fracture (eg, younger patients without a fracture history and bone mineral density [BMD] approaching normal) may be good candidates for discontinuation of therapy after 3-5 years. Patients at increased risk, such as older patients with a history of fracture and a BMD in the osteoporotic range, may benefit from continued therapy.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further investigation into the risks and benefits of long-term therapy, the usefulness of markers of bone turnover or BMD in determining duration or interruption of therapy, and surveillance or fracture risk after therapy discontinuation are needed.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       For additional information, please refer to file://www.nejm.org/doi/pdf/10.1056/NEJMp1202619.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F131404\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Binosto&trade;;",
"     </li>",
"     <li>",
"      Fosamax&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F131405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Alendronate-FC;",
"     </li>",
"     <li>",
"      Apo-Alendronate&reg;;",
"     </li>",
"     <li>",
"      CO Alendronate;",
"     </li>",
"     <li>",
"      Dom-Alendronate;",
"     </li>",
"     <li>",
"      Fosamax&reg;;",
"     </li>",
"     <li>",
"      JAMP-Alendronate;",
"     </li>",
"     <li>",
"      Mylan-Alendronate;",
"     </li>",
"     <li>",
"      PHL-Alendronate;",
"     </li>",
"     <li>",
"      PMS-Alendronate;",
"     </li>",
"     <li>",
"      PMS-Alendronate-FC;",
"     </li>",
"     <li>",
"      Q-Alendronate;",
"     </li>",
"     <li>",
"      ratio-Alendronate;",
"     </li>",
"     <li>",
"      Riva-Alendronate;",
"     </li>",
"     <li>",
"      Sandoz-Alendronate;",
"     </li>",
"     <li>",
"      Teva-Alendronate",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F131424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Bisphosphonate Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F131408\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Patients should receive supplemental calcium and vitamin D if dietary intake is inadequate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis in postmenopausal females:",
"     </b>",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis: 5 mg once daily",
"     <b>",
"      or",
"     </b>",
"     35 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment: 10 mg once daily",
"     <b>",
"      or",
"     </b>",
"     70 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis in males:",
"     </b>",
"     Oral: 10 mg once daily",
"     <b>",
"      or",
"     </b>",
"     70 mg once weekly",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Osteoporosis secondary to glucocorticoids in males and females:",
"     </b>",
"     Oral: Treatment: 5 mg once daily; a dose of 10 mg once daily should be used in postmenopausal females who are not receiving estrogen",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Paget's disease of bone in males and females:",
"     </b>",
"     Oral: 40 mg once daily for 6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Retreatment: Relapses during the 12 months following therapy occurred in 9% of patients who responded to treatment. Specific retreatment data are not available. Following a 6-month post-treatment evaluation period, treatment with alendronate may be considered in patients who have relapsed based on increases in serum alkaline phosphatase, which should be measured periodically. Retreatment may also be considered in those who failed to normalize their serum alkaline phosphatase.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F131409\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F131410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &ge;35 mL/minute: No dosage adjustment  necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;35 mL/minute: Use not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F131411\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment necessary.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F131381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 5 mg, 10 mg, 35 mg, 40 mg, 70 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Fosamax&reg;: 70 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet for solution, oral [effervescent]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Binosto&trade;: 70 mg [contains sodium 650 mg/tablet; strawberry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F131366\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes tablet for solution",
"    </p>",
"   </div>",
"   <div class=\"block meg drugH1Div\" id=\"F11441253\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Guide",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Binosto&trade;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM318435.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM318435.pdf",
"     </a>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;\">",
"     Fosamax&reg;:",
"     <a href=\"file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241519.pdf\" target=\"_blank\">",
"      file://www.fda.gov/downloads/Drugs/DrugSafety/UCM241519.pdf",
"     </a>",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F131385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer first thing in the morning and &ge;30 minutes before the first food, beverage (except plain water), or other medication of the day. Patients should be instructed to stay upright (not to lie down) for at least 30 minutes",
"     <b>",
"      and",
"     </b>",
"     until after first food of the day (to reduce esophageal irritation).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamax&reg;: Must be taken with 6-8 oz of plain water.  Do not take with mineral water or with other beverages.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Binosto&trade;: Dissolve one tablet in 4 oz of room temperature plain water only (not mineral water or flavored water); once effervescence stops, wait &ge;5 minutes and stir the solution for ~10 seconds and then drink.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F131384\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of osteoporosis in postmenopausal females (Fosamax&reg;, Binosto&trade;); prevention of osteoporosis in postmenopausal females (Fosamax&reg;); treatment of osteoporosis in males (Fosamax&reg;, Binosto&trade;); Paget's disease of the bone in patients who are symptomatic, at risk for future complications, or with alkaline phosphatase &ge;2 times the upper limit of normal (Fosamax&reg;); treatment of glucocorticoid-induced osteoporosis in males and females with low bone mineral density who are receiving a daily dosage &ge;7.5 mg of prednisone (or equivalent) (Fosamax&reg;)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F131431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Alendronate may be confused with risedronate",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Fosamax&reg; may be confused with Flomax&reg;, Fosamax Plus D&reg;, fosinopril, Zithromax&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Fosamax  [U.S., Canada, and multiple international markets] may be confused with Fisamox brand name for amoxicillin [Australia]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F131422\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Incidence of adverse effects (mostly GI) increases significantly in patients treated for Paget's disease at 40 mg/day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%: Endocrine &amp; metabolic: Hypocalcemia (transient, mild, 18%); hypophosphatemia (transient, mild, 10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (up to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (1% to 7%), acid reflux (1% to 4%), dyspepsia (1% to 4%), nausea (1% to 4%), flatulence (up to 4%), diarrhea (1% to 3%), gastroesophageal reflux disease (1% to 3%), constipation (up to 3%), esophageal ulcer (up to 2%), abdominal distension (up to 1%), gastritis (up to 1%), vomiting (up to 1%), dysphagia (up to 1%), gastric ulcer (1%), melena (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Musculoskeletal pain (up to 6%), muscle cramps (up to 1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Alopecia, anastomotic ulcer, angioedema, atrial fibrillation; bone, muscle, or joint pain (occasionally severe, considered incapacitating in rare cases); diaphyseal femur fracture, dizziness, duodenal ulcer, episcleritis, erythema, esophageal cancer, esophageal erosions, esophageal perforation, esophageal stricture, esophageal ulcers, esophagitis, fever, flu-like syndrome, hypersensitivity reactions, hypocalcemia (symptomatic), joint swelling, low-energy femoral shaft and subtrochanteric fractures, lymphocytopenia, malaise, myalgia, oropharyngeal ulceration, osteonecrosis (jaw), peripheral edema, photosensitivity (rare), pruritus, rash, scleritis (rare), Stevens-Johnson syndrome, taste perversion, toxic epidermal necrolysis, urticaria, uveitis (rare), vertigo, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F131388\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to alendronate, other bisphosphonates, or any component of the formulation; hypocalcemia; abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia; inability to stand or sit upright for at least 30 minutes; increased risk of aspiration (effervescent tablets; oral solution)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F131370\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone fractures: Atypical femur fractures have been reported in patients receiving bisphosphonates for treatment/prevention of osteoporosis. The fractures include subtrochanteric femur (bone just below the hip joint) and diaphyseal femur (long segment of the thigh bone). Some patients experience prodromal pain weeks or months before the fracture occurs. It is unclear if bisphosphonate therapy is the cause for these fractures, although the majority have been reported in patients taking bisphosphonates. Patients receiving long-term (&gt;3-5 years) therapy may be at an increased risk.  Discontinue bisphosphonate therapy in patients who develop a femoral shaft fracture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bone/joint/muscle pain: Severe (and occasionally debilitating) bone, joint, and/or muscle pain have been reported during bisphosphonate treatment. The onset of pain ranged from a single day to several months. Consider discontinuing therapy in patients who experience severe symptoms; symptoms usually resolve upon discontinuation. Some patients experienced recurrence when rechallenged with same drug or another bisphosphonate; avoid use in patients with a history of these symptoms in association with bisphosphonate therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal mucosa irritation: May cause irritation to upper gastrointestinal mucosa. Esophagitis, dysphagia, esophageal ulcers, esophageal erosions, and esophageal stricture (rare) have been reported with oral bisphosphonates; risk increases in patients unable to comply with dosing instructions. Use with caution in patients with dysphagia, esophageal disease, gastritis, duodenitis, or ulcers (may worsen underlying condition). Discontinue use if new or worsening symptoms develop.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypocalcemia: Hypocalcemia has been reported with the use of bisphosphonates. Prior to therapy initiation, hypocalcemia must be corrected; ensure adequate calcium and vitamin D intake.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Osteonecrosis of the jaw (ONJ): ONJ has been reported in patients receiving bisphosphonates. Risk factors include invasive dental procedures (eg, tooth extraction, dental implants, boney surgery); a diagnosis of cancer, with concomitant chemotherapy or corticosteroids; poor oral hygiene, ill-fitting dentures; and comorbid disorders (anemia, coagulopathy, infection, pre-existing dental disease). Most reported cases occurred after I.V. bisphosphonate therapy; however, cases have been reported following oral therapy. A dental exam and preventative dentistry should be performed prior to placing patients with risk factors on chronic bisphosphonate therapy. The manufacturer's labeling states that discontinuing bisphosphonates in patients requiring invasive dental procedures may reduce the risk of ONJ. However, other experts suggest that there is no evidence that discontinuing therapy reduces the risk of developing ONJ (Assael, 2009). The benefit/risk must be assessed by the treating physician and/or dentist/surgeon prior to any invasive dental procedure. Patients developing ONJ while on bisphosphonates should receive care by an oral surgeon.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment (not recommended for use in patients with Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;35 mL/minute).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Effervescent tablet: Each effervescent tablet contains 650 mg of sodium (NaCl 1650 mg). Use with caution in patients following a sodium-restricted diet.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298701\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F131375\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglycosides: May enhance the hypocalcemic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of antacids containing polyvalent cations within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Magaldrate; Sodium Bicarbonate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: May enhance the adverse/toxic effect of Alendronate. Specifically gastrointestinal adverse events.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral calcium supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Bisphosphonate Derivatives may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the serum concentration of Bisphosphonate Derivatives. Management: Avoid administration of oral magnesium salts within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Bisphosphonate Derivatives. Specifically, polyvalent cation-containing multivitamins may decrease the absorption of orally-administered bisphosphonate derivatives. Management: Avoid administration of polyvalent cation-containing multivitamins within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the adverse/toxic effect of Bisphosphonate Derivatives. Both an increased risk of gastrointestinal ulceration and an increased risk of nephrotoxicity are of concern.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Bisphosphonate Derivatives may enhance the hypocalcemic effect of Phosphate Supplements.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May diminish the therapeutic effect of Bisphosphonate Derivatives.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Bisphosphonate Derivatives may enhance the adverse/toxic effect of SUNItinib. Specifically, the risk of osteonecrosis of the jaw may be increased.  Management: Monitor for development of osteonecrosis of the jaw in patients receiving sunitinib and bisphosphonates.  Avoid invasive dental procedures if possible.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F131400\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ethanol: May increase risk of osteoporosis and gastric irritation. Management: Avoid ethanol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Food: All food and beverages interfere with absorption. Coadministration with caffeine may reduce alendronate efficacy. Coadministration with dairy products may decrease alendronate absorption. Beverages (especially orange juice and coffee) and food may reduce the absorption of alendronate as much as 60%. Management: Alendronate must be taken first thing in the morning and &ge;30 minutes before the first food, beverage (except plain water), or other medication of the day.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F131377\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F131391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy have not been established in pregnant women. Animal studies have shown delays in delivery and fetal/neonatal death (secondary to hypocalcemia). Bisphosphonates are incorporated into the bone matrix and gradually released over time. Theoretically, there may be a risk of fetal harm when pregnancy follows the completion of therapy. Based on limited case reports with pamidronate, serum calcium levels in the newborn may be altered if administered during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F131415\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F131392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ensure adequate calcium and vitamin D intake; women and men &ge;50 years of age should consume 1200-1500 mg/day of elemental calcium and 800-1000 units/day of vitamin D. Alendronate must be taken first thing in the morning and at least 30 minutes before the first food, beverage (except plain water), or medication/supplement of the day. Effervescent tablets contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F131390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, effervescent",
"     </b>",
"     (Binosto Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70 mg (4): $168.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Alendronate Sodium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (100): $292.68",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $87.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     35 mg (4): $81.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mg (30): $197.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70 mg (4): $81.95",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Fosamax Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     70 mg (4): $115.12",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F131379\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Osteoporosis: Bone mineral density as measured by central dual-energy x-ray absorptiometry (DXA) of the hip or spine (prior to initiation of therapy and at least every 2 years; after 6-12 months of combined glucocorticoid and alendronate treatment); annual measurements of height and weight, assessment of chronic back pain; serum calcium and 25(OH)D; may consider monitoring biochemical markers of bone turnover",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paget&rsquo;s disease: Alkaline phosphatase; pain; serum calcium and 25(OH)D",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F131382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Calcium (total): Adults: 9.0-11.0 mg/dL (2.05-2.54 mmol/L), may slightly decrease with aging; phosphorus: 2.5-4.5 mg/dL (0.81-1.45 mmol/L)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F131393\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Adronat (AU);",
"     </li>",
"     <li>",
"      Aldren 70 (TH);",
"     </li>",
"     <li>",
"      Aldrox (CN);",
"     </li>",
"     <li>",
"      Alenato (AR);",
"     </li>",
"     <li>",
"      Alend (KP);",
"     </li>",
"     <li>",
"      Alendovenir (IL);",
"     </li>",
"     <li>",
"      Alendrate (NZ);",
"     </li>",
"     <li>",
"      Alendrex (NZ);",
"     </li>",
"     <li>",
"      Alendro (AU);",
"     </li>",
"     <li>",
"      Alendrobell (AU);",
"     </li>",
"     <li>",
"      Alendronate (TH);",
"     </li>",
"     <li>",
"      Alendros (KP);",
"     </li>",
"     <li>",
"      Alenfos (KP);",
"     </li>",
"     <li>",
"      Allentop (HK);",
"     </li>",
"     <li>",
"      Alnax (PY);",
"     </li>",
"     <li>",
"      Alovell (ID, PH);",
"     </li>",
"     <li>",
"      Arendal (PE);",
"     </li>",
"     <li>",
"      Armol (CO, DO, EC, GT, HN, NI, PA, SV);",
"     </li>",
"     <li>",
"      Bifosa (IN);",
"     </li>",
"     <li>",
"      Bisbon (KP);",
"     </li>",
"     <li>",
"      Bonaid (KP);",
"     </li>",
"     <li>",
"      Bonalon (JP);",
"     </li>",
"     <li>",
"      Bonapex (EG);",
"     </li>",
"     <li>",
"      Endronax (BR);",
"     </li>",
"     <li>",
"      Forosa (PH);",
"     </li>",
"     <li>",
"      Fosalan (IL);",
"     </li>",
"     <li>",
"      Fosamax (AR, AT, AU, BB, BE, BG, BM, BR, BS, BZ, CH, CL, CN, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, GY, HK, IE, IT, JM, KP, MX, MY, NL, NO, NZ, PE, PK, PL, PR, PT, RU, SE, SG, SR, TH, TT, TW, VE);",
"     </li>",
"     <li>",
"      Fosmin (EC, PE);",
"     </li>",
"     <li>",
"      Fosval (PY);",
"     </li>",
"     <li>",
"      Gendarin (SE);",
"     </li>",
"     <li>",
"      Malend (KP);",
"     </li>",
"     <li>",
"      Marvil (PE, UY);",
"     </li>",
"     <li>",
"      MaxiBone (IL);",
"     </li>",
"     <li>",
"      MaxiBone 70 (IL);",
"     </li>",
"     <li>",
"      Nichospor (ID);",
"     </li>",
"     <li>",
"      Oseotenk (AR);",
"     </li>",
"     <li>",
"      Osficar (CO);",
"     </li>",
"     <li>",
"      Ossmax (AU);",
"     </li>",
"     <li>",
"      Osteo-Plus (PH);",
"     </li>",
"     <li>",
"      Osteocor (PH);",
"     </li>",
"     <li>",
"      Osteodron (PH);",
"     </li>",
"     <li>",
"      Osteofar (ID);",
"     </li>",
"     <li>",
"      Osteofos (HK, IN);",
"     </li>",
"     <li>",
"      Osteopor (UY);",
"     </li>",
"     <li>",
"      Osteosan (CN);",
"     </li>",
"     <li>",
"      Osteovan (CR);",
"     </li>",
"     <li>",
"      Ostex (CO);",
"     </li>",
"     <li>",
"      Porosal (VE);",
"     </li>",
"     <li>",
"      Ralenost (TH);",
"     </li>",
"     <li>",
"      Reventa (PH);",
"     </li>",
"     <li>",
"      Tevanate (BG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F131369\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A bisphosphonate which inhibits bone resorption via actions on osteoclasts or on osteoclast precursors; decreases the rate of bone resorption, leading to an indirect increase in bone mineral density. In Paget's disease, characterized by disordered resorption and formation of bone, inhibition of resorption leads to an indirect decrease in bone formation; but the newly-formed bone has a more normal architecture.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F131387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 28 L (exclusive of bone)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: ~78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: None",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Fasting: 0.6%; reduced up to 60% with food or drink",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Exceeds 10 years",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine; feces (as unabsorbed drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Dental Association Council on Scientific Affairs, &ldquo;Dental Management of Patients Receiving Oral Bisphosphonate Therapy: Expert Panel Recommendations,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2006, 137(8):1144-50. Available at file://jada.ada.org/cgi/content/full/137/8/1144",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/16873332/pubmed\" id=\"16873332\" target=\"_blank\">",
"        16873332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Assael LA, &ldquo;Oral Bisphosphonates as a Cause of Bisphosphonate-Related Osteonecrosis of the Jaws: Clinical Findings, Assessment of Risks, and Preventive Strategies,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2009, 67(5 Suppl):35-43.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/19371813/pubmed\" id=\"19371813\" target=\"_blank\">",
"        19371813",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Author Unknown, &ldquo;Safety Update: Bone-Building Drugs: Risks Explained,&rdquo;",
"      <i>",
"       Consum Rep Health",
"      </i>",
"      , 2006, 18(5):3.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cartsos VM, Zhu S, and Zavras AI, &ldquo;Bisphosphonate Use and the Risk of Adverse Jaw Outcomes: A Medical Claims Study of 714,217 People,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2008, 139(1):23-30.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/18167381/pubmed\" id=\"18167381\" target=\"_blank\">",
"        18167381",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chesnut CH 3rd, McClung MR, Ensrud KE, et al, &ldquo;Alendronate Treatment of the Postmenopausal Osteoporatic Woman: Effect of Multiple Dosages on Bone Mass and Bone Remodeling,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 1995, 99(2):144-52.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/7625419/pubmed\" id=\"7625419\" target=\"_blank\">",
"        7625419",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Edwards BJ, Hellstein JW, Jacobsen PL, et al, &ldquo;Updated Recommendations for Managing the Care of Patients Receiving Oral Bisphosphonate Therapy: An Advisory Statement From the American Dental Association Council on Scientific Affairs,&rdquo;",
"      <i>",
"       J Am Dent Assoc",
"      </i>",
"      , 2008, 139(12):1674-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/19047674/pubmed\" id=\"19047674\" target=\"_blank\">",
"        19047674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Filleul O, Crompot E, and Saussez S, \"Bisphosphonate-Induced Osteonecrosis of the Jaw: A Review of 2,400 Patient Cases,\"",
"      <i>",
"       J Cancer Res Clin Oncol",
"      </i>",
"      , 2010, 136(8):1117-24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/20508948/pubmed\" id=\"20508948\" target=\"_blank\">",
"        20508948",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      French AE, Kaplan N, Lishner M, et al, &ldquo;Taking Bisphosphonates During Pregnancy,&rdquo;",
"      <i>",
"       Can Fam Physician",
"      </i>",
"      , 2003, 49:1281-2.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/14594094/pubmed\" id=\"14594094\" target=\"_blank\">",
"        14594094",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lo JC, O'Ryan FS, Gordon NP, et al, &ldquo;Prevalence of Osteonecrosis of the Jaw in Patients With Oral Bisphosphonate Exposure,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2010, 68(2):243-53.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/19772941/pubmed\" id=\"19772941\" target=\"_blank\">",
"        19772941",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Management of Osteoporosis in Postmenopausal Women: 2010 Position Statement of The North American Menopause Society,&rdquo;",
"      <i>",
"       Menopause",
"      </i>",
"      , 2010, 17(1):25-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/20061894/pubmed\" id=\"20061894\" target=\"_blank\">",
"        20061894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marx RE, Sawatari Y, Fortin M, et al, &ldquo;Bisphosphonate-Induced Exposed Bone (Osteonecrosis/Osteopetrosis) of the Jaws: Risk Factors, Recognition, Prevention, and Treatment,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2005, 63(11):1567-75.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/16243172/pubmed\" id=\"16243172\" target=\"_blank\">",
"        16243172",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mavrokokki T, Cheng A, Stein B, et al, &ldquo;Nature and Frequency of Bisphosphonate-Associated Osteonecrosis of the Jaws in Australia,&rdquo;",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      , 2007, 65(3):415-23.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/17307586/pubmed\" id=\"17307586\" target=\"_blank\">",
"        17307586",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Osteoporosis Foundation, &ldquo;Clinician&rsquo;s Guide to Prevention and Treatment of Osteoporosis,&rdquo; Washington, DC, 2010. Available at  file://www.nof.org/files/nof/public/content/file/344/upload/159.pdf",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Orwoll E, Ettinger M, Weiss S, et al, &ldquo;Alendronate for the Treatment of Osteoporosis in Men,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2000, 343(9):604-10.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/10979796/pubmed\" id=\"10979796\" target=\"_blank\">",
"        10979796",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ralston SH, &ldquo;Pathogenesis of Paget's Disease of Bone,&rdquo;",
"      <i>",
"       Bone",
"      </i>",
"      , 2008, 43(5):819-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/18672105/pubmed\" id=\"18672105\" target=\"_blank\">",
"        18672105",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sellmeyer DE, &ldquo;Atypical Fractures as a Potential Complication of Long-term Bisphosphonate Therapy,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2010, 304(13):1480-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/20924014/pubmed\" id=\"20924014\" target=\"_blank\">",
"        20924014",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shane E, Burr D, Ebeling PR, et al, &ldquo;Atypical Subtrochanteric and Diaphyseal Femoral Fractures: Report of a Task Force of the American Society for Bone and Mineral Research,&rdquo;",
"      <i>",
"       J Bone Miner Res",
"      </i>",
"      , 2010, 25(11):2267-94.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/20842676/pubmed\" id=\"20842676\" target=\"_blank\">",
"        20842676",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Watts NB, &ldquo;Treatment of Osteoporosis With Bisphosphonates,&rdquo;",
"      <i>",
"       Rheum Dis Clin North Am",
"      </i>",
"      , 1994, 20(3):717-34.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/7984786/pubmed\" id=\"7984786\" target=\"_blank\">",
"        7984786",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Whyte MP, &ldquo;Clinical Practice. Paget's Disease of Bone,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2006, 355(6):593-600.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/16899779/pubmed\" id=\"16899779\" target=\"_blank\">",
"        16899779",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wysowski DK, &ldquo;Reports of Esophageal Cancer With Oral Bisphosphonate Use,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(1):89-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/10/24743/abstract-text/19118315/pubmed\" id=\"19118315\" target=\"_blank\">",
"        19118315",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9427 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-DA858D2583-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24743=[""].join("\n");
var outline_f24_10_24743=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10911786\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131404\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131405\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131424\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131408\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131409\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131410\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131411\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131381\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131366\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11441253\">",
"      Medication Guide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131385\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131384\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131431\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131422\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131388\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131370\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298701\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131375\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131400\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131377\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131391\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131415\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131392\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131390\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131379\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131382\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131393\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131369\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F131387\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9427\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9427|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?42/29/43477?source=related_link\">",
"      Alendronate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_10_24744="Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis";
var content_f24_10_24744=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/10/24744/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24744/contributors\">",
"     Remi Neviere, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/10/24744/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24744/contributors\">",
"     Polly E Parsons, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/10/24744/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24744/contributors\">",
"     Geraldine Finlay, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/10/24744/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 1, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is a clinical syndrome that complicates severe infection. It is characterized by the cardinal signs of inflammation (vasodilation, leukocyte accumulation, increased microvascular permeability) occurring in tissues that are remote from the infection. Systemic inflammatory response syndrome (SIRS) is an identical clinical syndrome that complicates a noninfectious insult (eg, acute pancreatitis, pulmonary contusion). Current theories about the onset and progression of sepsis and SIRS focus on dysregulation of the inflammatory response, including the possibility that a massive and uncontrolled release of proinflammatory mediators initiates a chain of events that lead to widespread tissue injury. This response can lead to multiple organ dysfunction syndrome (MODS), which is the cause of the high mortality associated with these syndromes.",
"   </p>",
"   <p>",
"    The definitions, epidemiology, risk factors, and outcomes of sepsis and SIRS are reviewed here. The pathophysiology and treatment of sepsis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=see_link\">",
"     \"Pathophysiology of sepsis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, and septic shock were initially defined in 1991 by a consensus panel convened by the American College of Chest Physicians (ACCP) and Society of Critical Care Medicine (SCCM) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/1\">",
"     1",
"    </a>",
"    ]. These definitions were reconsidered in 2001 during an International Sepsis Definitions Conference that included representatives from the ACCP, SCCM, American Thoracic Society (ATS), European Society of Intensive Care Medicine (ESICM), and Surgical Infection Society (SIS), and again in 2012 by the SCCM and ESICM [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. A practical modification of the definitions has been published, which provides exact hemodynamic definitions for septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/4\">",
"     4",
"    </a>",
"    ]. The definitions that we provide below are based upon these resources, but presented in a way that highlights the notion that both SIRS and sepsis exist on a continuum of severity that ends with multiple organ dysfunction syndrome (MODS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection is the invasion of normally sterile tissue by organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Bacteremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bacteremia is the presence of viable bacteria in the blood.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Systemic inflammatory response syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;SIRS is the clinical syndrome that results from a dysregulated inflammatory response to a noninfectious insult, such as an autoimmune disorder, pancreatitis, vasculitis, thromboembolism, burns, or surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis is the clinical syndrome that results from a dysregulated inflammatory response to an infection. Sepsis is defined as the presence (probable or documented) of infection together with systemic manifestations of infection. Diagnostic criteria for sepsis include infection (documented or suspected) and some of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      General variables",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Temperature &gt;38.3 or &lt;36&ordm;C",
"     </li>",
"     <li>",
"      Heart rate &gt;90",
"      <span class=\"nowrap\">",
"       beats/min",
"      </span>",
"      or more than two standard deviations above the normal value for age",
"     </li>",
"     <li>",
"      Tachypnea, respiratory rate &gt;20",
"      <span class=\"nowrap\">",
"       breaths/min",
"      </span>",
"     </li>",
"     <li>",
"      Altered mental status",
"     </li>",
"     <li>",
"      Significant edema or positive fluid balance (&gt;20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      over 24 hours)",
"     </li>",
"     <li>",
"      Hyperglycemia (plasma glucose &gt;140",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 7.7",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      in the absence of diabetes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inflammatory variables",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Leukocytosis (WBC count &gt;12,000 microL",
"      <sup>",
"       &ndash;1",
"      </sup>",
"      ) or leukopenia (WBC count &lt;4000 microL",
"      <sup>",
"       &ndash;1",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      Normal WBC count with greater than 10 percent immature forms",
"     </li>",
"     <li>",
"      Plasma C-reactive protein more than two standard deviations above the normal value",
"     </li>",
"     <li>",
"      Plasma procalcitonin more than two standard deviations above the normal value",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hemodynamic variables",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arterial hypotension (systolic blood pressure SBP &lt;90 mmHg, MAP &lt;70 mmHg, or an SBP decrease &gt;40 mmHg in adults or less than two standard deviations below normal for age)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Organ dysfunction variables",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Arterial hypoxemia (arterial oxygen tension",
"      <span class=\"nowrap\">",
"       [PaO",
"       <sub>",
"        2",
"       </sub>",
"       ]/fraction",
"      </span>",
"      of inspired oxygen [FiO",
"      <sub>",
"       2",
"      </sub>",
"      ] &lt;300)",
"     </li>",
"     <li>",
"      Acute oliguria (urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg/hr",
"      </span>",
"      for at least two hours despite adequate fluid resuscitation)",
"     </li>",
"     <li>",
"      Creatinine increase &gt;0.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 44.2",
"      <span class=\"nowrap\">",
"       micromol/L",
"      </span>",
"     </li>",
"     <li>",
"      Coagulation abnormalities (international normalized ratio [INR] &gt;1.5 or activated partial thromboplastin time [aPTT] &gt;60 seconds)",
"     </li>",
"     <li>",
"      Ileus (absent bowel sounds)",
"     </li>",
"     <li>",
"      Thrombocytopenia (platelet count &lt;100,000 microL",
"      <sup>",
"       &ndash;1",
"      </sup>",
"      )",
"     </li>",
"     <li>",
"      Hyperbilirubinemia (plasma total bilirubin &gt;4",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      or 70",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tissue perfusion variables",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Hyperlactatemia (&gt;1",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Decreased capillary refill or mottling",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Severe sepsis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe sepsis refers to sepsis-induced tissue hypoperfusion or organ dysfunction with any of the following thought to be due to the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Sepsis-induced hypotension",
"     </li>",
"     <li>",
"      Lactate above upper limits of laboratory normal",
"     </li>",
"     <li>",
"      Urine output &lt;0.5",
"      <span class=\"nowrap\">",
"       mL/kg/hr",
"      </span>",
"      for more than two hours despite adequate fluid resuscitation",
"     </li>",
"     <li>",
"      Acute lung injury with",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FIO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &lt;250 in the absence of pneumonia as infection source",
"     </li>",
"     <li>",
"      Acute lung injury with",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FIO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      &lt;200 in the presence of pneumonia as infection source",
"     </li>",
"     <li>",
"      Creatinine &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (176.8",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Bilirubin &gt;2",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (34.2",
"      <span class=\"nowrap\">",
"       micromol/L)",
"      </span>",
"     </li>",
"     <li>",
"      Platelet count &lt;100,000 microL",
"      <sup>",
"       &ndash;1",
"      </sup>",
"     </li>",
"     <li>",
"      Coagulopathy (INR &gt;1.5)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Sepsis-induced hypotension is defined as a systolic blood pressure (SBP) &lt;90 mmHg or mean arterial pressure (MAP) &lt;70 mmHg or a SBP decrease &gt;40 mmHg or less than two standard deviations below normal for age in the absence of other causes of hypotension.",
"   </p>",
"   <p>",
"    Sepsis-induced tissue hypoperfusion",
"    <strong>",
"    </strong>",
"    is defined as infection-induced hypotension, elevated lactate, or oliguria. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Septic shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Septic shock",
"    <strong>",
"    </strong>",
"    is defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation, which may be defined as infusion of 30",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of crystalloids (a portion of this may be albumin equivalent). Septic shock is a type of vasodilatory or distributive shock [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. In other words, it results from a marked reduction in systemic vascular resistance, often associated with an increase in cardiac output. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=see_link\">",
"     \"Shock in adults: Types, presentation, and diagnostic approach\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Multiple organ dysfunction syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple organ dysfunction syndrome (MODS) refers to progressive organ dysfunction in an acutely ill patient, such that homeostasis cannot be maintained without intervention. It is at the severe end of the severity of illness spectrum of both SIRS and sepsis. MODS can be classified as primary or secondary:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Primary MODS is the result of a well-defined insult in which organ dysfunction occurs early and can be directly attributable to the insult itself (eg, renal failure due to rhabdomyolysis)",
"     </li>",
"     <li>",
"      Secondary MODS is organ failure that is not in direct response to the insult itself, but is a consequence of the host&rsquo;s response (eg, acute respiratory distress syndrome in patients with pancreatitis)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are no universally accepted criteria for individual organ dysfunction in MODS. However, progressive abnormalities of the following organ-specific parameters are commonly used to diagnose MODS and scoring systems are used to predict ICU mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       PaO",
"       <sub>",
"        2",
"       </sub>",
"       /FiO",
"       <sub>",
"        2",
"       </sub>",
"      </span>",
"      ratio",
"     </li>",
"     <li>",
"      Platelet count",
"     </li>",
"     <li>",
"      Serum bilirubin",
"     </li>",
"     <li>",
"      Serum creatinine (or urine output)",
"     </li>",
"     <li>",
"      Glasgow coma score",
"     </li>",
"     <li>",
"      Hypotension",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4127955\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The population at risk of developing sepsis is large. At any given moment, approximately 50 percent of ICU patients have a nosocomial infection and, therefore, are at high risk for sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/6\">",
"     6",
"    </a>",
"    ]. Other risk factors include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bacteremia &ndash; Patients with bacteremia often develop systemic consequences of infection. In a study of 270 blood cultures, 95 percent of positive blood cultures were associated with sepsis, severe sepsis, or septic shock [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Advanced age (&ge;65 years) &ndash; The incidence of sepsis is disproportionately increased in older adult patients and age is an independent predictor of mortality due to sepsis. Moreover, older adult non-survivors tend to die earlier during hospitalization and older adult survivors more frequently require skilled nursing or rehabilitation after hospitalization [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Immunosuppression &ndash; Comorbidities that depress host-defense (eg, neoplasms, renal failure, hepatic failure, AIDS) and immunosuppressant medications are common among patients with sepsis, severe sepsis, or septic shock.",
"     </li>",
"     <li>",
"      Diabetes and cancer &ndash; Diabetes and some cancers may alter the immune system, result in an elevated risk for developing sepsis, and increase the risk of nosocomial sepsis.",
"     </li>",
"     <li>",
"      Community acquired pneumonia &ndash; Severe sepsis and septic shock develop in approximately 48 and 5 percent, respectively, of patients with community-acquired pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetic factors &ndash; Both experimental and clinical studies have confirmed that genetic factors can increase the risk of infection. In few cases, monogenic defects underlie vulnerability to specific infection, but genetic factors are typically genetic polymorphisms. Genetic studies of susceptibility to infection have initially focused on defects of antibody production, or a lack of T cells, phagocytes, natural killer cells, or complement. Recently, genetic defects have been identified that impair recognition of pathogens by the innate immune system, increasing susceptibility to specific classes of microorganisms [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4128146\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the late 1970s, it was estimated that 164,000 cases of sepsis occurred in the United States each year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. This has dramatically increased, with more recent estimates indicating that more than 1,665,000 cases of sepsis are diagnosed in the United States annually (",
"    <a class=\"graphic graphic_figure graphicRef71861 \" href=\"UTD.htm?23/26/23983\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/16,19\">",
"     16,19",
"    </a>",
"    ]. This trend has also been noted outside of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/20-23\">",
"     20-23",
"    </a>",
"    ] and is thought to be a consequence of advancing age, immunosuppression, and multidrug-resistant infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of sepsis varies among the different racial and ethnic groups, but appears to be highest among African-American males (",
"    <a class=\"graphic graphic_figure graphicRef64115 \" href=\"UTD.htm?17/31/17919\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/16\">",
"     16",
"    </a>",
"    ]. The incidence is also greatest during the winter, probably due to the increased likelihood of a respiratory source [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/24\">",
"     24",
"    </a>",
"    ]. In the United States, patients &ge;65 years of age account for nearly 60 percent of all episodes of severe sepsis and this is likely to increase over the next 20 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/16,25,26\">",
"     16,25,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4128337\">",
"    <span class=\"h2\">",
"     Pathogens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The contribution of various infectious organisms to the burden of sepsis has changed over time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/3,27-29\">",
"     3,27-29",
"    </a>",
"    ]. Gram positive bacteria are most frequently identified in patients with sepsis in the United States, although the number of cases of Gram negative sepsis remains substantial. The incidence of fungal sepsis has increased over the past decade, but remains lower than bacterial sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/3,16\">",
"     3,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4128344\">",
"    <span class=\"h2\">",
"     Disease severity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The severity of disease appears to be increasing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/30\">",
"     30",
"    </a>",
"    ]. In one retrospective analysis, the proportion of patients with sepsis who also had at least one dysfunctional organ (ie, severe sepsis) increased from 26 to 44 percent over a ten-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. The most common manifestations of severe organ dysfunction were acute respiratory distress syndrome, acute renal failure, and disseminated intravascular coagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4128153\">",
"    <span class=\"h2\">",
"     Mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis has a high mortality rate, with estimates ranging from 20 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/16,31,34-37\">",
"     16,31,34-37",
"    </a>",
"    ]. However, the mortality rate appears to have decreased (",
"    <a class=\"graphic graphic_figure graphicRef74265 \" href=\"UTD.htm?41/30/42477\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/16,31,38\">",
"     16,31,38",
"    </a>",
"    ]. Mortality rates increase stepwise according to disease severity. In one study, the mortality rate of SIRS, sepsis, severe sepsis, and septic shock was 7, 16, 20, and 46 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/33\">",
"     33",
"    </a>",
"    ]. Most deaths occur within the first six months; however, mortality remains elevated at one-year among patients who survived sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Patients who survive sepsis also appear to have a persistent decrement in their quality of life [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PROGNOSTIC FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical characteristics that impact the severity of sepsis and, therefore, the outcome include the host&rsquo;s response to infection, the site and type of infection, and the timing and type of antimicrobial therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Host response",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anomalies in the host's inflammatory response may indicate increased susceptibility to severe disease and mortality. As examples, consider the failure to develop a fever (or hypothermia) and leukopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. Failure to develop a fever (defined as a temperature below 35.5&ordm;C) was more common among non-survivors of sepsis than survivors (17 versus 5 percent) in one study of 519 patients with sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/41\">",
"     41",
"    </a>",
"    ]. Leukopenia (a white blood cell count less than",
"    <span class=\"nowrap\">",
"     4000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    was similarly more frequent among non-survivors than survivors (15 versus 7 percent) in study of 612 patients with Gram negative sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A patient&rsquo;s comorbidities and functional health status are also important determinants of outcome in sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/41\">",
"     41",
"    </a>",
"    ]. Risk factors for mortality include new-onset atrial fibrillation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/44\">",
"     44",
"    </a>",
"    ], an age above 40 years [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/25\">",
"     25",
"    </a>",
"    ], and comorbidities such as AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/45\">",
"     45",
"    </a>",
"    ], liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/46\">",
"     46",
"    </a>",
"    ], cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/47\">",
"     47",
"    </a>",
"    ], alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/46\">",
"     46",
"    </a>",
"    ],",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immune suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/45\">",
"     45",
"    </a>",
"    ]. Age is probably a risk factor for mortality because of its association with comorbid illnesses, impaired immunologic responses, malnutrition, increased exposure to potentially resistant pathogens in nursing homes, and increased utilization of medical devices, such as indwelling catheters and central venous lines [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/16,25,48\">",
"     16,25,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Site of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;The site of infection in patients with sepsis may be an important determinant of outcome, with urosepsis generally being associated with the lowest mortality rates [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/41,49\">",
"     41,49",
"    </a>",
"    ]. One study found that mortality from sepsis was 50 to 55 percent when the source of infection was unknown, gastrointestinal, or pulmonary, compared to only 30 percent when the source of infection was the urinary tract [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Approximately 50 percent of patients with severe sepsis are bacteremic at the time of diagnosis according to one study [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/50\">",
"     50",
"    </a>",
"    ]. This is consistent with a study of 85,750 hospital admissions, which found that the incidence of positive blood cultures increased along a continuum, ranging from 17 percent of patients with sepsis to 69 percent with septic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/51\">",
"     51",
"    </a>",
"    ]. However, the presence or absence of a positive blood culture does not appear to influence the outcome, suggesting that prognosis is more closely related to the severity of sepsis than the severity of the underlying infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/51,52\">",
"     51,52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Type of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sepsis due to nosocomial pathogens has a higher mortality than sepsis due to community-acquired pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]. Increased mortality is associated with bloodstream infections due to methicillin-resistant staphylococcus aureus (odds ratio 2.70, 95% CI 2.03-3.58), non-candidal fungus (odds ratio 2.66, 95% CI 1.27-5.58), candida (odds ratio 2.32 95% CI 1.21-4.45), methicillin-sensitive staphylococcus aureus (odds ratio 1.9, 95% CI 1.53-2.36), and pseudomonas (odds ratio 1.6, 95% CI 1.04-2.47), as well as polymicrobial infections (odds ratio 1.69, 95% CI 1.24-2.30) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/53\">",
"     53",
"    </a>",
"    ]. When bloodstream infections become severe (ie, severe sepsis or septic shock), the outcome is similar regardless of whether the pathogens are Gram-negative or Gram-positive bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/8,55\">",
"     8,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Antimicrobial therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies have shown that appropriate antibiotic therapy (ie, antibiotics to which the pathogen is sensitive) has a beneficial impact on bacteremic sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/43,52\">",
"     43,52",
"    </a>",
"    ]. In one report, for example, early institution of adequate antibiotic therapy was associated with a 50 percent reduction in the mortality rate compared to antibiotic therapy to which the infecting organisms were resistant [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/43\">",
"     43",
"    </a>",
"    ]. In contrast, prior antibiotic therapy (ie, antibiotics within the past 90 days) may be associated with increased mortality, at least among patients with Gram negative sepsis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/56\">",
"     56",
"    </a>",
"    ]. This is probably because patients who have received prior antibiotic therapy are more likely to have higher rates of antibiotic resistance, making it less likely that appropriate antibiotic therapy will be chosen empirically.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13664798\">",
"    <span class=\"h2\">",
"     Restoration of perfusion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Failure to aggressively try to restore perfusion early (ie, failure to initiate early goal-directed therapy) may also be associated with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24744/abstract/57\">",
"     57",
"    </a>",
"    ]. This is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=see_link&amp;anchor=H3877618#H3877618\">",
"     \"Evaluation and management of severe sepsis and septic shock in adults\", section on 'Interventions to restore perfusion'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=see_link\">",
"       \"Patient information: Sepsis in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4127684\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sepsis and the systemic inflammatory response syndrome (SIRS) are consequences of a dysregulated inflammatory response to infectious and non-infectious insults, respectively. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sepsis exists on a continuum of severity: infection is the invasion of normally sterile tissue by organisms; bacteremia is the presence of viable bacteria in the blood; sepsis is defined as the presence (probable or documented) of infection together with systemic manifestations of infection; severe sepsis refers to sepsis plus sepsis-induced organ dysfunction; and septic shock is defined as sepsis-induced hypotension persisting despite adequate fluid resuscitation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      SIRS is a similar syndrome in which two or more abnormalities in temperature, heart rate, respiration, or white blood cell count occur in response to a non-infectious insult. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Systemic inflammatory response syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Multiple organ dysfunction syndrome refers to progressive deterioration of organ function in an acutely ill patient. It is the most severe end of the spectrum for both sepsis and SIRS. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Multiple organ dysfunction syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Risk factors for sepsis include a nosocomial infection, bacteremia, advanced age, immunosuppression, and community-acquired pneumonia. Genetic defects have also been identified that may increase susceptibility to specific classes of microorganisms. (See",
"      <a class=\"local\" href=\"#H4127955\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence and severity of sepsis appear to be increasing, with Gram positive bacteria being the pathogens that are most commonly isolated from patients with sepsis. Mortality due to sepsis is high, but appears to have decreased. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Poor prognostic factors include the inability to mount a fever, leukopenia, age &gt;40 years, certain comorbidities (eg, AIDS, hepatic failure, cirrhosis, cancer, alcohol dependence, immunosuppression), a non-urinary source of infection, a nosocomial source of infection, and inappropriate antibiotic coverage. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Prognostic factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/1\">",
"      American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992; 20:864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/2\">",
"      Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med 2003; 31:1250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/3\">",
"      Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013; 41:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/4\">",
"      Annane D, Bellissant E, Cavaillon JM. Septic shock. Lancet 2005; 365:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/5\">",
"      Marshall JC, Cook DJ, Christou NV, et al. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med 1995; 23:1638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/6\">",
"      Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA 1995; 274:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/7\">",
"      Sands KE, Bates DW, Lanken PN, et al. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997; 278:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/8\">",
"      Bone RC, Fisher CJ Jr, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/9\">",
"      Ziegler EJ, Fisher CJ Jr, Sprung CL, et al. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/10\">",
"      Abraham E, Wunderink R, Silverman H, et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group. JAMA 1995; 273:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/11\">",
"      Dhainaut JF, Vincent JL, Richard C, et al. CDP571, a humanized antibody to human tumor necrosis factor-alpha: safety, pharmacokinetics, immune response, and influence of the antibody on cytokine concentrations in patients with septic shock. CPD571 Sepsis Study Group. Crit Care Med 1995; 23:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/12\">",
"      Jones GR, Lowes JA. The systemic inflammatory response syndrome as a predictor of bacteraemia and outcome from sepsis. QJM 1996; 89:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/13\">",
"      Martin GS, Mannino DM, Moss M. The effect of age on the development and outcome of adult sepsis. Crit Care Med 2006; 34:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/14\">",
"      Dremsizov T, Clermont G, Kellum JA, et al. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest 2006; 129:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/15\">",
"      Netea MG, van der Meer JW. Immunodeficiency and genetic defects of pattern-recognition receptors. N Engl J Med 2011; 364:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/16\">",
"      Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/17\">",
"      Kreger BE, Craven DE, Carling PC, McCabe WR. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med 1980; 68:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/18\">",
"      Shubin H, Weil MH. Bacterial shock. JAMA 1976; 235:421.",
"     </a>",
"    </li>",
"    <li>",
"     Elixhauser A, Friedman B, Stranges E. Septicemia in U.S. Hospitals, 2009. Agency for Healthcare Research and Quality, Rockville, MD file://www.hcup-us.ahrq.gov/reports/statbriefs/sb122.pdf (Accessed on February 15, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/20\">",
"      Esper AM, Martin GS. Extending international sepsis epidemiology: the impact of organ dysfunction. Crit Care 2009; 13:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/21\">",
"      Blanco J, Muriel-Bomb&iacute;n A, Sagredo V, et al. Incidence, organ dysfunction and mortality in severe sepsis: a Spanish multicentre study. Crit Care 2008; 12:R158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/22\">",
"      Harrison DA, Welch CA, Eddleston JM. The epidemiology of severe sepsis in England, Wales and Northern Ireland, 1996 to 2004: secondary analysis of a high quality clinical database, the ICNARC Case Mix Programme Database. Crit Care 2006; 10:R42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/23\">",
"      Danai P, Martin GS. Epidemiology of sepsis: recent advances. Curr Infect Dis Rep 2005; 7:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/24\">",
"      Danai PA, Sinha S, Moss M, et al. Seasonal variation in the epidemiology of sepsis. Crit Care Med 2007; 35:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/25\">",
"      Angus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/26\">",
"      Angus DC, Kelley MA, Schmitz RJ, et al. Caring for the critically ill patient. Current and projected workforce requirements for care of the critically ill and patients with pulmonary disease: can we meet the requirements of an aging population? JAMA 2000; 284:2762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/27\">",
"      Uslan DZ, Crane SJ, Steckelberg JM, et al. Age- and sex-associated trends in bloodstream infection: a population-based study in Olmsted County, Minnesota. Arch Intern Med 2007; 167:834.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/28\">",
"      Pop-Vicas A, Tacconelli E, Gravenstein S, et al. Influx of multidrug-resistant, gram-negative bacteria in the hospital setting and the role of elderly patients with bacterial bloodstream infection. Infect Control Hosp Epidemiol 2009; 30:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/29\">",
"      Klotz SA, Chasin BS, Powell B, et al. Polymicrobial bloodstream infections involving Candida species: analysis of patients and review of the literature. Diagn Microbiol Infect Dis 2007; 59:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/30\">",
"      Whittaker SA, Mikkelsen ME, Gaieski DF, et al. Severe Sepsis Cohorts Derived From Claims-Based Strategies Appear to be Biased Toward a More Severely Ill Patient Population*. Crit Care Med 2013; 41:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/31\">",
"      Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Rapid increase in hospitalization and mortality rates for severe sepsis in the United States: a trend analysis from 1993 to 2003. Crit Care Med 2007; 35:1244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/32\">",
"      Esper A, Martin GS. Is severe sepsis increasing in incidence AND severity? Crit Care Med 2007; 35:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/33\">",
"      Rangel-Frausto MS, Pittet D, Costigan M, et al. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/34\">",
"      Padkin A, Goldfrad C, Brady AR, et al. Epidemiology of severe sepsis occurring in the first 24 hrs in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003; 31:2332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/35\">",
"      Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 2006; 34:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/36\">",
"      Dombrovskiy VY, Martin AA, Sunderram J, Paz HL. Facing the challenge: decreasing case fatality rates in severe sepsis despite increasing hospitalizations. Crit Care Med 2005; 33:2555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/37\">",
"      Winters BD, Eberlein M, Leung J, et al. Long-term mortality and quality of life in sepsis: a systematic review. Crit Care Med 2010; 38:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/38\">",
"      Lagu T, Rothberg MB, Shieh MS, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/39\">",
"      Perl TM, Dvorak L, Hwang T, Wenzel RP. Long-term survival and function after suspected gram-negative sepsis. JAMA 1995; 274:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/40\">",
"      Sasse KC, Nauenberg E, Long A, et al. Long-term survival after intensive care unit admission with sepsis. Crit Care Med 1995; 23:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/41\">",
"      Knaus WA, Sun X, Nystrom O, Wagner DP. Evaluation of definitions for sepsis. Chest 1992; 101:1656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/42\">",
"      Peres Bota D, Lopes Ferreira F, M&eacute;lot C, Vincent JL. Body temperature alterations in the critically ill. Intensive Care Med 2004; 30:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/43\">",
"      Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. IV. Re-evaluation of clinical features and treatment in 612 patients. Am J Med 1980; 68:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/44\">",
"      Walkey AJ, Wiener RS, Ghobrial JM, et al. Incident stroke and mortality associated with new-onset atrial fibrillation in patients hospitalized with severe sepsis. JAMA 2011; 306:2248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/45\">",
"      Poutsiaka DD, Davidson LE, Kahn KL, et al. Risk factors for death after sepsis in patients immunosuppressed before the onset of sepsis. Scand J Infect Dis 2009; 41:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/46\">",
"      O'Brien JM Jr, Lu B, Ali NA, et al. Alcohol dependence is independently associated with sepsis, septic shock, and hospital mortality among adult intensive care unit patients. Crit Care Med 2007; 35:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/47\">",
"      Danai PA, Moss M, Mannino DM, Martin GS. The epidemiology of sepsis in patients with malignancy. Chest 2006; 129:1432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/48\">",
"      Girard TD, Opal SM, Ely EW. Insights into severe sepsis in older patients: from epidemiology to evidence-based management. Clin Infect Dis 2005; 40:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/49\">",
"      Krieger JN, Kaiser DL, Wenzel RP. Urinary tract etiology of bloodstream infections in hospitalized patients. J Infect Dis 1983; 148:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/50\">",
"      Bone RC, Fisher CJ Jr, Clemmer TP, et al. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989; 17:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/51\">",
"      Brun-Buisson C, Doyon F, Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996; 154:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/52\">",
"      Zahar JR, Timsit JF, Garrouste-Orgeas M, et al. Outcomes in severe sepsis and patients with septic shock: pathogen species and infection sites are not associated with mortality. Crit Care Med 2011; 39:1886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/53\">",
"      Shorr AF, Tabak YP, Killian AD, et al. Healthcare-associated bloodstream infection: A distinct entity? Insights from a large U.S. database. Crit Care Med 2006; 34:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/54\">",
"      Labelle A, Juang P, Reichley R, et al. The determinants of hospital mortality among patients with septic shock receiving appropriate initial antibiotic treatment*. Crit Care Med 2012; 40:2016.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/55\">",
"      Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. The Veterans Administration Systemic Sepsis Cooperative Study Group. N Engl J Med 1987; 317:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/56\">",
"      Johnson MT, Reichley R, Hoppe-Bauer J, et al. Impact of previous antibiotic therapy on outcome of Gram-negative severe sepsis. Crit Care Med 2011; 39:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24744/abstract/57\">",
"      Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. N Engl J Med 2001; 345:1368.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1657 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.247-05EE575892-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24744=[""].join("\n");
var outline_f24_10_24744=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4127684\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Bacteremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Systemic inflammatory response syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Severe sepsis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Septic shock",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Multiple organ dysfunction syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4127955\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4128146\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4128337\">",
"      Pathogens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4128344\">",
"      Disease severity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4128153\">",
"      Mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PROGNOSTIC FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Host response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Site of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Type of infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Antimicrobial therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13664798\">",
"      Restoration of perfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4127684\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/1657\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/1657|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/26/23983\" title=\"figure 1\">",
"      Trends in hospital stays with septicemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17919\" title=\"figure 2\">",
"      Incidence of sepsis by race",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/30/42477\" title=\"figure 3\">",
"      Sepsis in-hospital mortality",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/51/21306?source=related_link\">",
"      Evaluation and management of severe sepsis and septic shock in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/20/5449?source=related_link\">",
"      Pathophysiology of sepsis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/50/33569?source=related_link\">",
"      Patient information: Sepsis in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/62/6120?source=related_link\">",
"      Shock in adults: Types, presentation, and diagnostic approach",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_10_24745="Approach to the patient with eosinophilia";
var content_f24_10_24745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the patient with eosinophilia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Peter F Weller, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/10/24745/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/10/24745/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A broad variety of allergic, infectious, neoplastic, and idiopathic diseases are associated with increased blood",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue eosinophilia and range in severity from self-limited conditions to life-threatening disorders. The major causes of blood and tissue eosinophilia will be reviewed here (",
"    <a class=\"graphic graphic_table graphicRef76434 \" href=\"UTD.htm?26/0/26636\">",
"     table 1",
"    </a>",
"    ). The biology and function of eosinophils, diseases with eosinophilic involvement of specific organs, and the clinical manifestations, pathophysiology, diagnosis, and treatment of the hypereosinophilic syndromes are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=see_link\">",
"     \"Diseases with eosinophilic involvement of specific organs\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=see_link\">",
"     \"Treatment of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given the diversity of medical conditions that may be associated with increased blood eosinophilia, the evaluation of such patients must include consideration of the diverse medical conditions that may contribute to eosinophilia. Levels of blood eosinophilia are labile, and absolute thresholds for various clinical conditions cannot be definitively established. In the setting of asthma, eosinophils levels are usually less than",
"    <span class=\"nowrap\">",
"     1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/1\">",
"     1",
"    </a>",
"    ]. In the setting of Churg-Strauss Syndrome (often with asthma), however, blood eosinophil levels are greater than",
"    <span class=\"nowrap\">",
"     1500/mm",
"     <sup>",
"      3",
"     </sup>",
"     .",
"    </span>",
"    Low levels of blood eosinophils have been observed in the setting of eosinophil-mediated cardiac damage [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/2\">",
"     2",
"    </a>",
"    ]. However, sustained elevated levels of blood eosinophilia should prompt ongoing pursuit of an etiology for the eosinophilia and monitoring for organ-associated damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Definitions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although accepted upper limits of normal blood eosinophil numbers vary somewhat, a value above 500",
"    <span class=\"nowrap\">",
"     eosinophils/microL",
"    </span>",
"    of blood is abnormal in the vast majority of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/3,4\">",
"     3,4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The degree of eosinophilia can be categorized into mild (500 to 1500",
"      <span class=\"nowrap\">",
"       cells/microL),",
"      </span>",
"      moderate (1500 to 5000",
"      <span class=\"nowrap\">",
"       cells/microL)",
"      </span>",
"      or severe (&gt;5000",
"      <span class=\"nowrap\">",
"       cells/microL).",
"      </span>",
"     </li>",
"     <li>",
"      The term &ldquo;hypereosinophilia&rdquo; refers to eosinophil levels",
"      <span class=\"nowrap\">",
"       &gt;1500/microL,",
"      </span>",
"      which can be associated with tissue and organ damage, regardless of the underlying cause.",
"     </li>",
"     <li>",
"      The term &ldquo;hypereosinophilic syndrome&rdquo; has been variously defined, with one proposal being the presence of an eosinophil count",
"      <span class=\"nowrap\">",
"       &gt;1500/microL",
"      </span>",
"      in the absence of a discernable secondary cause (eg, allergic diseases, drug hypersensitivity, parasitic helminth infections, HIV infection, nonhematologic malignancies) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/5,6\">",
"       5,6",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Categories of eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral eosinophilia can be divided into categories of primary, secondary, or idiopathic eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Primary eosinophilia usually occurs in the context of hematologic malignancies, such as acute leukemias or chronic myeloid disorders, when there is evidence of clonal expansion of eosinophils.",
"   </p>",
"   <p>",
"    The most common infectious cause for secondary eosinophilia is a tissue invasive parasite. Noninfectious causes of secondary eosinophilia include allergic disorders, medications, toxins, autoimmune diseases, and endocrine disorders, such as Addison's disease. Eosinophils can also be seen in Hodgkin's and non-Hodgkin lymphoma and other metastatic cancers, but the associated eosinophils are not of a clonal nature in this situation.",
"   </p>",
"   <p>",
"    A diagnosis of idiopathic eosinophilia is considered when a thorough evaluation does not identify either a primary or secondary cause of eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Patient evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood eosinophilia most commonly reflects an allergic, infectious, or neoplastic process [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. A thorough investigation of a patient with eosinophilia requires consideration of the patient's history, physical examination, and information from laboratory and imaging studies.",
"   </p>",
"   <p>",
"    In the initial evaluation, information regarding allergic symptoms, international travel, current and recent medications, and constitutional symptoms should be sought. If the medication and allergy history is unrevealing, three stool specimens should be examined for ova and parasites. In the setting of international travel or other geographic exposures to helminthic parasites, then additional work-up including serologic tests depends on the geographic area that the patient visited. Those with symptoms consistent with allergic rhinitis may be diagnosed by examination of a nasal smear for eosinophils. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Allergic disorders'",
"    </a>",
"    below.) Patients with a suspected clonal disorder will need a hematologic evaluation. (See",
"    <a class=\"local\" href=\"#H17\">",
"     'Hematologic and neoplastic disorders'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Eosinophilic inflammation of specific organs alters the differential diagnosis (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=see_link\">",
"     \"Diseases with eosinophilic involvement of specific organs\"",
"    </a>",
"    ). Blood eosinophil numbers do not necessarily indicate the extent of eosinophil involvement in affected tissues because the cells are primarily tissue-dwelling and are several hundredfold more abundant in tissues than in blood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/9\">",
"     9",
"    </a>",
"    ]. Eosinophils are most numerous in tissues with a mucosal epithelial interface with the environment, such as the respiratory, gastrointestinal, and lower genitourinary tracts. Patient evaluation may require biopsy of the specific organ of concern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ALLERGIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilia commonly results from atopic conditions, such as atopic dermatitis, asthma, and various forms of rhinitis, as well as allergic drug reactions. The mechanism of drug-induced eosinophilia frequently is not IgE-mediated and is not well characterized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Atopic dermatitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripheral blood eosinophilia is present in some patients with atopic dermatitis and may be associated with concomitant food allergy and lower rates of remission over time [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood eosinophilia is common in allergic asthma and eosinophil numbers are increased in airway tissues in both allergic and nonallergic asthma, although blood eosinophilia in asthma is usually less than",
"    <span class=\"nowrap\">",
"     1500/mm",
"     <sup>",
"      3",
"     </sup>",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/13\">",
"     13",
"    </a>",
"    ]. Sputum eosinophilia is characteristic of asthma and assists in differentiation from chronic obstructive pulmonary disease [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/14\">",
"     14",
"    </a>",
"    ]. Sputum, but not blood, eosinophilia is also prominent in the syndrome of chronic cough with eosinophilic bronchitis in the absence of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/15\">",
"     15",
"    </a>",
"    ], and may be occasionally encountered in patients with emphysema, chronic bronchitis, and interstitial pulmonary fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/16\">",
"     16",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=see_link\">",
"     \"Diagnosis of asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Rhinitis syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In allergic rhinitis, nasal eosinophilia is more common than peripheral blood eosinophilia. Nasal eosinophilia with or without blood eosinophilia is not specific for allergic rhinitis and may be present in other conditions, including [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Nasal polyposis, with or without asthma and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      sensitivity",
"     </li>",
"     <li>",
"      Nonallergic rhinitis with eosinophilia syndrome (NARES)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These disorders are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link\">",
"     \"Aspirin exacerbated respiratory disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6201733\">",
"    <span class=\"h2\">",
"     Gastrointestinal disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilic gastrointestinal disorders represent a family of diseases including eosinophilic esophagitis, gastritis, and colitis. These topics are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=see_link\">",
"     \"Treatment of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=see_link\">",
"     \"Eosinophilic gastroenteritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Medication-related eosinophilia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The administration of many conventional or alternative medications may produce eosinophilia; thus, a detailed history of current or past medication use is required when evaluating a patient with this condition.",
"   </p>",
"   <p>",
"    The attribution of eosinophilia to a specific medication is made on the basis of a temporal relationship of eosinophilia and a potential offending agent. Although eosinophilia presumably results from augmented activities of one or more eosinophil growth factor cytokines (eg, interleukin-5), the mechanisms underlying blood or specific tissue eosinophilia remain to be defined for many drug-associated eosinophilias. Because of the heterogeneity of mechanisms that may produce medication-related eosinophilia, there is no consistent time course over which to expect resolution of eosinophilia following cessation of a candidate medication.",
"   </p>",
"   <p>",
"    Blood eosinophilia by itself need not necessitate cessation of drug therapy but should lead to an evaluation of organs likely to be involved in eosinophil-associated drug reactions, including the lungs, kidneys, and heart (",
"    <a class=\"graphic graphic_table graphicRef62569 \" href=\"UTD.htm?34/44/35531\">",
"     table 2",
"    </a>",
"    ). If organ dysfunction develops, cessation of the inciting drug is necessary. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=see_link\">",
"     \"Drug allergy: Classification and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=see_link\">",
"     \"An approach to the patient with drug allergy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INFECTIOUS DISEASES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Important infectious causes of eosinophilia include parasitic and fungal diseases as well as specific retroviral infections. Most acute bacterial or viral infections characteristically produce eosinopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/1\">",
"     1",
"    </a>",
"    ]. Even in patients with eosinophilia due to parasitic or allergic diseases, the development of intercurrent bacterial or viral infections leads to suppression of blood eosinophilia until the superimposed acute infection has resolved.",
"   </p>",
"   <p>",
"    Thus, heightened or even normal blood eosinophil numbers in a febrile patient should prompt consideration of a noninfectious cause, such as an eosinophilic syndrome-related illness or adrenal insufficiency. The mechanisms responsible for infection-related eosinopenia have not been precisely delineated but the phenomenon probably is due to heightened endogenous corticosteroid production and the actions of various inflammatory mediators [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Parasitic infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilia is prominent in a number of helminthic parasitic diseases. The eosinophilic response to helminths is determined both by the host's immune response and by the parasite, including its distribution, migration, and development within the infected host.",
"   </p>",
"   <p>",
"    The level of eosinophilia parallels the magnitude and extent of tissue invasion by helminthic larvae or adults. The height of the eosinophilia peaks early in the course of infection with several helminths since the migration of larvae is greatest at this time (",
"    <a class=\"graphic graphic_table graphicRef82384 \" href=\"UTD.htm?19/22/19820\">",
"     table 3",
"    </a>",
"    ). However, the absence of eosinophilia does not exclude the presence of these organisms.",
"   </p>",
"   <p>",
"    For established infections, tissue eosinophilia around helminths may not be accompanied by blood eosinophilia when the organism is antigenically sequestered within tissues (eg, intact echinococcal cysts) or is limited solely to the intestinal lumen (eg, tapeworms or adult Ascaris roundworms). Intermittent leakage of fluids from echinococcal cysts can transiently stimulate increases in blood eosinophilia and elicit urticaria, bronchospasm, or anaphylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .) Several helminths can lead to long-lasting eosinophilia (",
"    <a class=\"graphic graphic_table graphicRef59981 \" href=\"UTD.htm?10/42/10924\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Infections with a diversity of helminthic parasites elicit eosinophilia via stimulation of Th2-like lymphocyte responses [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. The TH2 response is characterized by production of IL-4 and IL-5, subsequently generating IgG1 and IgE-secreting cells, and eliciting eosinophilia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Diagnostic considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Amongst the helminths, the principal parasites that need to be evaluated are Strongyloides stercoralis, hookworm, filariae, and Toxocara canis. The diagnostic considerations can also vary according to geographic origin. One report, for example, evaluated 128 Indochinese patients with eosinophilia, the cause of which was not apparent by routine screening [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/22\">",
"     22",
"    </a>",
"    ]. Hookworm (55 percent) and S. stercoralis (38 percent) were the most common organisms identified. In contrast, a study performed in African immigrants found that the most commonly diagnosed parasitic infections were filariae (30 percent), schistosomes (17 percent), hookworms (17 percent), and whipworms (8 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following caveats also need to be considered when evaluating a patient with eosinophilia:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strongyloides can persist for decades without causing major symptoms. The infection elicits varying degrees of eosinophilia ranging from minimal to such high magnitude that it is mistaken for a hypereosinophilic syndrome. Disseminated, fatal disease (hyperinfection syndrome) can develop in patients unsuspectingly given corticosteroids or immunosuppressive therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/24\">",
"       24",
"      </a>",
"      ]. In the patient with eosinophilia, serology is useful in detecting strongyloidiasis when fecal examinations are unrevealing [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/22,25\">",
"       22,25",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=see_link&amp;anchor=H10#H10\">",
"       \"Strongyloidiasis\", section on 'Role of immunosuppression'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Visceral larva migrans due to Toxocara canis should be considered in children with a propensity for geophagous pica and ingestion of dirt contaminated by dog ascarid eggs. Serologic testing can confirm the diagnosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=see_link\">",
"       \"Toxocariasis: visceral and ocular larva migrans\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast to infections with multicellular helminthic parasites, infections with single-celled protozoan parasites, including enteric Giardia lamblia and Entamoeba histolytica, do",
"      <strong>",
"       NOT",
"      </strong>",
"      characteristically elicit blood eosinophilia. Identification of these protozoan pathogens in stool examinations does not complete a diagnostic workup for eosinophilia since other potential pathogens should still be sought [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/26\">",
"       26",
"      </a>",
"      ]. There are two exceptions to the general rule that protozoan parasites, including those in the GI tract, do not elicit eosinophilia: Dientamoeba fragilis and Isospora belli. Thus, in patients with symptoms of enteric infection (eg, loose stools or diarrhea) and eosinophilia, diagnostic trophozoites of D. fragilis or oocysts of I. belli should be sought in stool examinations. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35237?source=see_link\">",
"       \"Dientamoeba fragilis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=see_link\">",
"       \"Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Laboratory evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis can be narrowed based upon clinical findings and geographic considerations. Depending on the travel history, stool examination for ova and parasites should be done when certain helminthic infections are being considered (eg, Strongyloides, Hookworm, Fasciolopsis buski, Clonorchis sinensis). In the case of light infections, multiple stools may need to be examined.",
"   </p>",
"   <p>",
"    Patients with negative stool examinations may have tissue- or blood-dwelling helminthic infections that require serologic tests for diagnosis (eg, Trichinella spiralis, Wuchereria bancrofti, Toxocara canis, Schistosoma, Echinococcus).",
"   </p>",
"   <p>",
"    Urine sedimentation can be considered for the evaluation of suspected Schistosoma haematobium or in the setting of chyluria due to Wuchereria bancrofti. Sputum analysis can be ordered for suspected pulmonary infection with Strongyloides or Paragonimus.",
"   </p>",
"   <p>",
"    The optimal management of the asymptomatic traveler or immigrant with eosinophilia is uncertain. Up to 50 percent of patients never have a cause of their eosinophilia identified despite exhaustive evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/27\">",
"     27",
"    </a>",
"    ]. Others have suggested a strategy of using empiric anthelminthic therapies [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Fungal infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspergillosis, in the form of allergic bronchopulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/29\">",
"     29",
"    </a>",
"    ], and coccidioidomycosis are associated with eosinophilia. Blood eosinophilia is found in most patients with allergic bronchopulmonary aspergillosis and in approximately 25 percent of patients with primary coccidioidomycosis, in which it peaks during the second or third week of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/30\">",
"     30",
"    </a>",
"    ]. Eosinophilia also may be seen in disseminated coccidioidomycosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=see_link&amp;anchor=H13#H13\">",
"     \"Allergic bronchopulmonary aspergillosis\", section on 'ABPA and pulmonary eosinophilia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=see_link&amp;anchor=H6#H6\">",
"     \"Primary coccidioidal infection\", section on 'Clinical manifestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     HIV and other retroviral infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Modest to marked eosinophilia of unknown cause occasionally is observed in HIV-1-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. The eosinophilia is usually due to one of the following conditions rather than being directly induced by HIV-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Leukopenia may lead to an increased eosinophil percentages without absolute eosinophilia, and any therapy with GM-CSF can stimulate actual eosinophilia",
"     </li>",
"     <li>",
"      Reactions to medications, including those for prophylaxis against opportunistic infections",
"     </li>",
"     <li>",
"      Adrenal insufficiency due to cytomegalovirus and other infections with consequent eosinophilia [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/36\">",
"       36",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22312?source=see_link\">",
"       \"Pituitary and adrenal gland dysfunction in HIV-infected patients\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eosinophilic folliculitis, a common dermatologic disorder in HIV-positive patients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/37\">",
"       37",
"      </a>",
"      ]&nbsp;(see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24359?source=see_link\">",
"       \"HIV-associated eosinophilic folliculitis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Marked hypereosinophilia has developed uncommonly in association with the hyperimmunoglobulin E syndrome or exfoliative dermatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, eosinophilia is more often associated with human T-lymphotropic virus (HTLV)-I and especially HTLV-II infections [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC AND NEOPLASTIC DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Eosinophilia may result from either benign or malignant hematologic disorders or in association with solid tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Hypereosinophilic syndromes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The hypereosinophilic syndromes are associated with marked peripheral eosinophilia and involvement of multiple organs such as the heart, gastrointestinal tract, lungs, brain, and kidneys [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/43\">",
"     43",
"    </a>",
"    ]. While some types of hypereosinophilic syndromes remain idiopathic, others are associated with aberrant lymphocytes or with chromosomal abnormalities resulting in constitutive activation of receptor tyrosine kinases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=see_link\">",
"     \"Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mastocytosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Systemic mastocytosis is characterized by proliferation and accumulation of mast cells in various organs including the skin, liver, spleen, bone marrow, and lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/46\">",
"     46",
"    </a>",
"    ]. Patients present with symptoms resulting from organomegaly, hematologic or cutaneous abnormalities, and complications arising from the release of mast cell mediators. Peripheral eosinophilia accompanies systemic mast cell disease in up to 20 percent of cases, and bone marrow biopsies often show excess eosinophils [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=see_link\">",
"     \"Evaluation and diagnosis of mastocytosis (cutaneous and systemic)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Leukemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute eosinophilic leukemia is a variant of the FAB M4 phenotype of acute myelomonocytic leukemia and has the common FAB M4 characteristic of chromosomal 16 abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=see_link\">",
"     \"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=see_link&amp;anchor=H993131070#H993131070\">",
"     \"Cytogenetics in acute myeloid leukemia\", section on 'Inv(16) and t(16;16)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other acute leukemias that may be associated with eosinophilia include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Precursor B-cell acute lymphoblastic leukemia with t(5;14) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/51\">",
"       51",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Precursor T-cell lymphoblastic lymphoma with t(8;13) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/52\">",
"       52",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Chronic eosinophilic leukemia is a rare clonal chronic myeloproliferative disorder characterized by overproduction of dysplastic eosinophils with normal plasma concentrations of interleukin (IL)-3 and IL-5, bone marrow hyperplasia with myeloid dysplasia, and a tendency to progress to acute myeloid leukemia (AML). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical manifestations and diagnosis of chronic myeloid leukemia\", section on 'Chronic eosinophilic leukemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Lymphoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;As many as 15 percent of patients with Hodgkin lymphoma and 5 percent with B cell non-Hodgkin lymphoma have modest peripheral blood eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/53\">",
"     53",
"    </a>",
"    ]. Lesional eosinophilia is most common with nodular sclerosing Hodgkin lymphoma, and heavy eosinophilic infiltration indicates a poorer prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eosinophilia in Hodgkin lymphoma has been correlated with the expression of IL-5 mRNA by Reed-Sternberg cells [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/55\">",
"     55",
"    </a>",
"    ]. T-cell lymphoblastic lymphoma and adult T-cell",
"    <span class=\"nowrap\">",
"     leukemia/lymphoma",
"    </span>",
"    have also been associated with eosinophilia via a similar mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/56-58\">",
"     56-58",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=see_link\">",
"     \"Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other malignancies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other neoplasms are occasionally associated with blood eosinophilia and lesional eosinophilic infiltration. In the S&eacute;zary syndrome, dysregulated cytokine production from Th2-like lymphocytes is associated with increased serum IgE and eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. Tumor-associated eosinophilia occurs with large cell non-keratinizing cervical tumors, large cell undifferentiated lung carcinomas, squamous carcinomas of the vagina, penis, skin, and nasopharynx, adenocarcinomas of the stomach, large bowel and uterine body, and transitional cell bladder carcinoma. The finding of eosinophilic infiltration does not reliably affect prognosis in these disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     RHEUMATIC DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among rheumatic conditions, tissue",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    blood eosinophilia occur primarily as a feature of the eosinophilia-myalgia syndrome and idiopathic eosinophilic synovitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Eosinophilia-myalgia syndrome and toxic oil syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;The eosinophilia-myalgia syndrome was attributed to ingestion of a contaminated preparation of L-tryptophan, while the toxic oil syndrome was caused by ingestion of edible oil adulterated with denatured rapeseed oil [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/61\">",
"     61",
"    </a>",
"    ]. Both of these entities are chronic, persistent, multisystem diseases in which eosinophilia develops. Few new cases of these two syndromes have been reported since the offending agents were recognized. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/65?source=see_link&amp;anchor=H14#H14\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\", section on 'L-tryptophan'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/4/65?source=see_link&amp;anchor=H13#H13\">",
"     \"Risk factors for and possible causes of systemic sclerosis (scleroderma)\", section on 'Contaminated rapeseed oil'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Idiopathic eosinophilic synovitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic eosinophilic synovitis is an acute painless monoarthritis that develops 12 to 24 hours after minor trauma and most commonly affects the knee and metatarsophalangeal joints [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. Effusions are large but not usually accompanied by other signs of arthritis such as warmth, erythema or pain. The condition must be differentiated from other causes of synovial eosinophilia, including tuberculous, filarial infections, metastatic carcinoma, urticaria, Lyme disease, and following arthrography or radiation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/64-67\">",
"     64-67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Eosinophilia is uncommon in other rheumatic diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/68\">",
"     68",
"    </a>",
"    ], but occasionally accompanies dermatomyositis, severe rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/69\">",
"     69",
"    </a>",
"    ], progressive systemic sclerosis, or Sj&ouml;gren's syndrome complicated by polymyopathy and vasculitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/70\">",
"     70",
"    </a>",
"    ]. When eosinophilia occurs in rheumatoid arthritis, the differential diagnosis includes the development of concomitant vasculitis or hypersensitivity reactions to therapeutic agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/71\">",
"     71",
"    </a>",
"    ]. Eosinophilia is unusual in systemic scleroderma, and its presence suggests the alternative diagnosis of eosinophilic fasciitis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/72\">",
"     72",
"    </a>",
"    ]. Eosinophilic infiltration into muscle is uncommon but accompanies trichinellosis and has been reported in the hypereosinophilic syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/43\">",
"     43",
"    </a>",
"    ] and eosinophilic myositis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/73\">",
"     73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=see_link\">",
"     \"Trichinellosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Vasculitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Churg-Strauss syndrome is the major vasculitis syndrome associated with eosinophilia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Eosinophilia is unusual in other vasculitides, but is occasionally observed in connective tissue diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/74\">",
"     74",
"    </a>",
"    ], thromboangiitis obliterans with eosinophilia of the temporal arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/75\">",
"     75",
"    </a>",
"    ], and unusual cases of granulomatosis with polyangiitis (Wegener&rsquo;s) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/76,77\">",
"     76,77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MISCELLANEOUS CAUSES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Adrenal insufficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;The loss of endogenous glucocorticoids in any cause of adrenal insufficiency results in blood eosinophilia. Glucocorticoids exert eosinopenic effects, at least in part by stimulating eosinophil, but not neutrophil, apoptosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/78\">",
"     78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that the presence of relative eosinophilia in critically ill patients is associated with clinical signs of relative adrenal insufficiency. In a study of 612 consecutive admissions to a medical-surgical intensive care unit, 40 of 570 assessable patients (7 percent) had relative eosinophilia (eosinophils greater than 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/79\">",
"     79",
"    </a>",
"    ]. Low-dose adrenocorticotropin stimulation testing was abnormal in 10 of these 40 patients (25 percent). Clinical suspicion for the presence of adrenal insufficiency was high in 8 of the 10 patients, and treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    resulted in hemodynamic improvement in seven.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Atheroembolic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cholesterol embolization can lead to an increased erythrocyte sedimentation rate, hypocomplementemia, thrombocytopenia, eosinophilia, eosinophiluria, renal insufficiency, livedo reticularis,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    purple toes [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/80\">",
"     80",
"    </a>",
"    ]. Blood eosinophilia may be the sole clinical clue to this disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=see_link\">",
"     \"Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Immunodeficiency states",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some primary immunodeficiency syndromes are associated with eosinophilia, including the hyper-IgE syndrome (which is characterized by chronic dermatitis and recurrent infections) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/82\">",
"     82",
"    </a>",
"    ] and Omenn's syndrome (combined immunodeficiency with hypereosinophilia) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/83\">",
"     83",
"    </a>",
"    ]. Thymoma may be associated with bone marrow eosinophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/10/24745/abstract/84\">",
"     84",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=see_link\">",
"     \"T cell negative, B cell negative, NK cell positive severe combined immunodeficiency\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/1\">",
"      Bass DA, Gonwa TA, Szejda P, et al. Eosinopenia of acute infection: Production of eosinopenia by chemotactic factors of acute inflammation. J Clin Invest 1980; 65:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/2\">",
"      Blauwet LA, Breen JF, Edwards WD, Klarich KW. Atypical presentation of eosinophilic endomyocardial disease. Mayo Clin Proc 2005; 80:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/3\">",
"      Tefferi A. Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment. Mayo Clin Proc 2005; 80:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/4\">",
"      Roufosse F, Weller PF. Practical approach to the patient with hypereosinophilia. J Allergy Clin Immunol 2010; 126:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/5\">",
"      Klion AD, Bochner BS, Gleich GJ, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol 2006; 117:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/6\">",
"      Simon HU, Rothenberg ME, Bochner BS, et al. Refining the definition of hypereosinophilic syndrome. J Allergy Clin Immunol 2010; 126:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/7\">",
"      Brito-Babapulle F. The eosinophilias, including the idiopathic hypereosinophilic syndrome. Br J Haematol 2003; 121:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/8\">",
"      Lombardi C, Passalacqua G. Eosinophilia and diseases: clinical revision of 1862 cases. Arch Intern Med 2003; 163:1371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/9\">",
"      Weller PF. The immunobiology of eosinophils. N Engl J Med 1991; 324:1110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/10\">",
"      Jenerowicz D, Czarnecka-Operacz M, Silny W. Peripheral blood eosinophilia in atopic dermatitis. Acta Dermatovenerol Alp Panonica Adriat 2007; 16:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/11\">",
"      Noh G, Jin H, Lee J, et al. Eosinophilia as a predictor of food allergy in atopic dermatitis. Allergy Asthma Proc 2010; 31:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/12\">",
"      Horwitz AA, Hossain J, Yousef E. Correlates of outcome for atopic dermatitis. Ann Allergy Asthma Immunol 2009; 103:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/13\">",
"      Bousquet J, Chanez P, Lacoste JY, et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/14\">",
"      Ronchi MC, Piragino C, Rosi E, et al. Role of sputum differential cell count in detecting airway inflammation in patients with chronic bronchial asthma or COPD. Thorax 1996; 51:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/15\">",
"      Gibson PG, Hargreave FE, Girgis-Gabardo A, et al. Chronic cough with eosinophilic bronchitis: examination for variable airflow obstruction and response to corticosteroid. Clin Exp Allergy 1995; 25:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/16\">",
"      Vieira VG, Prolla JC. Clinical evaluation of eosinophils in the sputum. J Clin Pathol 1979; 32:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/17\">",
"      Mullarkey MF. Eosinophilic nonallergic rhinitis. J Allergy Clin Immunol 1988; 82:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/18\">",
"      Jankowski R, Wayoff M, Faure G, et al. [Immunohistology of polyps of the nose and paranasal sinuses. Physiopathologic value]. Ann Otolaryngol Chir Cervicofac 1990; 107:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/19\">",
"      Georgiou S, Maroulis J, Monastirli A, et al. Anaphylactic shock as the only clinical manifestation of hepatic hydatid disease. Int J Dermatol 2005; 44:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/20\">",
"      Liu Z, Liu Q, Pesce J, et al. Requirements for the development of IL-4-producing T cells during intestinal nematode infections: what it takes to make a Th2 cell in vivo. Immunol Rev 2004; 201:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/21\">",
"      Weller PF. Eosinophilia in travelers. Med Clin North Am 1992; 76:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/22\">",
"      Nutman TB, Ottesen EA, Ieng S, et al. Eosinophilia in Southeast Asian refugees: evaluation at a referral center. J Infect Dis 1987; 155:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/23\">",
"      Pardo J, Carranza C, Muro A, et al. Helminth-related Eosinophilia in African immigrants, Gran Canaria. Emerg Infect Dis 2006; 12:1587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/24\">",
"      Nucci M, Portugal R, Pulcheri W, et al. Strongyloidiasis in patients with hematologic malignancies. Clin Infect Dis 1995; 21:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/25\">",
"      Gill GV, Bailey JW. Eosinophilia as a marker for chronic strongyloidiasis--use of a serum ELISA test to detect asymptomatic cases. Ann Trop Med Parasitol 1989; 83:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/26\">",
"      Nutman TB. Asymptomatic peripheral blood eosinophilia redux: common parasitic infections presenting frequently in refugees and immigrants. Clin Infect Dis 2006; 42:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/27\">",
"      Libman MD, MacLean JD, Gyorkos TW. Screening for schistosomiasis, filariasis, and strongyloidiasis among expatriates returning from the tropics. Clin Infect Dis 1993; 17:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/28\">",
"      Muennig P, Pallin D, Sell RL, Chan MS. The cost effectiveness of strategies for the treatment of intestinal parasites in immigrants. N Engl J Med 1999; 340:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/29\">",
"      Bergner RK, Bergner A. Marked peripheral eosinophilia: a clue to allergic bronchopulmonary aspergillosis in office practice. N Engl Reg Allergy Proc 1985; 6:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/30\">",
"      Koepke A, Albus C, Barth A, et al. [Coccidioidomycosis--differential diagnosis of lung infiltrates with peripheral eosinophilia]. Dtsch Med Wochenschr 1989; 114:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/31\">",
"      Schermoly MJ, Hinthorn DR. Eosinophilia in coccidioidomycosis. Arch Intern Med 1988; 148:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/32\">",
"      Harley WB, Blaser MJ. Disseminated coccidioidomycosis associated with extreme eosinophilia. Clin Infect Dis 1994; 18:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/33\">",
"      Sanchez-Borges M, Orozco A, Di Biagio E, et al. Eosinophilia in early-stage human immunodeficiency virus infection. J Allergy Clin Immunol 1993; 92:494.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/34\">",
"      Cohen AJ, Steigbigel RT. Eosinophilia in patients infected with human immunodeficiency virus. J Infect Dis 1996; 174:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/35\">",
"      Friedman, H, Kaslow, R, Winkelstein, A, et al. Longitudinal changes in hematologic manifestations of HIV infection in the multicenter AIDS cohort study (MACS) (abstract). Int Conf AIDS 1991; 7:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/36\">",
"      Marinacci, G, Brighi, S, Ricchi, E, et al. Adrenal insufficiency and acquired immunodeficiency syndrome. Int Conf AIDS 1993; 9:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/37\">",
"      Skiest DJ, Keiser P. Clinical significance of eosinophilia in HIV-infected individuals. Am J Med 1997; 102:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/38\">",
"      Paganelli R, Scala E, Mezzaroma I, et al. Immunologic aspects of hyperimmunoglobulinemia E-like syndrome in patients with AIDS. J Allergy Clin Immunol 1995; 95:995.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/39\">",
"      Drabick JJ, Magill AJ, Smith KJ, et al. Hypereosinophilic syndrome associated with HIV infection. Military Medical Consortium for Applied Retroviral Research. South Med J 1994; 87:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/40\">",
"      May LP, Kelly J, Sanchez M. Hypereosinophilic syndrome with unusual cutaneous manifestations in two men with HIV infection. J Am Acad Dermatol 1990; 23:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/41\">",
"      Kaplan MH, Hall WW, Susin M, et al. Syndrome of severe skin disease, eosinophilia, and dermatopathic lymphadenopathy in patients with HTLV-II complicating human immunodeficiency virus infection. Am J Med 1991; 91:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/42\">",
"      Plumelle Y, Gonin C, Edouard A, et al. Effect of Strongyloides stercoralis infection and eosinophilia on age at onset and prognosis of adult T-cell leukemia. Am J Clin Pathol 1997; 107:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/43\">",
"      Weller PF, Bubley GJ. The idiopathic hypereosinophilic syndrome. Blood 1994; 83:2759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/44\">",
"      Roufosse F, Cogan E, Goldman M. The hypereosinophilic syndrome revisited. Annu Rev Med 2003; 54:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/45\">",
"      Gotlib J, Cools J, Malone JM 3rd, et al. The FIP1L1-PDGFRalpha fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood 2004; 103:2879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/46\">",
"      Golkar L, Bernhard JD. Mastocytosis. Lancet 1997; 349:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/47\">",
"      Yam LT, Yam CF, Li CY. Eosinophilia in systemic mastocytosis. Am J Clin Pathol 1980; 73:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/48\">",
"      Miranda RN, Esparza AR, Sambandam S, Medeiros LJ. Systemic mast cell disease presenting with peripheral blood eosinophilia. Hum Pathol 1994; 25:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/49\">",
"      L&ouml;ffler H, Gassmann W, Haferlach T. AML M1 and M2 with eosinophilia and AML M4Eo: diagnostic and clinical aspects. Leuk Lymphoma 1995; 18 Suppl 1:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/50\">",
"      Bain BJ. Eosinophilic leukaemias and the idiopathic hypereosinophilic syndrome. Br J Haematol 1996; 95:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/51\">",
"      Grimaldi JC, Meeker TC. The t(5;14) chromosomal translocation in a case of acute lymphocytic leukemia joins the interleukin-3 gene to the immunoglobulin heavy chain gene. Blood 1989; 73:2081.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/52\">",
"      Inhorn RC, Aster JC, Roach SA, et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995; 85:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/53\">",
"      Navarro-Rom&aacute;n L, Medeiros LJ, Kingma DW, et al. Malignant lymphomas of B-cell lineage with marked tissue eosinophilia. A report of five cases. Am J Surg Pathol 1994; 18:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/54\">",
"      Enblad G, Sundstrom C, Glimelius B. Infiltration of eosinophils in Hodgkin's disease involved lymph nodes predicts prognosis. Hematol Oncol 1993; 11:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/55\">",
"      Samoszuk M, Nansen L. Detection of interleukin-5 messenger RNA in Reed-Sternberg cells of Hodgkin's disease with eosinophilia. Blood 1990; 75:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/56\">",
"      Abruzzo LV, Jaffe ES, Cotelingam JD, et al. T-cell lymphoblastic lymphoma with eosinophilia associated with subsequent myeloid malignancy. Am J Surg Pathol 1992; 16:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/57\">",
"      Murata K, Yamada Y, Kamihira S, et al. Frequency of eosinophilia in adult T-cell leukemia/lymphoma. Cancer 1992; 69:966.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/58\">",
"      Samoszuk M, Ramzi E, Cooper DL. Interleukin-5 mRNA in three T-cell lymphomas with eosinophilia. Am J Hematol 1993; 42:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/59\">",
"      Borish L, Dishuck J, Cox L, et al. S&eacute;zary syndrome with elevated serum IgE and hypereosinophilia: role of dysregulated cytokine production. J Allergy Clin Immunol 1993; 92:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/60\">",
"      Tancrede-Bohin, E. Arch Dermatol 2004; 140:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/61\">",
"      Kaufman LD, Krupp LB. Eosinophilia-myalgia syndrome, toxic-oil syndrome, and diffuse fasciitis with eosinophilia. Curr Opin Rheumatol 1995; 7:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/62\">",
"      Brown JP, Rola-Pleszczynski M, M&eacute;nard HA. Eosinophilic synovitis: clinical observations on a newly recognized subset of patients with dermatographism. Arthritis Rheum 1986; 29:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/63\">",
"      Atanes A, Fern&aacute;ndez V, N&uacute;&ntilde;ez R, et al. Idiopathic eosinophilic synovitis. Case report and review of the literature. Scand J Rheumatol 1996; 25:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/64\">",
"      Kay J, Eichenfield AH, Athreya BH, et al. Synovial fluid eosinophilia in Lyme disease. Arthritis Rheum 1988; 31:1384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/65\">",
"      Goldenberg DL, Kelley W, Gibbons RB. Metastatic adenocarcinoma of synovium presenting as an acute arthritis. Diagnosis by closed synovial biopsy. Arthritis Rheum 1975; 18:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/66\">",
"      Hasselbacher P, Schumacher HR. Synovial fluid eosinophilia following arthrography. J Rheumatol 1978; 5:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/67\">",
"      Lanham JG, Elkon KB, Pusey CD, Hughes GR. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore) 1984; 63:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/68\">",
"      Kargili A, Bavbek N, Kaya A, et al. Eosinophilia in rheumatologic diseases: a prospective study of 1000 cases. Rheumatol Int 2004; 24:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/69\">",
"      Winchester RJ, Koffler D, Litwin SD, Kunkel HG. Observations on the eosinophilia of certain patients with rheumatoid arthritis. Arthritis Rheum 1971; 14:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/70\">",
"      BLOCH KJ, BUCHANAN WW, WOHL MJ, BUNIM JJ. SJOEGREN'S SYNDROME. A CLINICAL, PATHOLOGICAL, AND SEROLOGICAL STUDY OF SIXTY-TWO CASES. Medicine (Baltimore) 1965; 44:187.",
"     </a>",
"    </li>",
"    <li>",
"     Spry CJF. A Comprehensive Review and Guide to the Scientific and Medical Literature, Oxford Medical Publications, Oxford 1988.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/72\">",
"      Falanga V, Medsger TA Jr. Frequency, levels, and significance of blood eosinophilia in systemic sclerosis, localized scleroderma, and eosinophilic fasciitis. J Am Acad Dermatol 1987; 17:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/73\">",
"      Kaufman LD, Kephart GM, Seidman RJ, et al. The spectrum of eosinophilic myositis. Clinical and immunopathogenic studies of three patients, and review of the literature. Arthritis Rheum 1993; 36:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/74\">",
"      Chen KR, Su WP, Pittelkow MR, Leiferman KM. Eosinophilic vasculitis syndrome: recurrent cutaneous eosinophilic necrotizing vasculitis. Semin Dermatol 1995; 14:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/75\">",
"      Lie JT, Michet CJ Jr. Thromboangiitis obliterans with eosinophilia (Buerger's disease) of the temporal arteries. Hum Pathol 1988; 19:598.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/76\">",
"      Yousem SA, Lombard CM. The eosinophilic variant of Wegener's granulomatosis. Hum Pathol 1988; 19:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/77\">",
"      Krupsky M, Landau Z, Lifschitz-Mercer B, Resnitzky P. Wegener's granulomatosis with peripheral eosinophilia. Atypical variant of a classic disease. Chest 1993; 104:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/78\">",
"      Meagher LC, Cousin JM, Seckl JR, Haslett C. Opposing effects of glucocorticoids on the rate of apoptosis in neutrophilic and eosinophilic granulocytes. J Immunol 1996; 156:4422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/79\">",
"      Beishuizen A, Vermes I, Hylkema BS, Haanen C. Relative eosinophilia and functional adrenal insufficiency in critically ill patients. Lancet 1999; 353:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/80\">",
"      Wilson DM, Salazer TL, Farkouh ME. Eosinophiluria in atheroembolic renal disease. Am J Med 1991; 91:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/81\">",
"      Levine J, Rennke HG, Idelson BA. Profound persistent eosinophilia in a patient with spontaneous renal atheroembolic disease. Am J Nephrol 1992; 12:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/82\">",
"      Hochreutener H, W&uuml;thrich B, Huwyler T, et al. Variant of hyper-IgE syndrome: the differentiation from atopic dermatitis is important because of treatment and prognosis. Dermatologica 1991; 182:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/83\">",
"      Schanden&eacute; L, Ferster A, Mascart-Lemone F, et al. T helper type 2-like cells and therapeutic effects of interferon-gamma in combined immunodeficiency with hypereosinophilia (Omenn's syndrome). Eur J Immunol 1993; 23:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/10/24745/abstract/84\">",
"      Fitzmaurice RJ, Gardner DL. Thymoma with bone marrow eosinophilia. J R Soc Med 1990; 83:270.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5691 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-118.97.94.19-D760560F04-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24745=[""].join("\n");
var outline_f24_10_24745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Definitions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Categories of eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Patient evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALLERGIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Atopic dermatitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Rhinitis syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6201733\">",
"      Gastrointestinal disorders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Medication-related eosinophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INFECTIOUS DISEASES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Parasitic infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Diagnostic considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Laboratory evaluation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Fungal infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HIV and other retroviral infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      HEMATOLOGIC AND NEOPLASTIC DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mastocytosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Lymphoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other malignancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      RHEUMATIC DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Eosinophilia-myalgia syndrome and toxic oil syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Idiopathic eosinophilic synovitis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Vasculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MISCELLANEOUS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Atheroembolic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Immunodeficiency states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/5691\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/5691|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/0/26636\" title=\"table 1\">",
"      Eosinophil associated diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?34/44/35531\" title=\"table 2\">",
"      Eosinophilia drug reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/22/19820\" title=\"table 3\">",
"      Helminths with marked eos",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/42/10924\" title=\"table 4\">",
"      Helminths with prolonged eos",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/48/33545?source=related_link\">",
"      Allergic bronchopulmonary aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/62/24554?source=related_link\">",
"      An approach to the patient with drug allergy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/9/19609?source=related_link\">",
"      Clinical manifestations and diagnosis of chronic myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/58/20393?source=related_link\">",
"      Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/24/30090?source=related_link\">",
"      Clinical manifestations, pathophysiology, and diagnosis of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/35/568?source=related_link\">",
"      Clinical presentation and patterns of disease distribution in classical Hodgkin lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/42/39594?source=related_link\">",
"      Cytogenetics in acute myeloid leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/1/19482?source=related_link\">",
"      Diagnosis of asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/26/35237?source=related_link\">",
"      Dientamoeba fragilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/37/40535?source=related_link\">",
"      Diseases with eosinophilic involvement of specific organs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/11/1210?source=related_link\">",
"      Drug allergy: Classification and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31994?source=related_link\">",
"      Embolism from atherosclerotic plaque: Atheroembolism (cholesterol crystal embolism)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/43/43703?source=related_link\">",
"      Eosinophilic gastroenteritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/44/30405?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of Cystoisospora infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/40/42631?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/13/18650?source=related_link\">",
"      Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/50/24359?source=related_link\">",
"      HIV-associated eosinophilic folliculitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/45/32474?source=related_link\">",
"      Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22312?source=related_link\">",
"      Pituitary and adrenal gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/26/425?source=related_link\">",
"      Primary coccidioidal infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/4/65?source=related_link\">",
"      Risk factors for and possible causes of systemic sclerosis (scleroderma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/59/11193?source=related_link\">",
"      Strongyloidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/56/20362?source=related_link\">",
"      T cell negative, B cell negative, NK cell positive severe combined immunodeficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/34/16935?source=related_link\">",
"      Toxocariasis: visceral and ocular larva migrans",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/16/44297?source=related_link\">",
"      Treatment of eosinophilic esophagitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/18/25898?source=related_link\">",
"      Treatment of the hypereosinophilic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/54/15207?source=related_link\">",
"      Trichinellosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_10_24746="Muscles of the anterior abdominal wall";
var content_f24_10_24746=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F72219%7ESURG%2F66280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F72219%7ESURG%2F66280&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Muscles of the anterior abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 691px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Muscles of the lateral abdominal wall",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 702px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24746=[""].join("\n");
var outline_f24_10_24746=null;
var title_f24_10_24747="Features of IPSID lymphomas";
var content_f24_10_24747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76348&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Clinical features of the different types of small intestinal lymphomas",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        IPSID-associated lymphoma",
"       </td>",
"       <td class=\"subtitle1\">",
"        Non-IPSID-associated lymphoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Median age",
"       </td>",
"       <td>",
"        25 years",
"       </td>",
"       <td>",
"        37 years",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gender",
"       </td>",
"       <td>",
"        Primarily males",
"       </td>",
"       <td>",
"        Slight male predominance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptoms and signs",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Abdominal pain",
"        <br/>",
"        Chronic diarrhea",
"        <br/>",
"        Malabsorption",
"        <br/>",
"        Severe weight loss",
"        <br/>",
"        Clubbing",
"        <br/>",
"        Ankle edema",
"       </td>",
"       <td colspan=\"1\" rowspan=\"1\">",
"        Abdominal pain",
"        <br/>",
"        Palpable abdominal mass",
"        <br/>",
"        Bleeding",
"        <br/>",
"        Intestinal obstruction",
"        <br/>",
"        Intestinal perforation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Paraprotein",
"       </td>",
"       <td>",
"        Usually present",
"       </td>",
"       <td>",
"        Usually absent",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    IPSID: Immunoproliferative small intestinal disease",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Salem, P, El-Hashimi, L, Allam, C, et al, Cancer 1987; 59:1670.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24747=[""].join("\n");
var outline_f24_10_24747=null;
var title_f24_10_24748="Single and combined maternal analyte changes and adverse outcome";
var content_f24_10_24748=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F54068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F54068&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Association between selected individual and combinations of markers and adverse pregnancy outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Marker(s)",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preterm birth at 32 wk or less",
"      </td>",
"      <td class=\"subtitle1\">",
"       Birth weight 5th percentile or less",
"      </td>",
"      <td class=\"subtitle1\">",
"       Preeclampsia",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fetal loss at 24 wk or less",
"      </td>",
"      <td class=\"subtitle1\">",
"       Fetal loss at greater than 24 wk",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AFP",
"      </td>",
"      <td>",
"       1.76 (0.81-3.84)",
"      </td>",
"      <td>",
"       2.49 (1.82-3.4)",
"      </td>",
"      <td>",
"       0.83 (0.44-1.56)",
"      </td>",
"      <td>",
"       3.63 (1.81-7.27)",
"      </td>",
"      <td>",
"       0.70 (0.10-5.03)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       hCG",
"      </td>",
"      <td>",
"       0.83 (0.43-1.58)",
"      </td>",
"      <td>",
"       0.99 (0.76-1.27)",
"      </td>",
"      <td>",
"       1.19 (0.88-1.61)",
"      </td>",
"      <td>",
"       1.54 (0.85-2.81)",
"      </td>",
"      <td>",
"       1.38 (0.63-3.01)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       uE3",
"      </td>",
"      <td>",
"       1.68 (0.61-4.64)",
"      </td>",
"      <td>",
"       1.97 (1.28-3.04)",
"      </td>",
"      <td>",
"       1.70 (0.92-3.15)",
"      </td>",
"      <td>",
"       7.00 (3.70-13.24)",
"      </td>",
"      <td>",
"       NA",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Inhibin A",
"      </td>",
"      <td>",
"       2.38 (1.44-3.95)",
"      </td>",
"      <td>",
"       1.68 (1.29-2.18)",
"      </td>",
"      <td>",
"       2.39 (1.75-3.26)",
"      </td>",
"      <td>",
"       0.98 (0.36-2.66)",
"      </td>",
"      <td>",
"       2.41 (1.04-5.56)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AFP + inhibin A",
"      </td>",
"      <td>",
"       20.37 (9.38-44.22)",
"      </td>",
"      <td>",
"       4.28 (2.20-8.32)",
"      </td>",
"      <td>",
"       4.26 (1.91-9.51)",
"      </td>",
"      <td>",
"       18.01 (7.51-43.19)",
"      </td>",
"      <td>",
"       9.2 (2.2-38.43)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       hCG + inhibin A",
"      </td>",
"      <td>",
"       3.28 (1.97-5.46)",
"      </td>",
"      <td>",
"       2.05 (1.52-2.77)",
"      </td>",
"      <td>",
"       3.73 (2.73-5.08)",
"      </td>",
"      <td>",
"       2.03 (0.88-4.65)",
"      </td>",
"      <td>",
"       4.27 (1.95-9.32)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       AFP + hCG + inhibin A",
"      </td>",
"      <td>",
"       5.51 (2.23-13.62)",
"      </td>",
"      <td>",
"       6.50 (3.89-10.89)",
"      </td>",
"      <td>",
"       7.04 (3.90-12.73)",
"      </td>",
"      <td>",
"       16.34 (7.56-35.33)",
"      </td>",
"      <td>",
"       6.93 (1.66-28.9)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Data are expressed as adjusted odds ratio (95% confidence interval).",
"    <div class=\"footnotes\">",
"     AFP: alpha-fetoprotein; hCG: human chorionic gonadotropin; uE3: unconjugated estriol; NA: not applicable.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Dugoff L. Society for Maternal-Fetal Medicine. First- and Second-Trimester Maternal Serum Markers for Aneuploidy and Adverse Obstetric Outcomes. Obstet Gynecol 2010; 115:1052. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24748=[""].join("\n");
var outline_f24_10_24748=null;
var title_f24_10_24749="Papillary composition";
var content_f24_10_24749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F79201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F79201&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of water intake on papillary composition",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 362px; height: 223px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous measurement of renal papillary osmolality, sodium concentration, and urea concentration in rats in the control state, after a water load, and 2 h after the reinstitution of fluid restriction plus the administration of ADH. Water loading, which is associated with the inhibition of ADH release, led to a marked reduction in papillary osmolality that was mostly due to the virtual abolition of urea accumulation. These changes rapidly returned toward normal when ADH was given.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Levitin, H, Goodman, A, Pigeon, G, Epstein, FH, J Clin Invest 1962; 41:1145.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24749=[""].join("\n");
var outline_f24_10_24749=null;
var title_f24_10_24750="Vitreous reaction in toxo";
var content_f24_10_24750=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62410&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Vitreous reaction in toxoplasmosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 340px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Funduscopic photograph from a patient with toxoplasmosis reveals a severe vitreous reaction.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Michael Tolentino, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24750=[""].join("\n");
var outline_f24_10_24750=null;
var title_f24_10_24751="Myocardial perfusion Chagas";
var content_f24_10_24751=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F71959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F71959&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Myocardial perfusion SPECT -",
"    <sup>",
"     201",
"    </sup>",
"    Thallium",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Myocardial perfusion scan with Thallium-201 from a 54-year-old male, asymptomatic patient with chronic Chagas' heart disease. A large reversible perfusion defect is present in the inferior, inferior-septal, and apical regions. The epicardial coronary arteries were normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jose A Marin-Neto, MD, PhD, FACC, Benedito C Maciel, MD, FACC, and Marcus V Simoes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_10_24751=[""].join("\n");
var outline_f24_10_24751=null;
